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PREFACE 
The most essential task of the immune system is the discrim-
ination between t• self" and "non-self" and the generation of an 
immune response to rid the organism of "non-self" elements, thus 
protecting and preserving its integrity. 
Malignant transformation of normal cells may be accompanied 
by phenotypic changes in the involved cells. Normal cell surface 
antigens may be lost, new antigens may be gained or other membra-
ne changes may occur which influence cell-to-cell interactions in 
the host. These changes may evoke an immune response which is a 
highly complex process involving the intricate interactions of 
lymphocytes, monocytes, cytokines, lymphokines, chemotaxis, anti-
bodies, the complement system and many other factors so far poor-
ly understood or unidentified. 
The discovery of interferon, interferon inducers and various 
other agents that can augment immune responses has focused the 
attention on the beneficial role that manipulation of the immune 
response may play in the treatment of cancer. 
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Developments of new technologies often pave the way for key 
advances and new concepts in science. Tumor biology has entered 
a new era as a result of the advent of monoclonal antibody 
hybridoma techniques and DNA recombinant genetic engeneering 
technology. It has led to the elucidation of the concept of 
oncogenes, the further unraveling of the immune response a~d an 
ever increasing ability to manipulate it. This has been realized 
in particular by the advent of procedures that provide large 
quanti ties of various highly purified recombinant interferons, 
lymphokines and various other factors that play a key role in the 
orchestration of the immune response. It has led to the identifi-
cation of the various subsets of lymphocytes and monocytes that 
take part in the antitumor immune response; it has revolutionized 
the serologic analysis of tumor-associated antigens and it has 
created favorable conditions for new and more refined approaches 
in the treatment of cancer. 
This thesis will focus on the antitumor and immunomodulative 
activity of the interferon-inducing compound ABPP (2-amino-5-
bromo-6-phenyl-4(3H)-pyrimidinone), the conditions necessary for 
optimal antitumor activity, 
nation with lymphokines 
the efficacy of using it in combi-
(Interferon-gamma, Interleukin-2), 
cytokines (Tumor Necrosis Factor) or chemotherapy (cyclophos-
phamide) in experimental studies with rats and mice, and finally 
on the use of recombinant Interferon-alphaA in the treatment of 
metastatic colorectal cancer in humans. 
CHAPTER I 
AIM AND OUTLINE OF THE THESIS 
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AIM AND OUTLINE OF THE THESIS 
PART I EXPERIMENTAL STUDIES WITH THE INTERFERON-INDUCER ABPP IN 
RATS AND MICE 
Biological response modifiers are agents that · exert their 
antitumor effects mainly or exclusively through modulation of 
host immune defense mechanisms. A common feature of these agents 
is their capacity to induce the production of endogenous inter-
ferons and/ or other lymphokines in vivo, and their capacity to 
activate various subsets of lymphocytes and monocytes that can 
lyse tumor cells in vitro and in vivo. Antiproliferative and 
immunomodulative effects as well as toxicity and side-effects 
observed in connection with the administration of these agents 
may differ greatly. Relatively recently the 6-aryl pyrimidinones, 
a series of small molecule biological response modifiers, were 
discovered. It was found that these agents varied greatly with 
respect to antiviral, antiproliferative and immunomodulative 
activity as well as with respect to the toxic side-effects. 
Because of its effective induction of endogenous interferon, its 
significant immunostimulatory effects on NK cells and its low 
toxicity, ABPP (2-amino-5-bromo-6-phenyl-4-(3H)-pyrimidinone) 
appeared to be one of the most interesting and promising pyrimid-
inones. Most of the initial literature concerning the biological 
effects of ABPP dealt with NK-cell activity, assessed in vitro 
by 51chromium release cytotoxicity assays with NK-cell sensitive 
target cells, and in vivo anti tumor activity against non-esta-
blished tumor (tumor cells in the blood born or early lodging 
phase) . Both assessments of potential anti tumor efficacy should 
be interpreted with great caution. It is known that most cultured 
tumor cell-lines are NI<-sensitive and that in vitro cytotoxic 
activity may correspond poorly with in vivo antitumor effects, 
whereas fresh tumor cell preparations are usually NK-resistant 
and the capacity of activated killer cells to lyse these targets 
(LAK cell activity) corresponds well with antitumor activity of 
these cells in vivo. The evaluation of in vivo antitumor effects 
should not be based on results obtained with "non-established" 
(day 0-1 after inoculation of the tumor) metastatic tumor only. 
Established metastatic tumor (day 3 or later after inoculation of 
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the tumor) is quite resistant to NK-cell mediated killing and 
corresponds much better with the relevant clinical situation 
where an effective adjuvant treatment regimen in the presence of 
micrometastases at the time of removal of the primary tumor 
determines the ultimate outcome of treatment. 
Because of the arguments presented above we studied (A) the 
capacity of ABPP to generate LAK cel,l activity in vivo; (B) the 
importance of tumor load (nonestablished, early established and 
advanced tumor) and tumor site on the outcome of treatment with 
ABPP; (C) ways to augment immunotherapeutic effects with ABPP by 
combining ABPP with: other biologicals (Interferon-gamma, Inter-
leukin-2, Tumor Necrosis Factor) and with (D) cyclophosphamide in 
a search for treatment schedules ,that may hold promise in an 
adjuvant setting. 
An outline of the approach is presented hereafter: 
I(A) Immunomodulative effects of ABPP 
Biological response modifiers are agents that exert their 
anti tumor effects mainly or exclusively through modulation of 
host immune defense mechanisms. Cytolysis in vivo is mediated by 
various subsets of lymphocytes. Natural killer (NK) cells, lymph-
okine activated killer (LAK) cells and macrophages are believed 
to be of prime importance. We investigated the effects of the 
administration of ABPP in vivo on the NK cell activity and LAK 
cell activity in the peripheral blood lymphocytes, splenocytes, 
and peritoneal exudate cells by in .vitro assessment of the levels 
of cytotoxicity of these lymphocytes in '51Chromium release assays 
against various tumor cell targets. The activation of monocytes 
was assessed by determination of the level of phagocytosis dis-
played by peritoneal exudate cells after administration of ABPP. 
I(B) In vivo antitumor effects of ABPP 
tumor load and tumor site. 
general nature, role of 
The in vivo antitumor effects of ABPP were studied in rats 
and mice. The general nature of the antitumor effects of ABPP was 
assessed by using a variety of tumors, differing in immunogen-
icity and histology, in local, local-regional and systemic tumor 
models in different animal species and strains. Significant anti-
tumor effects . of biological response modifiers are usually seen 
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only when the tumor load is small. By varying the time interval 
between tumor inoculation and the administration of ABPP, the 
antitumor effects of ABPP on small or advanced local tlllllor, and 
on nonestablished (day 0), early established (day 3) or advanced 
(day 7-10) metastatic tumor were investigated. 
Host defense mechanisms may differ qualitatively as well as 
quantitatively in different body compartments and organs. The 
outcome of immunotherapy may therefore be related to the tumor 
site. The immunological "make-up" of the blood with its great 
variety of immune competent cells; the lungs with organ-associ-
ated NK cells and alveolar macrophages; the liver with NK-cells 
and Kupffer cells; and the subcutis virtually without a permanent 
associated population of NK cells or macrophages, differs greatly 
and may well determine the efficacy of immunotherapeutic agents. 
These aspects were evaluated by studying the effects of ABPP in 
local tumor models (subcutaneous, subrenal capsule assay), a 
local-regional model (intraperitoneal), and metastatic tumor 
models in lung and liver. 
I(C) Potentiation of antitumor effects by combining ABPP with 
other biological response modifiers 
Since the antitumor effects of Interferon-gamma (IFN-gamma), 
Interleukin-2 (IL-2) and Tumor Necrosis Factor (TNF) are mediated 
through at least in part different mechanisms, we investigated 
whether a potentiation of the antitumor effects of ABPP· could be 
obtained by various combined treatment schedules. 
I(D) Potentiation of antitumor effects by combining ABPP with 
cyclophosphamide in various treatment schedules 
The combination of various treatment modalities may be more 
effective as single agent therapy as a result of the different 
mechanisms involved in the destruction of tumor cells. In this 
setting, synergistic antitumor effects may permit dose reductions 
of the constituents of combined treatment schedules which may 
result in the reduct·ion of the toxicity of the treatment regimen. 
Multiple treatment cycles may therefore be tolerated and result 
in an effective control of tumor growth. Cyclophosphamide was 
chosen as the cytostatic agent to assess the hypothesis put 
forward above. 
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PART II PHASE II STUDY WITH RECOMBINANT INTERFERON-alphaA 
(riFN-alphaA) IN PATIENTS WITH METASTATIC COLORECTAL 
CANCER 
.With the advent of recombinant interferon-alpha many trials 
were started to evaluate the potential role of IFN-alpha in the 
treatment of cancer. The antitumor and immunomodulative effects 
of two different treatment schedules with riFN-alphaA and their 
associated toxicity were evaluated in. 20 patients with metastatic 
colorectal cancer. 
II(A) Antitumor effects 
Antitumor effects of riFN-alphaA treatment were assessed by 
measuring metastatic lesions with CT-scan and ultrasound before, 
during and after treatment at 6 week intervals. 
II (B) Toxicity 
Toxicity of the two different treatment schedules was 
assessed by registration of the complaints of the patients on a 
weekly basis, by physical examinations and by extensive and 
frequent heamatological and biochemical laboratory blood tests. 
II(C) Immunomodulation 
Immunomodulative properties of the two treatment schedules 
with riFN-alphaA were investigated by assessment of: 
1. NK-cell activity of the peripheral blood lymphocytes before 
and at various points in time during treatment. 
2. Blastogenesis of peripheral blood lymphocytes after stimula-
tion with phytohaemagglutinin (PHA) before and during treatment. 
3. Influence of treatment on the leukocyte adherence inhibition 
(LA!) assay with peripheral blood lymphocytes of the patients. 
CHAPTER II 
THE INTERFERON SYSTEM 
II(l) GENERAL INTRODUCTION 
II(2) BIOLOGICAL ACTIONS OF INTERFERONS 
II(3) INTERFERON INDUCERS 
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II(l) GENERAL INTRODUCTION 
Introduction 
Identification of immunobiologically active cytokines and 
advances in DNA recombinant technology have increased the number 
of biological response modifiers (BRMs) that are potential candi,-
dates for immunotherapy of cancer in man. These agents exert 
their antitumor effect exclusively or mainly by modifying host 
immune responses and not by a direct effect on cancer cells. A 
better understanding of host responses to cancer cells and the 
explosive increase in· ways to manipulate these responses have 
caused a renewed interest in tumor biology and immunotherapy. 
Active specific ilomunotherapy, an approa.ch that attempts to 
induce specific immunity against one's own tumor by a variety of 
immunization procedures, has met with very little success sofar 
mainly because of the poor immunogenicity of most human tumors. 
Active nonspecific ilomunotherapy, an approach that attempts to 
augment the aspecific antitumor response mediated in particular 
by large granular lymphocytes ( LGLs) and macrophages, has been 
more successful. One specific area involving this aspecific 
augmentation of host immune responses is the interferon system. 
Definition 
Interferons (IFNs) are a family of inducible secretory 
glycoproteins produced both in vitro and in vivo by virtually any 
eukariotic cell in response to a variety of stimuli (Ho and 
Amstrong, 1975). They are intercellular messengers with a major, 
but not absolute species specificity. Upon binding with specific 
cell receptors (Revel et al., 1976; Branca and Baglioni, 1981) 
they can direct cells to alter the expression of some of their 
speciali~ed functions and bring about an IFN-induced phenotype. 
History 
Isaacs and Lindenmann discovered interferon in England in 
1957. They demonstrated that the incubation of pieces of chicken 
chorioallantoic membrane with heat inactivated influenza virus 
induced the production of a factor by . ,these cells that would 
subsequently, when added to a culture of ·live virus with fresh 
membranes, inhibit "interfere with" the replication of the 
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virus. This factor was therefore called interferon. When it 
became clear that interferon did not only have antiviral activity 
but could inhibit the proliferation of various cells, especially 
tumor cells, great interest was raised in its potential role in 
the treatment of cancer. In the early 1970's Cantells' work at 
the Finnish blood bank led to the production of sufficient 
quantities of interferon-alpha (IFN-alpha) from huffy cell layers 
to carry out small clinical trials like the osteosarcoma trial by 
Strander and coworkers ( 1980). The development of recombinant 
DNA technology and the successful cloning of IFN-beta in 1979 by 
Taniguchi and the subsequent cloning of the IFN-alpha subtypes 
and IFN-gamma broadened and accelerated IFN research and created 
the opportunity to perform various clinical trials. One of these 
trials, a phase II study in patients with disseminated colorectal 
cancer, will be presented as a part of this thesis. 
Interferon species 
The IFNs are classified according to differences in anti-
genic, biologic and chemical properties. The three distinct 
antigenic types of IFN are designed alpha, beta, and gamma. 
TABLE I 
Type 
IFN-alpha 
(Type I) 
IFN-beta 
(Type I) 
IFN-ganuna 
(Type II) 
CLASSIFICATION AND CHARACTERISTICS OF HUMAN INTERFERONS 
Source f Sub- Molecular pH "-Glyco-
species . Weight Stability sylation 
B-cell 
Null-cell > 15 16,000 + 
-Macrophage 
Recombinant 25,000 
Fibroblast 
Lymphoblast 1 20,000 + + 
Null-cell 
Epithelial cell 
Recombinant 
T-lymphocytes 
Null-cell 1-2 17,000 + 
Recombinant 
1 refers to natural int;erferon; recombinant interferons are not 
glycoselated 
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The IFNs alpha and beta (also called Type I IFNs) are stable at 
low pH, whereas treatment of IFN-gamma (also called Type II IFN) 
at pH 2 neutralizes its activity. Type I IFN can be induced in 
cells of diverse origin, although those used in clinical trials 
have been induced in leukocytes or lymphoblastoid cell lines 
(IFN-alpha) or in fibroblasts (IFN-beta) by viruses or synthetic 
poly-ribonucleotides. IFN-gamma is produced by T-lymphocytes 
after induction by a variety of specific mitogens or 
antigens. The classification and the main properties 
human interferons are summarized in Table I. 
Induction and Production of IFNs 
foreign 
of the 
Production of IFN requires the interaction of an IFN inducer 
and a cell sensitive to it. This reaction triggers the derepres-
sion of genetic information that leads to the transscription of 
IFN gene(s) and the appearance of IFN-mRNA, its translation into 
protein and secretion of the IFN glycoprotein (Burke, 1965; 
Vilcek et al., 1969). The kinetics of IFN induction and release 
vary with different inducer-cell systems. IFN appears extracellu-
lary within 4-12 hours, with rapid attainment of maximum levels 
for about 12 hours and then decreasing abruptly to return to 
undetectable amounts. Induction of IFN-alpha/beta is in general a 
more rapid process than the induction of IFN-gamma. Evidence 
exists that IFN biosynthesis results from a true inductive 
process, i.e. that it represents de novo synthesis (Stewart, 
1979). 
II(2) BIOLOGICAL ACTIONS OF INTERFERONS 
Antiviral 
The replication of a wide variety of viruses as well as 
microorganisms that multiply intracellularly is blocked in cells 
pretreated with IFN. Binding of IFN to its receptors triggers the 
induction of 2' ,5'-oligoadenylate synthetase which leads to endo-
ribonuclease activation, which in turn inhibits RNA transcription 
by degrading mRNA linked to double stranded RNA (Revel et al. , 
1980). Thereby it inhibits DNA and RNA synthesis ands thus the 
replication of intracellular virus. In addition to the 2' ,5'-
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oligoadenylate synthetase pathway, IFNs may lead to inhibition of 
protein synthesis by induction of a protein kinase and a phospho-
diesterase pathway (Senn, 1984). 
Antiproliferative 
As has been discussed in the section on antiviral effects 
IFNs can affect nucleic acid and protein synthesis. These same 
mechanisms that lead to the antiviral state are probably in part 
responsible for the antiproliferative effect on multiplying 
cells. IFNs have been shown to inhibit proliferation of malignant 
cells preferentially or more effectively than the proliferation 
of normal cells (Fleischmann et al.,1984). This may be explained 
by the assumption that RNA's involved in an exponentially expand-
ing process are turning over more rapidly than those involved in 
processes that have achieved a steady-state status (normal cellu-
lar processes) and that hence exponentially replicating tumor 
cells are much more vulnerable to the action of IFNs than normal 
cells. As IFNs inhibit the synthesis of various enzymes and 
other proteins a variety of mechanisms is probably involved in 
the direct antiproliferative effects of IFNs. For instance IFNs 
inhibit the synthesis of ornithine decarboxylase, an enzyme 
induced by mitogens, growth factors and tumor promoters and thus 
can counteract their effects ( Sreevalsan et al, 1980). Some of 
the most important effects of IFNs on cell proliferation may be 
the result of their effects on the differentiation of cells, the 
expression of oncogenes and the expression of surface antigens. 
These mechanisms may have antiproliferative effects or lead to an 
increased immune response because of an increased expression of 
antigens as will be outlined in the following sections. 
Differentiation and Antigen Expression 
Interferons have been shown to have a variety of effects on 
cell differentiation (Burke, 1986). An important recent finding 
which may suggest one cellular mechanism for causing different-
iation is the decreased c-myc and c-Ha-ras gene expression fol-
lowing IFN treatment. This effect on oncogene expression (Clemens 
, 1985) may be part of the antineoplastic action of IFN. The in-
crease in cell surface antigen expression is most likely another 
aspect of IFN biological effects which could be important in 
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tumor control. This has been demonstrated for F .. -receptors on 
lymphocytes and for class I and II major histocompatibility 
complex antigens (Paulnock and Borden, 1985;Stewart and Blanchard 
, 1985) on lymphocytes and several other cell types. In addition 
to augmentation of preexisting antigen IFN has also been shown to 
induce HLA expression in a variety of normal cells (Rossi, 1985). 
In neoplastic cells IFNs have been shown to induce HLA expression 
and to enhance the expression of surface tumor-associated anti-
gens (TAA) in several tumor cell lines (Giacomini et al.,1984 and 
1985; Greiner et al., 1984; Carrel et al., 1985). If increased 
'antigenicity occurs at a time when there is concurrent enhance-
ment of macrophage-antigen-presenting functions, this could well 
improve endogenous antitumor activity and account for one of the 
many indirect antitumor effects of IFNs. Yet another possible 
antitumor effect of IFNs has been reported recently. Tsujimoto et 
al. (1986) have shown that IFN-alpha and -beta, but IFN-gamma in 
particular, can enhance the expression of cellular receptors for 
tumor necrosis factor (TNF) on tumor cells. Ruggiero an coworkers 
(1985) however showed that syngergism between IFN-gamma and TNF 
was also observed in cell lines in which TNF receptors were not 
significantly increased by pretreatment with IFN-gamma. 
Immunomodulative 
The immunomodulative properties of the IFNs may constitute 
one of the many mechanism by which they exert their antitumor 
effects. Support for this view is found in experiments in which 
tumors known to be IFN-resistant in vitro did regress in vivo 
when the animal received systemic treatment with IFN (De Maeyer-
Guignard and De Maeyer, 1985). A variety of immune changes have 
been described. The literature is rather confusing due to the 
fact that timing and dose of treatment seem to be crucial as to 
what kind of effect is obtained. The most relevant effects appear 
to be those on NK cells and macrophages. In vitro work with 
human lymphocytes shows that IFN enhances the killing potential 
of NK cells both by recruitment of pre-NK cells and by increased 
cytotoxicity of activated cells (Herberman and Ortaldo, 1981). 
There is also evidence for augmentation of K cell - mediated 
antibody dependent cellular cytotoxicity (ADCC) (Borden et al., 
1982). In vivo data from clinical studies are confusing in that 
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both enhancement of NK cell activity (Einhorn et al., 1978; 
Lucero et al., 1982) and depression (Maluish et al., 1983; Spinn 
et al., 1983; Tank et al., 1984) have been reported. Low dose IFN 
treatment results in marked enhancement of NK cell activity 
(Einhorn et al., 1982; Edwards et al., 1985) while high doses 
beyond a "threshold" may have a suppressive effect on NK cells. 
Results from our study indicated that the effect of IFN on NK 
cells was determined to a large extent by the treatment schedule. 
Macrophages rather than NK cells are affected by IFN-gamma as 
this interferon appears to be identical with the macrophage act-
ivating factor (MAF) (Vilcek et al., 1985). Enhancement of phago-
cytosis, antiviral a~d bactericidal activity as well as antitumor 
cytotoxicity is the result of IFN-gamma mediated macrophage act-
ivation (Steward and Blanchard, 1985; Paulnock and Borden, .1985). 
It appears that the antitumor effects of IFNs are based on an 
intricate and complex network of actions, any or all of which may 
be important and may depend on time dosage and type of IFN used. 
II(3) INTERFERON INDUCERS 
Introduction 
Isaacs and Lindenmann used heat-inactivated influenza virus 
as interferon inducer during their classical experiments that led 
to the first description of interferon (1957). In addition to 
viruses and certain intracellular microbes a wide variety of 
different substances have been found to. stimulate interferon 
production in in vitro and/or in vivo. A classification of IFN 
inducers, as proposed by Torrence and DeClercq in 1982 is shown 
in Table II. The diversity of structural classes involved, coup-
led with the fact that different types of IFN may be produced, 
precluded thus far the development of a unifying hypothesis 
regarding their mode of action~ It is generally believed. that 
structural similarities between DNA viruses and double stranded 
RNA's like Poly I:C may be responsible for the induction of main-
ly Type I IFNs through similar mechanisms. In the case of low 
molecular weight interferon inducers like substituted pyrimid-
ines, to which ABPP belongs, interactions with nucleic acids may 
occur because of structural resemblance and these may be respons-
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ible for induction of IFN. The differences in structure between 
double stranded RNA's and low molecular weight interferon 
inducers, as well as the differences between the various agents 
within this class (Table II, group III), are staggering. However 
some low molecular weight IFN inducers have been shown to 
interact with nucleic acids and it may wel-l be that in some cases 
(metabolites of) these small molecule IFN inducers may modify the 
properties of the endogenous nucleic acids of ·an organism and 
convert these into interferon inducers (Torrence, 1982). 
TABLE II CLASSIFICATION OF INTERFERON INDUCERS 
I. Viruses 
II. Polyanions 
a. Nucleic acids 
b. Polyphosphates 
c. Polysulphates 
d. Polycarboxylates 
III. Low Molecular Weight (LMW) Inducers 
a. Tilorone and its Analogs 
b. Propaene Diamine Derivatives 
c. Pyrazolol Quinolines 
d. Acridine Derivatives 
e. Pyrimidines 
f. Mercaptoalkyl Arnines 
IV. Antibiotics 
v. Bacterial Products 
VI. Lymphocyte stimulating agents 
a. Mitogens 
b. Specific antigens 
c. Mixed lymphocyte culture 
d. Antilymphocyte antibody 
e. Enzymes 
VII. Microorganisms other than viruses 
a. Bacteria 
b. Protozoa 
c. Mycoplasmas 
d. Chlamydiae 
e. Rickettsiae 
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Pyrimidinones 
The 6-aryl pyrimidinones are a group of low molecular weight 
interferon inducers (Table II; group III) that can be readily 
synthesized by condensation of guanidine with b-ketoesters 
(Wierenga, 1980a). Introduction of a halogen at the 5' position 
is generally required for biological activity. These compounds 
are crystalline, have a high melting point, and they are poorly 
soluble in water at neutral pH. ABMP (2-amino-5-bromo-6-methyl-
4(3H)-pyrimidinone) was originally identified as an active inter-
feron inducing agent by Nichols et al. (1976). A direct relation-
ship appeared to exist between the ability ABMP to induce inter-
feron and mediate an antiviral state in vivo as mice were shown 
to be protected from the lethal consequences of infection with 
Semliki forest virus only by doses that induced interferon 
(Stringfellow, 1977). Because of ABMP's poor therapeutic index 
due to renal toxicity (Larsen et al., 1980) studies were initi-
ated to identify effective analogs. Three compounds emerged as 
the least toxic and biologically most active. They are (1) ABPP : 
2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (shown in Figure 1); 
(2) AIPP : 2-amino-5-iodo-6-phenyl-4(3H)-pyrimidinone, the iodo-
analog of ABPP; and ( 3) ABmFPP 2-amino-5-bromo-6-m-fluoro-
phenyl-4 ( 3H) -pyrimidinone, the 6-m-fluoro-phenyl analog of ABPP 
(Tracey and Richard, 1986; Li et al., 1987). After some initial 
work with AIPP and ABPP we have restricted ourselves to 
experimental work with ABPP, which will constitute the main part 
of this thesis. 
Figure 1 : Structure of ABPP 
0 
ABPP: 2-AMIN0-5-BROM0-6-PHENYL-4(3H)-PYRIMIDINONE 
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TABLE III : IMMUNOMODULATING EFFECTS OF ABPP 
Positive 
Induction of 
Induction of 
Induction of 
Activation of 
Generation of 
Activation of 
Activation of 
IFN Type I 
Interleukin-1 
Interleukin-2 
NK cells 
LAK cell activity 
macrophages 
B-cells 
(references) 
(Stringfellow, 1977) 
(Hamilton et al.,1980; 1982) 
(Richard and Tracey, 1985) 
(Tracey et al., 1984) 
(Lotzova et al., 1983; 1984) 
(Eggermont et a1., 1987a) 
(Li et al., 1985) 
(Fast et al., 1982) 
Increase of antibody production (Fast and Stringfellow, 1980) 
Increase of bone marrow 
colony forming units (Taggart et al., 1980) 
Negative 
Decrease in T cell cytotoxicity 
in vitro 
Decrease in T cell response to 
alloantigens 
Decrease in delayed type 
hypersensitivity in vivo 
(Taggart et al., 1980) 
(Taggart et al., 1980) 
(Pimm and Baldwin, 1985) 
ABPP is a potent IFN Type I (mainly alpha) inducer in various 
animal species as well as in humans (Stringfellow, 1980; Earhart 
et al., 1985) and has strong antiviral activity in various animal 
species (Wierenga, 1980b). ABPP can be administered subcutaneous-
ly (s.c.), intraperitoneally (i.p.) or orally. The latter two 
ways of administration have the best regional and systemic biolo-
gical effects. Many immunomodulating effects have been reported, 
most importantly the activation of NK cells (Lotzova et al., 
1983; 1984), the generation of LAK cell activity in vivo (Egger-
mont et al., 1987a) and the activation of macrophages (Li et al., 
1985). Activation of macrophages was shown to be important not 
only because of increasing cytotoxic activity of these cells but 
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mainly because of their role in the augmentation of NK-cell 
activity, probably via the induction or production of cytokines 
like IL-l and possibly IL-2 (Tracey and Richard, 1986). 
Stimulatory effects of ABPP on B-cell funtions but inhibitory 
effects on some T-cell functions have been reported. The immune-
modulating effects of ABPP are summarized in Table III. 
We investigated the immunomodulating and the antitumor effects of 
ABPP alone and in combination with IFN-gamma, TNF,- IL-2 and LAK 
cells and in combination with Cyclophosphamide in rats and mice. 
These experiments will be presented and their results discussed 
in the following 5 chapters of this thesis. 
CHAPTER III 
The content is an adapted version of the publication 
Site specific antitumor effects of 
2 Pyrimidinone compounds in rats 
Alexander M. M. Eggermont, Richard L. Marquet, Ron W. F. de 
Bruin, Bhupendra Tank, Willem Weimar and Johannes Jeekel. 
From the Laboratory for Experimental Surgery, Erasmus University, 
Rotterdam, the Netherlands 
Br J Cancer 54:337-339, 1986 

23 
Site specific anti tumor effects of 2 Pyrimidinone compounds in 
rats. 
Alexander M. M. Eggermont, Richard L. Marquet, Ron W.F. de Bruin, 
Bhupendra Tank, Willem Weimar and Johannes Jeekel. 
Summary 
Two pyrimidinones 2-amino-5-iodo-6-phenyl-4(3H)-pyrimidinone 
(AIPP) and 2-amino-5-bromo-6-phenyl-4 ( 3H) -pyrimidinone (ABPP) 
were tested for their antitumor effect on the spontaneous non-
immunogenic, transplantable liposarcoma LS175 in BN rats. AIPP 
and ABPP are strong inducers of natural killer (NK) cell activity 
as was confirmed in the present communication. AIPP is known to 
be a weak, ABPP a strong interferon inducer. Tumor growth in the 
subcutaneous model was significantly (p<0.003) inhibited by ABPP 
but not by AIPP, whereas the development of lung metastases was 
significantly (p<0.02) inhibited by both compounds. Since LS175 
has been shown by us in previous experiments to be sensitive to 
interferon, the difference between AIPP and ABPP in inhibition of 
subcutaneous tumor growth may be attributed to the interferon 
inducing properties of ABPP. NK cell activity, which is enhanced 
equally by both compounds, may be held responsible for the 
similar inhibition in the development of lung metastases after 
AIPP or ABPP. 
INTRODUCTION 
Recently a series of 5-halo-6-phenyl pyrimidinones has been 
found to induce interferon production in several animal species 
and in cultured human tissues (Stringfellow et al., 1980a;String-
fellow, 1980b). Moreover these compounds have been reported to 
modulate a variety of immune responses like the activation of NK 
cells (Lotzova et al., 1983; Taggart et al., 1980) and macro-
phages (Li et al., 1985). The pyrimidinones used in our experi-
ments are 2-amino-5-iodo-6-phenyl-4(3H)-pyrimidinone (AIPP) and 
2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP). They differ 
greatly in their ability to induce interferon production in vitro 
and in vivo (Stringfellow et al., 1980). AIPP is a very weak, 
ABPP a very strong interferon inducer. Both are equally active in 
enhancing NK cell activity, which is considered an interferon 
independent quality of these agents (Loughman et al., 1980). In a 
previous communication (Marquet et al., 1983) we have shown that 
subcutaneous growth of liposarcoma LS175 in BN rats is inhibited 
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by interferon. NK cells are known to be most effective against 
circulating tumor cells (Hanna et al., 1980). To investigate 
whether the induction of interferon may play a part in the anti-
tumor effects of AIPP and ABPP we compared the two agents in an, 
assumed NK cell dependent (lung metastasis) model and in an 
assumed NK cell independent (subcutaneous) model using the inter-
feron sensitive liposarcoma LS175 in BN rats. 
MATERIALS AND METHODS 
Rats 
Male rats of the inbred BN strain were used. The animals were 
bred under specific-pathogen-free conditions and were 10-12 weeks 
old. 
Tumor 
LS 175 is a liposarcoma of spontaneous origin in a female BN rat. 
The tumor is readily transplantable in syngeneic hosts. It is 
nonimmunogenic as judged by the in vivo method of Prehn and Main 
(_1957) and is NK resistant. When 2 rom cubes of tumor are implan-
ted subcutaneously (s.c.) the tumor is readily palpable within 1 
week. Tumor cell suspensions were prepared from s.c. tumor im-
plants in RPMI-medium, enriched with 15% fetal calf serum (FCS). 
Tumor cells were isolated by mechanical disruption using a razor 
blade mounted on an overhead stirrer as described by Rein-hold 
(1965). Single cells were isolated from non-dispersed clumps by 
sieving through nylon gauze. After two washings the viability of 
the cells was assessed with trypan blue. This was usually 50%. 
Experimental lung metastases : Lung metastases were created by 
injecting 1 x 10 5 tumor cells suspended in 0. 5 ml RPMI in the 
tail vein. The number of lung colonies was counted after 14 days. 
The lungs were excised, and fixed in Bouin's solution. Tumor 
nodules on the lung surface were counted with the naked eye. 
Experimental Agents 
2-amino-5-iodo-6-phenyl-4(3H)-pyrimidinone (AIPP) and 2-amino-
5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) were made by published 
procedures ( Wierenga et al., 1980) and provided by the Upjohn 
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Company, Kalamazoo, Michigan, USA. The agents were suspended in 
0.5ml phosphate buffered saline (PBS) and injected 
intraperitoneally (i.p.) at a dose of 250 mg/kg. 
51Chromium release assay for Cytotoxicity of NK cells 
Peripheral blood lymphocytes were prepared from heparinized blood 
samples. Mononuclear cells were seperated on a Ficoll - hypaque 
gradient and were used in a standard 3 hour 51Cr-release NK 
cytotoxicity assay as described by Ortaldo et al. ( 1977). The 
target cell was Yae-l and the cells were used at different 
effector to target ratios., All assays were performed in tripli-
cate in a total volume of 0.2ml RPMI containing 10% FCS. After a 
3 hr incubation the plates were centrifuged and supernatants were 
removed using the Titertek automatic harvesting system (Skatron, 
Norway) and counted in a LKB gamma counter. Specific lysis was 
evaluated at an effector to target cell ratio of 40:1. The amount 
of 51Cr released from the target cells in the absence of effector 
cells was defined as spontaneous release. 
Specific lysis was calculated as follows : % specific lysis 
(mean exp. cpm - spent. cpm) I (mean max. cpm - spent. ·.cpm) x 100 
The maximum release was calculated by adding 10% Cetavlon (ICI, 
UK) to an aliquot of target cells. 
Assessment of Macrophage activity 
The effect of a single injection of ABPP i.p. at a dose of 250 
mg/kg on macrophages was assessed by measuring the phagocytic 
activity of peritoneal exudate cells (PEC) indicated by the 
ingestion of latex particles at various time points after the 
administration of the drug. 
Experimental Procedures 
Subcutaneous tumor model : In the s. c. ·tumor model 2 rom cubes of 
tumor LS 175 were implanted s.c. in the left flank of BN rats. 
Tumor growth was assessed on day 4 1 7 and 12 by measuring with 
calipers the two largest perpendicular diameters of the tumor. 
The average diameter was taken as the measure of tumor size. 
Lung metastasis model In the lung metastasis model 1 x 10 5 
tumor cells were injected into the tail vein. On day 14 the rats 
were sacrificed and the number of lung colonies was counted. 
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The 'implantation of tumor cubes or the i. v. injection of tumor 
cells was preceded by i.p. injections of AIPP or ABPP at a dose 
of 250 mg/kg on day -3, -2 and -1. Controls were given a similar 
volume of phosphate buffered saline (PBS) i.p. 
NK cell cytotoxicity : was measured on day 1, 3 and 9 after a 
single injection of AIPP or ABPP (250 mg/kg, i.p.). The controls 
received an equal volume of PBS i.p. In all experiments each 
group consisted of 5 animals. 
Statistical Analysis 
The difference in s.c. tumor growth or the number of lung 
metastases between the different groups was tested with the 
Student-t test. 
RESULTS 
Enhancement of NK cell activity 
Figure 1 shows the NK-cell activity as measured on day 1, 3 and 9 
after a single injection of 250 mg/kg of AIPP or ABPP i.p. 
Control animals recieved PBS i.p. A rapidly established and long 
lasting 3 fold increase of NK-cell cytotoxicity is seen after 
administration of either pyrimidinone. 
Activation of macrophage activity 
Macrophage activity was assessed by measuring the ingestion of 
latex particles by peritoneal exudate cells at various points in 
time after injection of ABPP i. p. Phagocytosis increased 4 fold 
(within 4 hours) and was elevated for 4 days (data not shown). 
Effects on subcutaneous tumor growth 
Figure 2 shows the response of tumor LS175 to administration of 
AIPP or ABPP in a dose of 250 mg/kg i.p. on day -3, -2 and -1. A 
significant (p<0.003) inhibition of tumor growth was observed in 
the ABPP treated group whereas no inhibition was seen after 
treatment with AIPP. 
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Figure 1 Enhancement of NK-cell Activity by ABPP and AIPP 
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Figure 1 : Enhancement of NK cell activity in peripheral blood 
lymphocytes (PBL) after a .single i.p. injection of 250 mg/kg of 
AIPP or ABPP. Control animals received PBS i.p. (N=3). The per-
centage of specific lysis is shown as determined in a 3 hr 5 ~Chr 
release assay at an effector:target (Yae-l) ratio of 40:1. 
28 
Figure 2 Effect of AIPP and ABPP on Subcutaneous Tumor Growth 
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Figure 2 : Effect of treatment with AIPP and ABPP on growth of 
LS175. AIPP and ABPP were given at a dose of 250 mg/kg i.p. on 
day -3, -2 and -1. The difference between the diameter of the 
ABPP-treated group ( 1---1) and the control group ( 0---0) was 
statistically significant (p<O. 003). There was no significant 
inhibition of tumor growth in the AIPP treated group (D---D). 
(N=5) 
Effect on the development of lung metastases 
Table I shows the effect of AIPP and ABPP, when given ~t a dose 
of 250 mg/kg i.p. on day -3, -2 and -1 , on the development of 
lung metastases. The lung colonies were counted on day 14. A 
significantly (p < 0.02) lower number of metastases was found in 
the rats pretreated with AIPP or ABPP. No difference existed 
between the two treated groups. 
TABLE I 
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Effect of pretreatment with AIPP or ABPP 
on' the Development of Lung Metastases 
Pretreatment Mean Number of 
Metastases .:!:: SD 
Range 
PBS 39 + 12 24-56 
AIPP 18 + 7 10-23 
ABPP 13 + 3 10-16 
Effect of administration on day -3, -2 and -1 of 250 mg/kg of 
AIPP or ABPP i.p. on the development of lung metastases when 
counted on day 14 after injection o£ 1 x 105 cells of LS175 i.v .. 
A significantly (p<0.02) lower number of metastases were found 
after either AIPP or ABPP treatment.(N=5) 
DISCUSSION 
The inhibitory effect of both pyrimidinones on the develop-
ment of lung metastases is in agreement with the results reported 
by Milas et al. (1982) concerning immunogenic as well as nonimmu-
nogenic murine tumors. The activity of NK cells and macrophages 
at the time of i.v. tumor inoculation was strongly enhanced as a 
result of the pretreatment with either ABPP or AIPP. The activa-
tion of these two cell populations may well explain the results 
in the lung metastasis model. Hanna et al. (1980) have shown that 
tumor cells are most sensitive to NK cells when they are in a 
blood born or early lodging phase. The fact that tumor LS175 is 
NK resistant in vitro does not rule out an important role for 
activated NK cells in vivo to account for the lower number of 
lung metastases in the pyrimidinone treated groups : (i) In vitro 
NK resistant tumor cells may be less resistant in vivo to highly 
activated NK cells (Talmadge et al., 1984) (ii) Very high NK 
cell activity can be induced in the lungs of rats by pyrimidi-
nones (Lotzova et al., 1984) ; (iii) activated NK cells have been 
shown to produce a variety of lymphokines like IFN-gamma and IL-2 
(Kasahara et al., 1983). (iv) secretion of IFN-gamma by the organ 
associated NK cells (Wiltrout et al., 1985) or of a putative more 
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rapidly working macrophage activating factor (MAF) secreted by NK 
cells in the rat and in humans (Gomez et al., 1985) may lead to a 
highly effective in situ activation of alveolar macrophages. 
The tumor-site-specific setting of a high concentration of macro-
phages, directly as well as indirectly activated by the pyrimidi-
nones, could well explain the observed inhibition of the develop-
ment of lung metastases. 
The difference in tumor response to ABPP and AIPP in the s. c. 
tumor model may be due to the difference in IFN serum levels 
after the administration of these two agents. When we observe the 
growth curve of the tumors in th_e ABPP-treated group the tumor 
appears after 6-7 days. This is the only antitumor effect that 
can be observed sin<;:e tumor growth follows a parallel course to 
the other experimental groups wheri the tumor has become measur-
able. Apparently tumor suppression is only short lived and no 
prolonged inhibitory effect is seen. This could be explained by 
the fact that high levels of IFN are induced by ABPP for a period 
of only 24 hours (Oku et al., 1984 ; Lotzova et al., 1984). Since 
LS175 has been shown to be IFN sensitive and IFN can have a 
direct inhibitory effect on tumor growth, high levels of inter-
feron at the time of the s.c. tumor inoculation may have created 
the lag-time in tumor growth that is observed in the animals 
pretreated with ABPP. Since multiple injections with ABPP induce 
a hyporeactive state (Oku et al., 1984) as _is observed with many 
biological response modifiers (Talmadge et al., 1985), the anti-
tumor effect in the s.c tumor model offers little pros-pect for 
an effective role for ABPP in this setting. 
The antimetastatic effect of these pyrimidinones is the more im-
portant observation, especially since the tumor was NK resistant. 
Interactions between activated NK cells and macrophages, both of 
which are present in high numbers in the lungs, may have overcome 
this resistance and may have brought about the effective lysis of 
tumor cells by either cell population. Since the administration 
of pyrimidinones is virtually non toxic (Earhart et al., 1985) 
these agents may hold some promise in boosting anti-metastatic 
mechanisms in a perioperative or otherwise adjuvant setting. 
CHAPTER IV 
The content is an adapted version of the publication 
Effects of the interferon-inducer ABPP on colon cancer' in rats 
importance of tumor load and tumor site. 
Alexander M. M. Eggermont, Richard L. Marquet, Ron w. F. de Bruin 
and Johannes Jeekel. 
From the Laboratory for Experimental Surgery, Erasmus University, 
Rotterdam, the Netherlands 
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Effects of the interferon-inducer ABPP on colon cancer in rats 
importance of tumor load and tumor site. 
Alexander M. M. Eggermont, Richard L. Marquet, Ron W. F. de 
Bruin, Johannes Jeekel 
Summary 
ABPP 2-amino-5-bromo-6-phenyl-4 ( 3H) -pyrimidinone ) is a 
pyrimidinone with known interferon-inducing, natural killer (NK) 
cell activity enhancing, anti viral and anti tumor properties in 
several animal species. Its effect on CC531, a DMH induced, 
transplantable, weakly immunogenic adenocarcinoma of the colon in 
WAG rats, was studied. ABPP was found.to have no direct cytotoxic 
effect on CC531 cells .in vitro. When small cubes of tumor of 
equal weight were implanted under the renal capsule, the 
administration of 250 mg/kg of ABPP intraperitoneally (ip) on day 
0 and +1 led repeatedly to a significant ( p<0.02 to p<O.OOl ) 
inhibition of tumor growth, when measured on day +7. Lower doses 
or a single dose of ABPP could not achieve this effect. Late 
administration (on day +6 and +7) of 250 mg/kg of ABPP in this 
model was found to have no effect on tumor growth when measured 
on day +13. When 5 x 10 5 .tumor cells were injected in the portal 
vein, administration of 250 mg/kg of ABPP i.p. on day 0 and +1 
reduced significantly (p=O. 002) the number of liver metastases, 
when counted on day +30. Survival in this group was significantly 
prolonged (p<O.Ol). However when ABPP was given on day +6 and +7, 
significantly more (p<0.02) metastases in the liver were counted 
on day +30. The results show a significant antitumor effect of 
ABPP against tumor CC531 in the subrenal capsule assay ( SRCA) 
model as well as in the liver metastasis model when administered 
at the time of tumor inoculation. Late administration of ABPP 
does not inhibit tumor growth in the SRCA and significantly 
enhances the development of liver metastases. The role of timing, 
tumor ·site and the mechanisms by which this dual outcome of 
immunotherapy with ABPP is mediated is discussed. The results of 
these experiments may have important implications for the design 
of clinical studies with ABPP. 
INTRODUCTION 
ABPP is a relatively new biological response modifier (BRM) 
with various effects on the immune system. It induces the pro-
duction of endogenous interferon {IFN) in several animal species 
(Stringfellow et al., 1980a) and in man (Earhart et al., 1985). 
ABPP enhances NK cell activity (Taggart et al., 1980; Lotzova et 
al., 1983) and activates macrophages (Li et al., 1985). It has 
been shown to exert antitumor effects in subcutaneous (Sidky et 
al., 1985), lung metastasis (Milas et al., 1982) and in intra-
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peritoneal tumor models (Stringfellow, 1980b). Recently we re-
ported on its inhibiting effects on subcutaneous growth and on 
the development of lung metastases of a nonimmunogenic liposar-
coma in BN rats (Eggermont et al., 1986a). The results suggested 
that the antitumor effect in the subcutaneous model was evoked by 
the induction of IFN, whereas the inhibition of the development 
of lung metastases could be accounted for by the enhancement of 
NK cell activity. In the present study ABPP was used in a clinic-
ally more relevant tumor model : a transplantable weakly immuno-
genic adenocarcinoma of the colon (CC531) in WAG rats. In a pre-
vious communication (Marquet et al., 1984) we reported on the 
inhibitory effects of partially purified rat interferon (RIFN) on 
tumor CC-531 in the subrenal capsule assay and in the lung meta-
stasis model. In the liver metastasis model however RIFN treat-
ment appeared to be totally ineffective if not detrimental. The 
liver seemed to provide a protective environment against tumor 
immunity. The aim of the present study was to investigate the 
effects of ABPP on tumor CC531 in the subrenal capsule assay and 
in the liver metastasis model. Since tumor burden is an important 
factor in the clinical situation, the role of tumor load was 
studied with a special interest in site-specific tumor behaviour. 
MATERIAL AND METHODS 
Rats 
Male rats of the inbred WAG/Ro strain were used. The animals were 
bred under specific pathogen-free conditions and were 10-12 weeks 
old. 
Tumor 
Tumor CC531 is a 1,2 dimethylhydrazine-induced, moderately dif-
ferentiated adenocarcinoma of the colon in WAG rats. It is trans-
plantable in syngeneic animals and is weakly immunogenic as 
determined by the method described by Prehn and Main ( 1957). 
Spontaneous lung metastases do occur if the tumor is implanted 
subcutaneously ( s. c.). Artificial metastases can be induced in 
the lungs by intravenous (i.v.) injection of tumor cell 
suspensions, whereas liver metastases can be evoked by injection 
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of tumor cells into the portal vein. In the experiments discussed 
here, the tumor was in its 12th passage. A stationary culture of 
cell line CC531 has been established and is maintained in 
RPMI-medium enriched with 10% fetal calf serum (FCS). 
Tumor cell suspensions were prepared from s.c. tumor implants in 
RPMI-medium, enriched with 10% FCS. as decribed_in chapter III. 
Tumor models 
Liver metastasis model Liver metastases were evoked by 
injection of 5 x 10 5 tumor cells into the portal vein. Under 
ether anesthesia the portal vein was exposed via a small midline 
incision and 0.5 ml of suspension was injected via a 16 x 0.5 rnrn 
needle. The rats were laparotomized on day +30 and the number of 
liver metastases was counted. 
Subrenal capsule assay (SRCA) : Recipient animals were anesthesi-
zed with ether, a median laparotomy was done and both kidneys 
were exteriorized. A small knick was made in the capsule and a 
tumor cube of 6-8 mg was implanted and pushed up to the upper 
kidney pole. One w~ek after the first administration of ABPP the 
animals were killed, the tumors were enucleated and weighed. 
ABPP 
ABPP ( 2-amino-5-bromo-6-phenyl-4 ( 3H) -pyrimidinone) was made and 
provided by The Upjohn Company, Kalamazoo, Michigan, U.S.A. ABPP 
was suspended in phosphate buffered saline (PBS) and injected 
intraperitoneally (i.p.). 
Experimental Procedures 
To assess wether ABPP has a direct cytotoxic effect on CC531, 
tumor cells were obtained from the stationary cell line culture 
by trypsinisation for 10 minutes. The cells were counted and a 
dilution series ranging from 10 6 - 10-~ cells per ml was made in 
16 rnrn multi-well tissue culture plates (Costar, Cambridge, Mass., 
USA) in a volume of 1 ml and were allowed to adhere for 1 day 
before ABPP was added. Of each cell concentration one well was 
used as a control. In the other wells 0.25 fg up to 16 fg of ABPP 
dissolved in 0.5 ml PBS was added. After a 6-day incubation 
period with ABPP the number of cells in each well was counted in 
the microcell counter (TOA, Medical Electronics, Japan). In the 
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first two SRCA's groups of 5 animals were used. After insertion 
of the tumor cubes under the capsule of both kidneys 250 mg/kg of 
·ABPP was administered i.p. on day 0 and +1. The control animals 
recieved an equal volume (0.5 ml) of PBS i.p. The animal were 
killed on day +7; the tumors were enucleated and weighed. In the 
dose-response experiment 3 groups of 3 animals recieved SO, 150 
or 250 mg/kg of ABPP on day 0 only, and 3 groups of 3 animals 
recieved the same dose on day 0 and +1. Control animals recieved 
PBS. The tumors were enucleated and weighed on day +7. The effect 
of late administration of ABPP in the SRCA model was assessed 
using groups of 8 animals. ABPP was injected in a dose of 250 
mg/kg i.p. on day +6 and +7. Controls recieved PBS. The tumors 
were enucleated and weighed on day +13. In the liver metastasis 
model groups of 8 animals were used. 5 x 10 5 tumor cells were 
injected into the portal vein. In the first experiment 250 mg/kg 
of ABPP was administered i.p. on day 0 and +1, in the second 
experiment on· day +6 and +7. The number of liver metastases was 
counted on day +30. Controls animals recieved PBS i .p. on the 
same days. 
Statistical Analysis 
The results were analyzed by the Student t-test and the Wilcoxon 
rank sum test. 
RESULTS 
Assessment of direct cytotoxicity of ABPP 
No cytotoxic effect of any dose of ABPP against any of the 
various concentrations of CC531 cells was seen. The number of 
CC531 cells per well, counted on day +7, was virtually equal in 
all cases to the number of cells present in the respective con-
trol well. 
Early administration of ABPP in the Subrenal Capsule Assay 
Table I shows the response of CC531 to the administration of 
250 mg/kg of ABPP i.p. on day 0 and +1 in the SRCA in 2 separate 
experiments. A significant (p<0.02 - p<O.OOl) inhibition of tumor 
growth was observed in the ABPP treated animals. 
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Table I : Antitumor effect early administration of ABPP in SRCA 
Treatment Mean Tumor Weight (mg) ~ SD on day +7 
(1) PBS 35.5 
.:!: s.s 
ABPP 26.7 + 8.4 (p < 0.02) 
(2) PBS 24.8 
.:!: 6.2 
ABPP 12.8 
.:!: 5.8 (p < 0.001) 
In two separate experiments ( 1) and ( 2) ABPP was administered 
i.p. on day 0 and +1 in a dose of 250 mg/kg. Controls received 
PBS. The tumors were weighed on day +7. Each experimental group 
consisted of 5 animals (= 10 tumors). Tumor growth was signifi-
cantly inhibited by ABPP (p<0.02, p<0.001). 
Different doses of ABPP in the SRCA 
Table II shows the response of tumor CC531 to the 
administration of different doses of ABPP, when administered on 
day 0 only or on day 0 and +1, in the SRCA. Only when ABPP was 
administered in a dose of 250 mg/kg i.p. on day 0 and +1 a 
significant (p<0.03) inhibition of tumor growth was observed. 
Table II : Antitumor effect of different doses of ABPP in SRCA 
Treatment 
PBS 
ABPP on day 0 
Tumor Weight 2: SD 
24.3.:!: 6.7 
ABPP (50 mg/kg) 
ABPP (150 mg/kg) 
ABPP (250 mg/kg) 
24.9 + 10.1 NS 
31.0 + 6. 7 NS 
26.9.:!: 3.7 NS 
ABPP on day 0 and + 1 
Tumor Weight 2: SD 
55.8 + 12.2 
46.3 + 13.3 NS 
50.6 + 10.9 NS 
37.7.:!: 10.8 (p<0.03) 
ABPP was administered i.p. on day 0 only or on day 0 and +1 at a 
dose of 50, 150 or 250 mg/kg. Tumors were weighed on day +7. 
Controls received PBS. Each group consisted of 3 animals ( = 6 
tumors ) . Tumor growth was significantly inhibited only when ABPP 
was administered on day 0 and +1 at a dose of 250 mg/kg (p<0.03). 
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Late administration of ABPP in the SRCA 
Table III shows the response of tumor CC531 to the 
administration of 250 mg/kg of ABPP i.p. on day +6 and +7 in the 
SRCA. The tumors were enucleated and weighed on day +13. N.o 
effect on tumor growth was observed. 
Table III : Antitumor effect of late administration of ABPP in 
the SRCA 
Treatment Mean Tumor Weight ~ SD on day + 13 
PBS 67.4 + 35.8 
ABPP 55.9 + 26.4 NS 
ABPP (250 mg/kg} was administered i.p. on day +6 and +7. Controls 
recieved PBS. The tumors were weighed on day +13. Each group 
consisted of 8 animals ( = 16 tumors). No effect on tumor growth 
was observed. 
Early administration of ABPP in the liver metastasis model 
Table IV shows the response of tumor CC531 to the adminis-
tration of 250 mg/kg of ABPP i.p. on day 0 and +1 in the liver 
metastasis model. 5 x10 5 Cells were injected in the portal vein. 
Treatment was started the same day. A laparotomy was done on day 
+ 30 and the number of liver metastases was counted. One rat in 
the ABPP treated group died on day +2 due to a faulty injection 
on the previous day. In the ABPP treated group a highly signifi-
cant (p=0.002) lower number of liver metastases was observed on 
day + 30. 
The inhibition of the development of liver metastases after the 
early administration of ABPP was also reflected in a significant 
difference in survival between ABPP-treated animals and control 
animals. Median survival times were 46 days (range: 39-54) for 
the control group and 58 days (range: 47-64) for the ABPP treated 
group as depicted in Figure 1. This difference was statistically 
significant (p<0.01). 
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Table IV : Early administration of ABPP in liver metastasis model 
Treatment 
PBS 
ABPP 
Number of metastases 
on day + 30 
18, 22, 31, >40, 
>40, >40, >40, >40 
1, 2, 4, 7, 12, 15, >40 
Mean number + SD 
33.9 + 9.2 
11.5 ± 5.1 (p=0.002) 
ABPP treatment was started on the day of tumor inoculation. 250 
mg/kg of ABPP was administered i.p. on day 0 and +1. Controls 
received PBS. ABPP significantly inhibited the development of 
liver metastases (p=0.002) when counted on day + 30 
Figure 1 Early administration of ABPP prolongs the survival of 
rats with liver metastases of tumor CC531 
100r---------~-----------o e CONTROL J 
0 ABPP Pz < .01 
250 mg/kg 
0,+1 
80 
55 60 65 
DAYS 
Figure 1 : Survival times of rats, injected with 5 x 10 5 CC531 
tumor cells into the portal vein. 250 mg/kg of ABPP was given 
i.p. on day 0 and +1. Controls received PBS. There were 8 animals 
in the control group ( 1---1 ) and 7 in the ABPP treated group 
( 0---0). Differences in survival times were significant, p < 
0. 01. 
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Late administration of ABPP in the liver metastasis model 
Table V shows the response of tumor CC531 to the admini-
stration of 250 mg/kg of ABPP i.p. on day +6 and +7 in the liver 
metastasis model. The rats were killed on day +30 and the number 
of metastases was counted. A significantly ( p < 0. 0 2) higher 
number of metastases was observed in the ABPP treated animals. 
Table V : Late administration of ABPP in liver metastases model 
Treatment 
PBS 
ABPP 
Number of metastases 
on day + 30 
2, 3, 5, 5, 5, 7, 8 
6, 9, 9, 9, 10, 15, 25 
Mean Number + SD 
5.0 + 2.1 
11.9 + 6.4 (p<0.02) 
ABPP treatment was started 6 days after tumor inoculation. 250 
mg/kg of ABPP was administered on day +6 and +7. Controls receiv-
ed PBS. Each experimental group consisted of 7 animals. Late ABPP 
treatment significantly enhanced the development of liver meta-
stases (p<0.02). 
DISCUSSION 
The effect of ABPP on the weakly immunogenic adenocarcinoma 
of the colon , CC531, was studied. Since it was shown that ABPP 
exerts no direct cytotoxicity against CC531 cells, it can be 
assumed that the observed tumor inhibiting or enhancing effects 
are due to ABPP-induced changes of the hosts.immune status. When 
administered early (on day 0 and +1); ABPP, used in a dose of 250 
mg/kg, was shown to have a significant tumor growth inhibiting· 
effect in the subrenal capsule assay. Late administration of ABPP 
had no effect on tumor growth. The same response of tumor CC531 
was seen after treatment with RIFN (Marquet et al., 1984). The 
SRCA model may be considered to be comparable to the s.c. tumor 
growth model. Since inhibition of s. c. growth of a liposarcoma 
was found to depend most likely on induction of IFN by ABPP 
(Eggermont et al., 1986) the effect on CC531 in the SRCA is 
probably mediated by ABPP-induced IFN as well. In the liver 
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metastasis model early administration of ABPP was also highly 
effective. The observed inhibition of the development of liver 
metastases is probably mediated the enhancement of NK cell activ-
ity.- ABPP is a very potent and very rapid activator of NK cell 
cytotoxicity (Lotzova et al., 1983), and NK cells aJ;"e known to be 
most effective against circulating tumor emboli (Riccardi et al., 
1979; Hanna and Fidler, 1980). In our on lung metastases with 
the liposarcoma in BN rats the inhibition of lung metastases of a 
liposarcoma in rats treated with ABPP was found to depend most 
likely on enhanced NK cell activity and to be independent of 
induction of IFN (Eggermont et al., 1984). The most striking 
result of our experiments is the enhancement of liver metastases 
after late administration of ABPP. Numerous reports in the liter-
ature on a dual outcome of immunotherapy have been related to: 
(1) timing (Vaage, 1980), (2) dose (Ishibashi et al., 1978), (3) 
route of administration (Proctor et al., 1976), ( 4) tumor site 
(Ryd et al., 1979) and (5) manipulation of the tumor (Col-merauer 
et al., 1980). Host factors rather than direct effects of the 
agents are considered to determine the dual outcome. Similarly 
liver-specific immunological components may explain the dis-
crepant effects of early and late administration of ABPP in the 
liver metastasis model. When ABPP was administrated late, the 
tumor cells had ample time to colonize the liver. Local factors 
may explain the enhancement of tumor growth, observed after the 
late administration of ABPP. Kupffer cells may play an important 
role si~ce they may have rapidly degraded tumor-associated anti-
gens, just like their activation can lead to prolonged graft sur-
vival of allogeneic organ transplants (Sakai, 1970) or opsonise 
and clear antigen reactive cells as described by Hutchinson 
"( 1980). Both mechanisms could facilitate tumor growth. Enhance-
ment of Kupffer cell activity in rats, caused by tumor challenge, 
has been reported by Antikatzides and Saba (1977). It reaches its 
peak level after 6 days. If ABPP enhances the activity of Kupffer 
cells as does IFN (Huang, 1980) peak level activity may have been 
prolonged and may have led to the enhanced development of the 
liver metastases. When ABPP is administered early, the activation 
of Kupffer cells, wich may lead to a suppression of anti tumor 
activity as described above by increased clearance of tumor 
antigens or antigen reactive T cells, is of no consequence since 
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the tumor cells have been adequately dealt with in the blood born 
and early lodging phase by activated NK cells. This would explain 
the observed inhibition of the development of liver metastases 
after early administration and the enhanced develop-ment after 
late administration of ABPP. An alternative or additi-ve 
explanation of enhanced development of liver metastases hinges on 
the role of suppressor T cells. Numerous publications, review-ed 
by Schatten et al. (1984), have established that animals bearing 
progressive tumors acquire suppressor T cells. Although mainly 
localized in the spleen they can develop in and be recruited by 
the. liver so that one can speak of a splenohepatic suppressor 
axis (Vuitton et al., 1977) .. If ABPP stimulates suppressor T cell 
function in a similar fashion as can be seen after the 
administration of interferon-alpha (Schnaper et al., 1983), the 
observed enhancement of tumor development in the liver as a 
preferential suppressor T cell containing organ can be explained 
as well as the lack of ·enhancement observed in the SRCA model . 
Recent evidence for a special role of Kupffer cells has been 
provided by Okumura and coworker (1987). They showed that Kupffer 
cells can suppress NK cell activity athrough the production of 
prostaglandins and 
facilitated tumor 
experiments. 
thus provide a good 
growth in the liver 
explanation 
as observed 
for 
in 
the 
our 
In conclusion: it has been demonstrated that ABPP can inhibit and 
enhance the growth of colon cancer CC531 in WAG rats. The outcome 
of treatment depends on timing of the administration of the drug 
and on tumor site-specific host factors. These findings may have 
serious implications for the design of clinical studies with 
ABPP. 
CHAPTER V 
The content is an adapted compilation of the publications : 
Efficacy of treatment with ABPP and recombinant gamma-Interferon 
on colon cancer in rats depends on tumor site, tumor load and 
treatment schedule 
Alexander M. M. Eggerrnont, Richard L. Marquet, Ron W. F. de Bruin 
and Johannes Jeekel 
From the Laboratory for Experimental Surgery, Erasmus University, 
Rotterdam, the Netherlands 
Surgical Forum 37:342-344, 1986 
Combined treatment of colon adenocarcinoma in rats with Tumor 
Necrosis Factor (TNF) and the Interferon-inducer ABPP 
Richard L. Marquet, Alexander M. M. Eggerrnont, Ron W. F. de 
Bruin, Walter Fiers and Johannes·Jeekel 
From the Laboratory for Experimental Surgery, Erasmus University, 
Rotterdam, the Netherlands 
Cancer Prevention and Detection (in press, 1987) 
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Efficacy of combined treatment of colon adenocarcinoma in rats 
with the interferon-inducer ABPP and recombinant Rat Interferon-
ganuna (rRIFN-ganuna) or recombinant Murine Tumor Necrosis Factor 
(rMuTNF). 
Summary 
We have previously shown that the early administration (day 
0, 1) of the interferon (type I) inducer ABPP has significant 
antitumor activity against the colon adenocarcinoma CC531 in rats 
in the subrenal capsule assay (SRCA). The late administration 
(day 6, 7) of ABPP never resulted in a significant inhibition of 
tumor growth. Synergistic antitumor activity of combinations of 
Type I and Type II interferons in vitro as well as in vivo has 
been reported in the literature. Likewise synergistic antitumor 
activity has been described when Interferons (especially IFN-
gamma) was used in combination with Tumor Necrosis Factor (TNF). 
We investigated whether the administration of recombinant rat 
interferon-gamma (rRIFN-gamma) synergized with in vivo ABPP-
induced endogenous IFN-alpha in the SRCA tumor model. The early 
administration of ABPP had a significant antitumor effect in all 
experiments. The late administration of ABPP never reduced tumor 
growth significantly. rRIFN-gamma alone never had a significant 
antitumor effect. When given in combination with the early ad-
ministration of ABPP no additional antitumor effect was seen. 
When the administration of rRIFN-gamma preceded the late ad-
ministration of ABPP a significant inhibition of tumor growth, 
and therefore a synergistic antitumor effect was observed. 
Secondly we investigated the potential efficacy of the combined 
treatment with ABPP and recombinant murine tumor necrosis factor 
(rMuTNF) in the SRCA. In these experiments the administration of 
rMuTNF on day 0, 2 and 4 always led to a significant reduction of 
tumor growth. When administered in combination with ABPP an 
additive antitumor effect was seen. These experiments indicate 
that va-rious biologicals can be succesfully used in combination. 
This may lead to dose reductions of each agent and thus deminish 
toxicity. Furthermore timing and proper sequencing of treatment 
appeared crucial and illustrates the need for further research in 
order to design optimal combination treatment schedules. 
INTRODUCTION 
With regard to the biological activities of interferon (IFN) 
alpha and beta (type I) and IFN-gamma (type II) differences have 
been observed with respect to the sensitivity of cell lines 
(Blalock et al., 1980) and viruses (Rubin and Gupta, 1980) to the 
various IFNs. In vitro and in vivo studies have shown that Type 
I and Type II IFNs can potentiate each other in terms of their 
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antiviral (Fleischman et al., 1979) and anticellular (Fleischman 
et al., 1980) activities. The molecular mechanism of action of 
IFN-gamma may be different from the other IFNs (Dianzani et al., 
1980), which may be the basis for the reported synergistic activ-
ity. We have previously shown that the early administration of 
the interferon (IFN) inducing pyrimidinone ABPP has antitumor 
effect in vivo against a colon adenocarcinoma in the subrenal 
capsule assay ( SRCA) and in a liver metastasis model in rats 
(Eggermont et al., 1986b). When treatment was started one week 
after tumor inoculation however no antitumor effect was seen in 
the SRCA and a detrimental effect in the liver metastasis model 
was observed. In order to find a way to use ABPP effectively in 
the advanced or established tumor setting we investigated the 
possible role of IFN-gamma and developed a treatment schedule 
with synergistic antitumor activity. 
Similarly we investigated the possible benefits of combined 
treatment with ABPP and tumor necrosis factor (TNF). Tumor 
necrosis factor is a protein produced mainly by activated mono-
cytes and probably also by activated natural killer (NK) cells. 
It was originally demonstrated in the serum of animals treated 
with BCG and endotoxin (Carswell et al., 1970). Tumor necrosis 
factor has been functionally defined by its cytostatic and cyto-
lytic properties to some tumor cell lines in vitro and has the 
capacity to induce necrosis of solid transplantable tumors in 
mice (Old, 1985). Its mechanism of action is still largely un-
known. There is evidence that inactivation or destruction of 
protein-dependent cellular function is important (Ruff and Gif-
ford, 1981); that TNF may need to be internalized and that lyzo-
somal activity may be required for cell killing (Kull and Cuatre-
casas, 1981); but also that components of the cell membrane may 
be the primary targets of TNF (Darzynkiewicz et al., 1984). In 
vitro synergistic anticell~lar activity when TNF is combined with 
IFNs, especially with IFN-gamma, has been reported (Williamson et 
al., 1981; Sugarman et al., 1985). Balkwill and coworkers (1986) 
reported recently on the synergistic antitumor effects observed 
in vivo when human xenografts in nude mice were treated with 
exogenous IFN-alpha or -gamma in combination with TNF. This 
suggests that at least in part the cytotoxic effects of IFNs and 
TNF are attained by different pathways. The possibly potenti-
47 
ating antitumor effect of ABPP-induced endogenous interferon 
(type I) and exogenous TNF was investigated. We will demonstrate 
in this communication that such an effect could be obtained. 
MATERIAL AND METHODS 
Rats 
Male rats of the inbred WAG/Ro strain were used. The animals were 
bred under pathogen free conditions and were 10-12 weeks old. 
Tumor 
Characteristics of the weakly immunogenic adenocarcinoma of the 
colon CC531 in WAG/Ro rats were described in chapter IV. 
Subrenal capsule assay (SRCA) 
The subrenal capsule assay was described in chapter IV. 
Agents 
ABPP was administered i.p. in all experiments at a dose of 250 
mg/kg dissolved in 1 ml _phosphate buffered saline (PBS). ABPP 
was given either "early" (day 0 and +1) or "late" (day 6 and 7). 
rRIFN-gamma 
Recombinant Rat IFN-gamma was a gift from dr. P. van der Meide, 
Primate Center TNO, Rijswijk, the Netherlands. Details of cloning 
, expression and purification of rRIFN-gamma have been published 
by Dykema et al. (1985). The preparation contained 10 6 antiviral 
units per mg protein and had a purity of 25%. In an earlier 
communication we have reported on the antiproliferative and immu-
nomodulating properties of rRIFN-gamma (IJzermans et al., 1985). 
rRIFN-gamma was administered either i.p. by means of an implant-
able osmotic pump (Alzet) to deliver 10 6 units in 7 days or by 
intravenous (i.v.) injections of 2 x 10 5 units daily for 5 days. 
rMuTNF 
Recombinant murine tumor necrosis factor was a gift from Dr. w. 
Fiers, Laboratory of Molecular Biology, State University of 
Ghent, Belgium. Details of cloning, expression and purification 
of rMuTNF have been published elsewhere (Fransen et al., 1985). 
The preparation used was 99 % pure and contained 72 x 10 6 units 
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per mg protein. rMuTNFR was administered on days 0, 2 and 4 i.v. 
at a dose of 1 ug. 
Statistical Analysis 
The results were analyzed using the Student-t test. In all 
experiments the experimental groups consisted of at least 8 
animals. 
RESULTS 
Early administration of ABPP in combination with rRIFN-gamma 
In all SRCA experiments the early administration of ABPP 
inhibited tumor growth significantly (p < 0.01) whereas the 
administration of rRIFN-gamma i.p. by osmotic pump (experiment 1) 
and i.v. (experiment 2) had no effects at all. Combined treat-
ment was not superior to treatment with ABPP alone. The results 
are summarized in Table I. 
Table I : Anti tumor effect of simultaneous early administration 
of ABPP and rRIFN-gamma in the SRCA 
Treatment Mean Tumor Weight + SEM on day + 7 
Experiment 1 
PBS 
rRIFN-gamma 
ABPP 
ABPP + rRIFN-gamma 
Experiment 2 
PBS 
rRIFN-gamma 
ABPP 
ABPP + rRIFN-gamma 
36.4 + 1.9 mg 
37.7 + 2.4 mg 
26.7 + 2.7 mg 
25.7 + 2.7 mg 
-----------------------------
27.7 + 1.9 mg 
26.8 + 2.1 mg 
13.9 + 1.6 mg 
14.7 + 2.7 mg 
p < 0.01 
p < 0.01 
p < 0.0001 
p < 0.001 
experiment l:rRIFN-gamma 10 6 units, ip, via osmotic pump day 0-6 
experiment 2:rRIFN-gamma 2 x 10 5 units, iv, daily on day 0-5 
SEM = standard error of the mean. N = 8 
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Late administration of ABPP preceded by rRIFN-gamma 
When ABPP was administered on day 6 and 7 no significant 
inhibition of tumor growth was observed. The daily administration 
of 2 x 10s units of rRIFN-garnma on day 0-5 had no antitumor 
effect by itself but the combined treatment with ABPP had 
significant antitumor effect (p < 0. 03). 
depicted in Figure 1. 
This experiment is 
Figure 1 
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Figure 1 : In the SRCA, groups of at least 8 rats were treated 
either with phosphate buffered saline (PBS); rRIFN-gamma 2 x 10s 
units for five days ((0-5) i.v.; ABPP 250 mg/kg i.p. on day 6+7; 
or ABPP on day 6 and 7 preceded by rRIFN-gamma i.v. from day 0-5. 
On day 13 the tumors were enucleated and weighed. Single agent 
treatment was ineffective. Combination treatment with rRIFN-
gamma preceding the late administration of ABPP had-significant 
antitumor effect (P < 0.03). SEM =standard error of the mean. 
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Combined treatment with ABPP and rMuTNF 
In two consecutive experiments early administration of ABPP 
led to a significant inhibition of tumor growth as measured on 
day 7 (P < 0.001). Administration of rMuTNF (1 ug) on day 0, 2 
and 4 also had a significant antitumor effect (p < 0.01) A addi-
tive antitumor effect was observed when the combined treatment 
schedule was administered (p < 0. 0001). 
experiments are summarized in Table II. 
The results of these 
Table II Antitumor Effects of Combined Treatment with ABPP and 
rMuTNF in the SRCA 
Treatment 
Experiment 1 
PBS 
ABPP 
TNF 
ABPP + TNF 
Experiment 2 
PBS 
ABPP 
TNF 
ABPP + TNF 
Mean Tumor Weight ~ SEM on day +7 
42 ~ 3.1 mg 
26 ~ 1.9 mg p < 0.001 
24 ~ 2.1 mg p < 0.001 
13 + 2.2 mg p < 0.0001 
----------------------------
38 + 2.7 mg 
21 ~ 1.6 mg p < 0.001 
27 ~ 2.2 mg p < 0.01 
14 + 2.2 mg p < 0.0001 
experiment 1: ABPP+TNF vs ABPP: p<0.01; ABPP+TNF vs TNF: p<0.01 
experiment 2: ABPP+TNF vs ABPP: p<0.03; ABPP+TNF vs TNF: p<O.OOl 
SEM = standard error of the mean. N = 8 
DISCUSSION 
We have shown that synergistic or additive antitumor effects 
can be achieved by combining the administrat·ion of the interferon 
inducer ABPP with rRIFN-gamma or rMuTNF in the treatment of colon 
cancer CCS3i in WAG rats. Early administration of ABPP had signi-
ficant antitumor activity in all 4 experiments. Simultaneous ad-
ministration of rRIFN-gamma never added to the antitumor effect. 
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This lack of in vivo antitumor effect of rRIFN-gamma is in line 
with previously published observations from our laboratory on the 
lack of in vivo antitumor activity against a nonimmunogenic lipo-
sarcoma in BN rats, in spite of proof of good activation in vitro 
of NK cells and macrophages (IJzermans et al., 1985). Only when 
rRIFN-gamma was used as a "primer", preceding the late adminis-
tration of ABPP, this sequential treatment schedule inhi):>i ted 
tumor growth significantly, while neither ABPP nor rRIFN-gamma 
agent alone was effective. This synergistic antitumor effect may 
be due to an upregulation of the expression of interferon type I 
receptors by IFN-gamma. When IFN-gamma precedes treatment with 
ABPP maximal expression of Type I IFN receptors may render tumor 
cells more sensitive to the ABPP-induced endogenous IFN-alpha and 
explain the observed synergism. The lack of an additive or syner-
gistic antitumor effect when ABPP is administered early and IFN-
gamma simultaneously may be due to (i) inhibition by compe-
tition with rRIFN-gamma for IFN-gamma receptors by the rapidly 
ABPP-induced endogenous IFN-alpha (Anderson et al., 1982) thus 
preventing the upregulating effects of IFN-gamma ; (ii) the fact 
that peak levels of ABPP-induced endogenous IFN-alpha are "short 
lived" (< 24 hours; Oku et al., 1984) and the upregulating effect 
of IFN-gamma may be too slow for the two effects to coincide and 
provide the opportunity for synergistic activity. It is notewor-
thy that Chapekar and Glazer (1985) reported similar observations 
in experiments assessing the anticellular activity of the combi-
nation of human riFN-gamma and Poly( I) .Poly(C) against human 
colon cancer cells in vitro. Only when IFN-gamma preceded treat-
ment with Poly(I).Poly(C) a highly synergistic antiproliferative 
effect was observed in their experiments. Of interest are also 
the reports on the priming effect of IFN-gamma on the subsequent 
induction of cytotoxicity of macrophages by a variety of biolog-
ical response modifiers derived from microorganisms (Nagao et 
al., 1986) or by muramyl dipeptide analog (Utsugi and Sane, 
1986). 
The additive antitumor effect of the combined treatment with ABPP 
and rMuTNF in the SRCA is comparable to the efficacy of the com-
bination of rRIFN-gamma and rMuTNF in the same tumor model (Mar-
quet et al., 1987 in press). This is of importance since .TNF was 
shown to be quite toxic in that communication and combination 
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treatment schedules may render non-toxic doses of each agent 
effective. IFN-gamma has been shown to augment the cytotoxic 
activity of TNF in vitro (Williamsen et al., 1983; Sugarman et 
al., 1985; Fransen et al., 1986). There is no evidence that ABPP 
induces IFN-gamma. We have never been able to demonstrate in vivo 
induction of class II antigens, a hall mark of IFN-gamma activity 
as previously reported by IJzermans et al. (1986), after the ad-
ministration of ABPP (Marguet, unpublished observations). Appar-
ently IFN-alpha can also augment the antitumor effects of TNF 
(Balkwill et al., 1986). It has recently been demonstrated that 
IFN-gamma, but also IFN-alpha/beta, albeit to a lesser degree, 
enhance the expression of cellular s1;1rface receptors for TNF on 
several tumor cell lines (Tsujimoto et al., 1986a). These data 
seemed to suggest a causal relation::;hip between enhanced TNF 
binding and increased cytotoxicity in IFN-treated cells. In an 
elegant study however, demonstrating the differential effects of 
Type I IFN and IFN-gamma on the binding of TNF to receptors in 
different human cell lines, Tsujimoto. and coworkers (1986b) 
showed that these two classes of IFN can have opposite e_ffects on 
the expression of TNF receptors and yet may both act synergistic-
ally with TNF in causing cytolysis. Therefore TNF receptor modul-
ation by IFNs was not considered a major mechanism of synergism 
between IFN and TNF. 
The experiments we have presented in this communication illustra-
te that the different mechanisms by which different biologicals 
exert t~eir antitumor effects can be exploited by obtaining addi-
tive or even synergistic antitumor effects by administering com-
bined treatment schedules. Further research in this field is 
warrented and may have clinical consequences in the forseeable 
future. 
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In vivo generation of lymphokine activated killer cell activity 
by ABPP and Interleukin-2 and their antitumor effects against 
immunogenic and nonimmunogenic tumors in murine tumor models 
Alexander M. M. Eggermont, Paul H. Sugarbaker, 
Richard L. Marquet and Johannes Jeekel 
Summary 
The capacity of the interferon inducer ABPP and recombinant 
interleukin-2 (IL-2) to generate lymphokine activated killer 
(LAK) cell activity in vivo was examined and compared to the 
cytolysis of fresh tumor cells by in vitro generated LAK cells. 
Various tumors differing in h'istology and immunogenicity were 
used in in vitro and in vivo experiments. The intraperitoneal 
administration of ABPP or IL-2 generated much higher levels of 
LAK cell activity in the peritoneal exudate than in the spleen. 
Administration of 2 injections of ABPP was as effective as a 
three day course of moderate doses of IL-2. Generation of LAK 
cell activity by IL-2 was dose dependent. Enormous numbers of 
highly lytic LAK cells were generated in the peritoneal exudate 
by high but toxic doses of IL-2. Attempts to increase in vitro 
generation of LAK cells by pretreatment of spleen donors with 
ABPP were unsuccessful. ABPP was effective against day 1 tumor 
but ineffective against established (day 3) tumor or advanced 
(day 8) tumor. Treatment of established tumor with IL-2 and LAK 
cells was not more effective when ABPP was given concurrently. In 
contrast when ABPP preceded IL-2 and LAK treatment an additional 
antitumor effect was seen. Immunogenic tumors were somewhat more 
sensitive to treatment with ABPP than nonimmunogenic tumors. Only 
a marginal difference in lysability in vitro existed. The 
antitumor effects of ABPP in vivo may therefore be mediated by 
other mechanisms than cytolysis by activated killer cells alone. 
These data taken together suggest that ABPP and IL-2 effects 
induce discernable levels of LAK cell activity, but do not 
synergize when combined. 
INTRODUCTION 
ABPP (2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone) is a small 
molecule biological that induces high levels of endogenous inter-
feron type I and modulates a variety of immune responses (Hamil-
ton et al., 1982; Stringfellow, 1981). Most previous reports have 
focused on the activation of natural killer (NK) cells and macro-
phages (Fast et al., 1982; Li et al., 1985; Lotzova et al.,1983; 
1984 and 1986). We investigated the ability of ABPP to generate 
lymphokine activated killer (LAK) cell activity in vivo. LAK cell 
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activity has been defined as the capacity of activated lymphoid 
cells to kill fresh tumor cells in short term 51Chromium release 
assays (Rosenberg, 1984; Rosenstein et al., 1984). The availabil-
ity of large quantities of recombinant interleukin-2 (IL-2) has 
caused a renewed interest in immunothe.rapeutic research programs. 
Its use alone and in combination with adoptively transferred LAK 
cells has shown great promise in animal models (Lafreniere and 
Rosenberg, 1985; Mule et al., 1984; Ottow et al., 1987a and b; 
Rosenberg et al., 1985a) as well as in humans (Rosenberg et al., 
1985b and 1987). 
In order to evaluate the potential of ABPP as an immunotherapeut-
ic agent we felt it appropriate to assess its capacity to induce 
LAK ce.ll activity in vivo in comparison to IL-2 and to assess the 
potential benefit of combination treatment with these two biolog-
icals. 
MATERIAL AND METHODS 
Mice 
C57BL/6 (BL/6) female mice were obtained from Jackson Laboratory 
(Bar Harbor, ME) and used when 9-12 weeks old. They-were main-
tained on laboratory chow and acidified water ad libitum in a 
pathogen free environment. 
Tumors 
The MCA-101, -102, -105 and -106 sarcomas, the MCA-38 colon 
adenocarcinoma and the B16 melanoma used in these experiments are 
syngeneic to BL/6 mice. MCA-101, -102, -105 and -106 sarcomas 
were induced in our laboratory by the intramuscular injection of 
0.1 ml of 1% 3-methycholanthrene (MCA) in sesame oil as described 
previously (Parker and Rosenberg, 1977). A large number of vials 
of MCA-101, -102, -105, and -106 sarcomas from the first passage 
generation were cryopreserved. After thawing, these tumors were 
passaged subcutaneously (s.c.) in C57BL/6 mice and were used 
within the first six transplant generations. The MCA-105 and -106 
tumors are weakly immunogenic and the MCA-101 and -102 tumors are 
nonimmunogenic (Papa et al., 1986). MCA-38 is a weakly immuno-
genic murine colon adenocarcinoma that was induced by the s. c. 
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injection of dimethylhydrazine (DMH) in C57BL/6 mice. This tumor 
was passaged s.c. and its use was not restricted to early passage 
generations. Cryopreserved cells from the nonirnrnunogenic natural 
killer-resistant B16 melanoma tumor line of C57/BL6 origin (Fid-
ler, 1973) were used, thawed, placed i'n tissue culture and subse-
quently used for s.c. passage in BL/6 mice. Single cell suspen-
sions of all tumors used were prepared as described· previously 
(Mule et al., 1984). Briefly, fresh tumors were excised, minced 
with scissors and stirred in a triple enzyme solution of deoxyri-
bonuclease, hyaluronidase and collagenase (Sigma Chemical Co., 
St. Louis, MO) for three hours at room temperature, filtered 
through 100 gauge nylon mesh (Nitex; Lawshe Industrial Co., 
Bethesda , MD), washed three times in Hanks balanced salt solu-
tion (HBSS; Biofluids, Rockville, MD) without calcium (Ca2+) and 
magnesium (Mg2+) and resuspended in HBSS or complete medium at 
the appropriate cell concentration for injection or in vitro 
assays. 
Interleukin-2 
Recombinant human interleukin-2 (IL-2) was kindly supplied by the 
Cetus Corporation (Emeryville, CA) (Rosenberg et al 1985a) and 
had a specific activity of 4 to 8 x 10 6 units/mg. IL-2 activity 
was measured by a standard bioassay as described previously 
(Donahue and Rosenberg, 1983). It was used for the preparation of 
LAK cells and for i.p. administration. 
ABPP 
ABPP was given at a dose of 250 mg/kg i .p., dissolved in 1 ml 
phosphate buffered saline (PBS)in all experiments. 
Generation of LAK cells in vitro 
LAK cells were generated as described previously (Mule et al., 
1984). Briefly BL/6 spleens were harvested aseptically and mashed 
in HBSS with the hub of a syringe and passed through a 100 gauge 
nylon mesh to produce a single cell suspension. Erythrocytes were 
lysed osmotically with ACK buffer (Media Unit, NIH, Bethesda, 
MD) . The remaining splenocytes were washed three times in HBSS 
and 5 x 10 8 cells were incubated in 750 ml culture flasks (Fal-
con, Oxnard, CA) containing 175 ml of complete medium and 175,000 
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units of IL-2 per flask. Complete medium (CM) contained RPM! 1640 
with 10% fetal calf serum (FCS) (both Biofluids, Rockville, MD), 
0,3% fresh glutamine, 100 ug/rnl of streptomycin, 100 units/rnl 
penicillin (all from the NIH Media Unit), 0.1 rnM non-essential 
amino acids, 0.1 rnM sodium pyruvate (all from Gibco Laboratories, 
Grand Island, NY), 5 x 10-s M 2-rnercapto-ethanol (Aldridge Chemi-
cal Co., Milwaukee, WI), 50 ug/rnl gentamicin (Shearing, Henil-
worth, NJ), and 0.5 ug/rnl of fungizone (Flow Labs, McLean, VA). 
The flasks were incubated for 72 hours at 37°C in a moist atmo-
sphere with 5% C02. The LAK cells were then harvested, passed 
over Ficoll (Lyrnpholyte-M, Cedarlane Laboratories, Hornby, Onta-
rio, Canada) to remove dead cells, washed three times is HBSS and 
resuspended in CM1 for in vitro assays or in HBSS for i.p. inject-
ions. 
51Chromium release cytotoxicity assay 
Spleens and peritoneal exudate cells were harvested from mice 
pretreated with HBSS, IL-2 or ABPP and were passed through a 100 
gauge nylon mesh, the erythrocytes lysed with ACK buffer, and the 
remaining lymphocytes pooled and washed three times with HBSS and 
resuspended in CM at 1 x 10 7 cells/rnl. Target cells were prepared 
by incubating one milliliter of one of the various fresh tumor 
cell suspensions (5 x 10 7 cells/rnl) with s 1 Cr (specific activity 
250-2500 rnci/rng) for 30 minutes. The labeled cells were washed 
three times and resuspended in CM at 1 x 10s cells/rnl. 0.1 rnl of 
labeled tumor cells and 0.1 rnl of effector cells were incubated 
in plates of 96 round bottom wels (Linbro Chemical Co., Harnden, 
CT). Each well contained 10 4 labeled targets and various numbers 
of effector cells. After an incubation of 4 hours, supernatants 
were harvested employing the Titertek collecting system (Flow 
Laboratories, Inc., McLean, VA). The percentage of specific lysis 
was calculated as follows: (experimental cprn - spontaneous cprn) I 
(maximal cprn - spontaneous crnp) x 100. Spontaneous cprn was the 
amount of s 1 Cr released from the targets in the absence of ef-
fectors. 
Tumor models 
In the intraperitoneal tumor model BL/6 mice received 1 x 10s 
MCA-105 tumor cells i .p. and were randomly allocated into a 
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treatment group. ABPP was administered at a dose of 250 mg/kg in 
1 ml PBS i. p. unless noted otherwise. Several administration 
schedules were applied as is specified in the Results section. 
Interleukin-2 was also given i.p. at various doses depending on 
experimental design. In the experiments involving the adminis-
tration of LAK cells and IL-2, 1 x 10 8 LAK cells were given i.p. 
three days after tumor inoculation and from day 3 through 7 
10,000 units of IL-2 were administered i.p. twice a day (b.i.d.). 
Animals not receiving LAK cells and/or IL-2 were injected with 
identical volumes of HBSS. About 14 days after the i.p. inocula-
tion of MCA-1 05 the animals were sacrified and the i. p. tumor 
mass scored in a blinded fashion on a scale from 0 - 3. The score 
was termed the Peritoneal Cancer Index (PC!) (Steller et al. , 
1985; Ottow et al., 1987a). The mice were ear-tagged and their 
numbers recorded prior to scoring. The abdomen of all mice was 
opened widely and scored for tumor load and mice of similar score 
were placed in the appropriate groups of a PCI of 0, 1, 2 or 3. A 
score of 0 is defined as no i.p. tumor, 1 as 2 3 pin point tumor 
foci (diameter 2 1 mm), 2 as moderate tumor and 3 as abundant 
i. p. tumor load replacing most of the peritoneal cavity. The 
peritoneal cancer index scoring system is illustrated in Figure 
1. After all mice were scored the ear tag was read and the data 
were analyzed. Experimental groups in the i.p. tumor experiments 
consisted of at least 6 mice. 
In the pulmonary metastasis model BL/6 mice received 3 x 10 5 
syngeneic tumor cells (MCA-102, -105 or -38) intravenously sus-
pended in 1 ml HBSS by way of the lateral tail vein. In two ex-
periments the mice were followed for survival. In one experiment 
the mice were sacrificed after each treatment group was given a_ 
letter code. The lungs of the mice were inflated with a 15% 
solution of· india ink for enumeration of metastatic ·pulmonary 
nodules (Wexler et al., 1966). Metastases are readily countable 
when "bleached" by Fekette's solution up to ~ 250. Lungs with 
metastases too numerou~ to count were therefore assigned an arbi-
trary value of 250 as described previously by Mule et al. (1984). 
Statistical Analysis 
Overall significance of difference in the intraperitoneal tumor 
experiments was examined with the Jonckheere test for trend (Hol-
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lander and Wolfe, 1973). If this test showed a two sided p value 
( P2) < 0. 05, pairwise comparisons of differences in tumor load 
were examined with the Wilcoxon rank sum test with a correction 
for ties. Significance of differences in the numbers of pulmonary 
metastases or differences in survival between groups was deter-
mined by the Wilcoxon rank sum test (Gehan, 1965). Two-sided p-
values are presented in all experiments. 
Figure 1 The Peritoneal Cancer Index 
PERITONEAL CANCER INDEX 
Figure 1 : The Peritoneal Cancer Index (PCI) Scoring System 
Intraperitoneal tumor load is scored on a ,scale from 0 - 3 
0 =no i.p. tumor; 1 = ~ 3 pin point foci ( diameter~ 1 mm); 
2 = moderate i.p. tumor; 3 = abundant i.p. tumor replacing most 
of the intraperitoneal cavity. In this particular experiment the 
melanoma Bl6 was used. Small tumor foci are indicated by the 
black arrows. 
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RESULTS 
In vitro cytolysis of NK-sensitive and NK-resistant tumor cells 
by in vivo ABPP-activated spleen cells 
BL/6 mice received 250 mg/kg of ABPP in PBS i.p. on day -3 
and -2. On day 0 their spleens were harvested. The enhancement of 
NK cell activity (Yae-l targets) as well as the generation of LAK 
cell activity (fresh NK resistant tumor targets) by ABPP were 
assessed in s~chromium release assays. Tumors differing in histo-
logy (sarcomas, adenocarcinoma, melanoma) and in immunogenicity 
were used in order to determine the general nature of the cyto-
toxicity of the ABPP-activated lymphocytes. For comparison· the 
cytotoxicity of in vitro generated LAK cells was determined in 
the same assays as well as the cytotoxicity displayed by spleno-
cytes from control animals that had received PBS. The results are 
shown in Figure 2. Both NK cell activity and LAK cell activity 
induced by ABPP in the spleen was very poor. The immunogenic 
tumors ~MCA-105, -106, and -38) seemed somewhat more easily lysed 
by ABPP-activated killer cells than the nonimmunogenic tumors 
(MCA-101, -102, and Bl6). This difference was marginal. Even at a 
100:1 effector to target ratio specific lysis did not exceed 30%. 
The in vivo generation of LAK cell activity in the spleen by ABPP 
was clearly inferior to the in vitro generation of LAK cells by 
incubation of splenocytes in IL-2 for 3 days. 
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Figure 2 Induction of LAK cell activity in splenocytes by ABPP 
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Figure 2 (top, middle, bottom) t'he capacity of splenocytes 
(SPL) to lyse the NK cell sensitive YAC-1 target (top); the NK 
resistant weakly immunogenic fresh tumor cells (LAK-targets) MCA-
105,-106, and -38 (middle); and the NK resistant (LAK targets) 
nonimmunogenic fresh tumor cells MCA-101, -102 and Bl6 (bottom); 
were assessed in 4 hour 51Chromium release assays. For comparison 
cytotoxicity of in vitro generated LAK cells is shown (X---X). 
Comparison of in vivo generation of LAK cell activity in the 
peritoneal exudate and the spleen by ABPP and IL-2 
BL/6 mice received 100,000 (lOOK) or 10,000 (lOK) units of 
IL-2 i.p., b.i.d., for three consecutive days (day -3, -2, -1) or 
were pretreated with 250 mg/kg of ABPP i.p. on day -3 and -2. 
Control animals received 1 ml of PBS i.p. only. On day 0 spleens 
and peritoneal exudate cells were harvested and their cytotoxi-
city against the fresh tumor cells (LAK-targets) MCA-105 (immuno-
genic) and MCA~l02 (nonimmunogenic) and against the cell line NK 
sensitive YAC-1 cells was determined. As a positive control in 
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vitro generated LAK cells were used as is shown in Figure 3. 
The in vivo generation of LAK cell activity was consistently 
higher in the peritoneal exudate than in the spleens after the 
administration of either ABPP or IL-2. The level of cytotoxicity 
generated by two i.p. injections of ABPP was comparable to the 
level generated by the i.p. administration of 10,000 units of IL-
2, twice a day, for three consecutive days. 
Figure 3 (top, middle , bottom) 
In vivo induction of activated NK cell (Yae-l) and LAK cell (MCA-
105, MCA-102) activity in the spleen and in the peritoneal exuda-
te by ABPP and low or high doses of IL-2. 
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Figure 3 : BL/6 mice received either 250 mg/kg of ABPP i.p. on 
day -3 and -2 or a three day course of 10 1 000 (lOK) or 100 1 000 ( 10 OK) units of IL- 2 i. p. 1 b. i. d. The cytotoxicity of spleno-
cytes (SPL) and peritoneal exudate cells (PEC) against YAC-1 
(top) 1 MCA-105 (middle) and MCA-102 (bottom) tumor cells was 
assessed in 4 hour s~cr release assays on day 0 and compared with 
the cytotoxicity displayed by ih vitro generated LAK cells. The 
generation of activated killer cells in the peritoneal exudate 
was clearly more effective than in the spleen. The IL-2 effect 
was dose dependent and the in vivo generation of LAK cell activ-
ity by high doses of IL-2 (0---0) was even more effective than 
the standard in vitro generation of LAK cell activity (X---X). 
In vivo generation of LAK cell activity by IL-2 is dose dependent 
High doses of IL-2 i.p. generated much higher levels of LAK cell 
activity in both the spleen and the peritoneal exudate than low 
doses. This is also illustrated in Figure 3. After 3 days of i.p. 
administration of 100 1 000 (lOOK) units of IL-2 1 b.i.d. 1 the LAK 
cell activity in the peritoneal exudate was very high and even 
superior to in vitro generated LAK cell activity. 
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Generation of LAK cells in vitro after pretreatment of spleen 
donors with ABPP in vivo 
BL/ 6 mice received 25 0 mg /kg of ABPP 1 i. p. 1 3 and 2 days 
prior to splenectomy for LAK cell generation in vitro. Cytolysis 
of fresh tumor cells (MCA-105 1 -102 and -38) by these LAK cells 
was compared to the cytolysis seen with standard LAK cells. 
Similar levels of cytotoxicity were observed in 4 hour 51Chromium 
release asssays with either LAK cell population. It was thus 
concluded that pretreatment with ABPP did not effect the in vitro 
generation of LAK cell activity 'data not shown). 
Effects of ABPP on immunogenic and nonimmunogenic tumors in an 
intraperitoneal tumor model 
BL/6 mice were inoculated with 1 x 10 5 tumor cells i.p. on 
day 0. ABPP was given at 4 different schedules as indicated in 
Table I. The mice were sacrificed on day 14 and the i.p. tumor 
load was scored blindly according to the peritoneal cancer index 
(PCI) system. Table I shows that a significant reduction in i.p. 
tumor load was observed after the administration of ABPP on day 1 
and 2 with the immunogenic tumors MCA-105 1 -106 and MCA-38 1 but 
not with the nonimmunogenic tumors MCA-101 and -102. When ABPP 
was administered on day 3 and 4 a small reduction in i.p. tumor 
load was noted in all experiments with the immunogenic tumors. In 
half of the experiments this difference was statistically signi-
ficant. ·This was not observed with the nonimmunogenic tumors. The 
administration on day 8 and 9 did not result in a significant 
reduction of i. p. tumor. These results show that the anti tumor 
effects of ABPP are clearly related to tumor load. Further more 
the results suggest that to a lesser degree they may also be 
related to the immunogenicity of the tumor. 
TABLE I : ANTITUMOR EFFECTS OF ABPP ON IMMUNOGENIC AND NONIHMUNOGENIC TUMORS IN AN INTRAPERITONEAL TUMOR MODEL 
EXP TUMOR CONTROL 
Immunogenic tumors 
1 MCA-105 3.00 + o.oo 
2 MCA-105 3.00 + o.oo 
3 MCA-105 2.87 + 0.09 
4 MCA-106 2.87 + 0.13 
5 MCA-38 2.80 +·0.13 
6 MCA-38 2.60 + 0.13 
Nonimmunogenic tumors 
7 MCA-101 1.90 + 0.31 
8 MCA-102 2.58 + 0.15 
9 MCA-102 2.67 + 0.15 
MEAN PCI + SEM 
ABPP1,2 
2.17 + 0.40 
(o:-o2) 
2.17 + 0.30 
(O.Ob9) 
2.17 + 0.31 
<o:-o2) 
1.89 + 0.26 
(0.009) 
1.67 + 0.28 
<o:-oo3) 
1.86 + 0.20 
<o:-oo4) 
1.40 + 0.40 
1.90 + 0.28 
(o:-o6) 
2.40 + 0.16 
ABPP3,4 
2.33 + 0.33 
(o:-o2) 
2.50 + 0.34 
2.83 + 0.17 
2.00 + 0.37 
<o:-o5) 
2.42 + 0.15 
(o:-o3). 
2.32 + 0.15 
(o:-o4) 
2.17 + 0.40 
1.90 + 0.28 
(o:-o6) 
2.42 + 0.19 
ABPP8,9 
2.33 + 0.33 
<o:-o2) 
3.00 + o.oo 
2.83 + 0.17 
2.33 + 0.31 
2.58 + 0.15 
-
2.67 + o.u 
2.50 + 0.21 
2.83 + 0.17 
ABPP3,4-8,9 
2.67 + 0.21 
2.50 + 0.34 
2.50 + 0.21 
2.42 + 0.15 
(o:-o3) 
2.17 + 0.31 
(o:-o5) 
2.17 + 0.17 
2.33 + 0.33 
2.67 + 0.31 
PCI = peritoneal cancer index ; SEH = standard error of the mean ; P2-values of pair-wise comparisons with control 
animals are indicated between brackets when differences were significant. ABPP was administered at a dose of 250 
mg/kg, i.p., on two consecutive days at different time intervals after i.p. tumor inoculation as is indicated at the 
top of the table. Fourteen days after i.p. tumor inoculation the mice were sacrificed and their i.p. tumor load was 
scored in a blinded fashion with the PCI-scoring system. 
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Effects of ABPP in a pulmonary metastasis model 
BL/6 mice received 3 x 10 5 tumor cells i.v. on day 0 (In the 
first experiment with MCA-105 1 x 10 5 cells were given i.v.). 
Treatment with ABPP was given in the same .manner as in the 
intraperitoneal tumor experiments. On day 14 the mice were 
sacrificed, the lungs inflated with Indian ink and harvested and 
put in Fekette's Solution. After this procedure the tumor 
colonies in the lung were enumerated in a blinded fashion. The 
results are depicted in Figure 4. In the pulmonary metastasis 
model the results were similar to those obtained in the 
intraperitoneal model. Again the antitumor effects of ABPP were 
primarily influenced by tumor load. Again the immunogenic tumors 
MCA-105 and MCA-38 seemed more sensitive to the effects of ABPP 
than the nonimmunogenic tumor MCA-102.· 
Effects of ABPP in combination with LAK cells and IL-2 
. . 
BL/6 mice were inoculated i .p. with 1 x 10 5 MCA-105 tumor 
cells and were treated with 10,000 units of IL-2 from day 3 
through 7. ABPP -was administered before or at the same time as 
the IL-2 + LAK treatment cycle. LAK cells (lxl0 8 ) were given i.p. 
on day 3 in 2 experiments. The mice were sacrificed on day 14 and 
scored for i.p. tumor. When ABPP was administered early (day 1, 
2) an additional tumor reducing effect was seen. The results of 
the experiments in which the administration of ABPP preceeded the 
administration of IL-2 and LAK are summarized above in Table II. 
Administration of ABPP concurrently with a course of IL-2 and LAK 
(on day 3 and 4) or afterwards (on day 8 and 9) did not effect 
the efficacy of treatment with IL-2 and LAK cells (these data are 
not shown). 
Figure 4 
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Antitumor effects of ABPP in the pulmonary metastasis 
models against immunogenic and nonimmunogenic tumors 
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MCA-102 
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Figure 4 (top, middle, bottom) Antitumor effect of ABPP on 
pulmonary metastases. BL/ 6 mice were inocula ted with 1 x 10 s 
MCA-105 tumor cells i.v. (top-left) and with 3 x 10 5 cells in all 
other experiments. ABPP given on day 1, 2 or 3, 4 and/or 8, 9 as 
shown at the bottom of the scatter diagram. The number of pulmon-
ary metastases was scored on day 14. Early administration of ABPP 
reduced ·the number pulmonary metastases of the immunogenic tumors 
significantly in all experiments (MCA-105: p <0. OS; MCA-38: p 
<0.01) but had no. clear antitumor effect on the nonirnrnunogenic 
tumor MCA-102. ABPP had no significant effect against established 
tumor regardless of its irnrnunogenicity. 
TABLE II 
EXP CONTROL 
1 3.0 + 0 
2 3.0 + 0 
3 2.87 + 0.09 
EFFECT OF EARLY ADMINISTRATION OF ABPP ON DAY 1 AND 2 FOLLOWED BY IL-2 + LAK 
MEAN PCI ± SEM 
ABPP 1-2 IL-2 ABPPl-2/IL-2 
2.17 + 0.40 2.67 + 0.34 1.00 + 0.37 
(o:-o2) (NS) (0.00008) 
-(0.008)-
2.17 + 0.30 2.50 + 0.34 1.33 + 0.33 
(0.009) (NS) (0.0004) 
-(0.04)-
2.17 + 0.31 2.33 + 0.33 1.83 + 0.40 
(o:-o2) (NS) (0.008) 
- NS-
IL-2+LAK 
2.17 + 0.31 
(0.003) 
ABPP1-2/IL-2+LAK 
0.83 + 0.40 
(0.00008) 
-(0.04)-
2.00 + 0.26 
(0.002) 
- NS-
2.00 + 0.26 
(0.002) 
PCI = {eritoneal cancer index ; SEM = standard error of the mean ; ABPP was administered at a dose of 250mg/kg, 
i.p., on day 1 and 2 after i.p. tumor inoculation. 1 x 108 LAK cells were administered i.p. on day 3 and IL-2 was 
given at a dose of 10,000 units, i.p., twice a day, from day 3 through 7. The mice were sacrificed at day 14 and 
their i.p. tumor load was scored blindly with the PCI scoring system. P2-values of pair-wise comparisons with the 
control animals are shown between brackets. 
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DISCUSSION 
Lymphokine activated killer cell activity has been defined 
as the capacity of lymphoid cells to lyse fresh tumor cells in 4 
hour 51Chromium release assays (Rosenberg, 1984; Rosenstein et 
al, 1984). Interleukin-2 has been shown to be the crucial lympho-
kine in inducing this capacity (Grimm et al, 1983). The experi-
ments described in this communication are the first to demon-
strate that the i.p. administration of the interferon inducer 
ABPP generates lymphoid cells in the peritoneal exudate, and to a 
much lesser degree in the spleen, that can lyse fresh tumor tar-
gets and thus by definition display LAK cell activity. Apparently 
the induction of endogenous interferon type I leads to a cascade 
of events that may well include the production of endogenous IL-2 
by activated NK cells (Kasahara et al, 1983) and the subsequent 
induction of LAK cell activity. Even though this activation 
process by way of the induction of endogenous lymphokines quite 
effectively generated a level of LAK cell activity comparable to 
the effects of a 3 day course of moderate doses of IL-2 b.i.d., 
only a limited level of LAK cell activity can be induced by ABPP. 
This is due to the fact that repetitive doses of ABPP do not 
further increase the endogenous production of lymphokines and 
induce a state of hyporesponsiveness (Oku et al, 1984). This is 
commonly seen after multiple administrations of several biolog-
ical response modifiers (Talmadge et al., 1985) and may be due to 
a subsequent decrease in the number of large granular lymphocytes 
(Saito et al., 1985). The observation that the level of LAK cell 
activity as well as the numbers of LAK cells generated in vivo 
depended on the dose of IL-2 used clearly underlines the thera-
peutic potential of this lymphokine. This proliferation of 
activated lymphoid cells by high doses of IL-2 , as demonstrated 
by Ettinghausen and collegues (1985), is evidently an important 
aspect of the efficacy of treatment of intraperitoneal tumor with 
moderately high doses of IL-2 alone (Ottow et al., 1987b; Egger-
mont et al. ,1987c; 1987h). The toxicity associated with these 
doses of IL-2 however is quite serious (Chang et al., 1984; Mato-
ry et al., 1985; Lotze et al., 1986) and is the main obstacle to 
exploit the antitumor effects of IL-2 maximally. 
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Since ABPP may upregulate the expression of IL-2 receptors 
(Brrideau and Wolcott, 1985) we investigated its potential use as 
a "primer" in order to increase LAK cell generation by IL-2. 
Splenocytes from mice that were pretreated with ABPP however were 
no better source for the in vitro generation of LAK cells than 
splenocytes from untreated mice. 
In intraperitoneal tumor experiments ABPP, when administered 
early (day 1, 2) '· prior to IL-2 and LAK cells, had an additional 
antitumor effect. This effect most likely reflects the tumor 
reduction achieved by ABPP on a day 1 tumor load which subse-
quently rendered the IL-2 plus LAK cell treatment more effective. 
The lack of p9tentiation of IL-2 plus LAK effects when ABPP was 
given concurrently as well as the lack of "priming effect" of 
ABPP on the in vitro generation of LAK cells as desribed above 
does not suggest that a synergistic effect between endogenously 
induced lymphokines and exogenously administered IL-2 exists. In 
view of recent reports on the negative effects that the adminis-
tration of exogenous IFN-alpha can have on· the activation of 
lymphocytes by IL-2 (Brunda et al., 1986) it must be stressed 
that no detrimental effect was seen as a result of the concurrent 
or prior administration of this interferon inducer. 
Initial tumor load was crucial as to whether tumor reduction 
was achieved by treatment with ABPP. This observation is in line 
with results reported earlier (Eggermont et al., 1986b). In 
contrast to our experience with immunogenic and non immunogenic 
tumors in rats (Eggermont et al., 1986a; 1986c) and results in 
murine models reported by Milas et al., ( 1982) a difference in 
sensitivity to treatment with ABPP between immunogenic and non-
immunogenic tumors was seen. The immunogenic tumors, especially 
the murine adenocarcinoma MCA-38, were more sensitive than the 
nonimmunogenic sarcomas MCA-101 and -102. This difference in vivo 
was bigger than the marginal difference in lysability that seemed 
to exist in vitro. These findings were corroborated by a remark-
able efficacy of combined treatment schedules of ABPP and cyclo-
phosphamide of the weakly immunogenic tumors (MCA-105 and MCA-38) 
as opposed to the much less spectacular results of this combina-
tion against the nonimmunogenic tumor MCA-102, as we reported 
recently in this journal (Eggermont et al., 1987b). This obser-
vation may reflect a difference in rate of tumor growth between 
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the nonimmunogenic and weakly immunogenic tumors. The antitumor 
effects of ABPP may however be mediated by more mechanisms than 
by LAK-like mediated cytolysis alone. It is concievable that the 
polyclonal activation of B cells or the increased production of 
antibodies (Fast et al., 1982) induced by ABPP enhances the anti-
tumor effects of ABPP through antibody dependent cellular cyto-
toxicity mediated tumor reduction (manuscript in preparation) . 
This mechanism then could well play a part in the efficacy of 
ABPP against immunogenic tumors but would be absent in the 
setting with nonimmunogenic tumors and explain its inefficacy 
against them. 
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Synergistic antitumor activity of cyclophosphamide and ABPP 
in the treatment of established and advanced tumors 
Summary 
in murine tumor models 
Alexander M. M. Eggermont, Paul H Sugarbaker, 
Richard L.Marquet and Johannes Jeekel 
We have previously shown that the in vivo administration of 
ABPP, an interferon inducing pyrimidinone, generates activated 
killer cells that can lyse fresh tumor cells in vitro in 4 hour 
""'-Chromium release assays. The' administration of this agent how-
ever has no effect on established tumor. In this communication we 
show that ABPP, when used in combination with low or moderate 
doses of cyclophosphamide, can be quite effective against early 
established (day 3) tumor as well as against far advanced, gross-
ly visible (day 8-10) tumor in both the intraperitoneal (i.p.) 
and the pulmonary metastasis model. The synergistic anti tumor 
activity of this chemoimmunotherapeutic regimen is very strong 
against immunogenic tumors but rather weak against nonimmunogenic 
tumors. Two treatment cycles were significantly more effective 
than one and multiple cycles even cured the majority of mice with 
established i.p. tumor. These experiments demonstrate the poten-
tial of chemoimmunotherapeutic regimens and high~ight the effica-
cy of multiple treatment cycles. 
INTRODUCTION 
We have shown previously that the intraperitoneal adminis-
tration of ABPP in BL/6 mice can generate high levels of activa-
ted killer cells in the peritoneal exudate (Eggermont et al., 
1987a). These cells are capable of lysing fresh tumor cells in 4 
hour 51Chromium release assays. They display therefore the lyrnph-
okine activated killer cell phenomenon (Rosenstein et al., 1984). 
Several pyrimidinones have been shown to be potent interferon in-
ducers (Hamilton et al., 1982, Stringfellow et al., 1980a) that 
modulate a variety of immune responses, in particular the activa-
tion of natural killer (NK) cells and macrophages (Lotzova et 
al., 1983; 1984; 1986; Li et al., 1985; Eggermont et al., 1986a). 
In various tumor models in mice as well as rats, we have shown 
that the administration of ABPP alone has no significant antitu-
mor effect against established tumor (Eggerrnont et al., 1986b; 
1987a). This is in line with observations made by others on the 
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antitumor effects of biological response modifiers (BRM) (Bast 
and Bast., 1976). The goal of this study was to investigate 
whether ABPP in combination with cyclophosphamide could be used 
successfully against established tumor. Li and colleagues (1984) 
have shown that the antitumor effect of ABPP against leukemia and 
the Bl6 melanoma can be greatly enhanced by early administration 
of cyclophosphamide preceding ABPP. We will show that significant 
reduction in tumor load and a survival benefit can be achieved 
when ABPP is administered in combination with cyclophosphamide in 
the treatment of established and even macroscopically visible 
metastatic tumor. Furthermore, we will show that the degree of 
synergism in antitumor effects is related to the immunogenicity 
of the tumors. 
MATERIAL AND METHODS 
Mice 
C57BL/6 (BL/6) female mice were obtained from Jackson Laboratory 
(Bar Harbor, ME) and used 9-12 weeks old. They were maintained on 
laboratory chow and acidified water ad libitum in a pathogen free 
environment. 
Tumor;:; 
The MCA-101, -102, -105, and -106 sarcomas and the MCA-38 colon 
adenocarcinoma used in these experiments are syngeneic to BL/6 
mice and were described in chapter VI. Single cell suspensions of 
all tumors used were prepared as described previously (Mule et 
al., 1984). 
AGENTS 
ABPP : ABPP was administered i.p. at a dose of 250 mg/kg dissol-
ved in 1 ml phosphate buffered saline (PBS) at various time 
intervals after tumor inoculation depeding on experimental 
design. 
Cyclophosphamide (CYTOXAN, CY) was purchased from Mead and 
Johnson and Co. (Evansville, IN). It was dissolved in sterile 
water to a concentration of 200 mg/m1 and further diluted with 
HBSS to a concentration depending on the experimental design. 
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Tumor models 
Intraperitoneal tumor model : BL/6 mice received 1 x 10 5 tumor 
cells i .p. and were randomly allocated into a treatment group. 
Treatment with ABPP was started on day 1, 3 or 8 and consisted. of 
one i.p. injection of 250 mg/kg on two consecutive days. Treat-
ment schedules are shown in Tables and the legends to the figu-
res. CY was administered i.p. or i.v. at various doses depending 
on experimental design. In combination treatment regimens CY was 
given 12 hours before the first of two ABBP injections. Control 
animals received equal volumes of HBSS needed for the administra-
tion of CY of ABPP. Fourteen days after the i.p. inoculation of 
. ' 
tumor the animals were sacrified and their intraperitoneal tumor 
load was assessed in a blinded fashion on a scale from 0 - 3. The 
score was termed the Peritoneal Cancer Index (PC!). Teh procedure 
was described in chapter VI. Each experimental group in the i.p. 
tumor experiments consisted of 6 - 12 mice. 
Pulmonary metastasis model : BL/6 mice received 3 x 10 5 syngeneic 
tumor cells intravenously by way of the lateral tail vein. Treat-
ment schedules were similar to those used in the intraperitoneal 
tumor experiments. The mice were sacrificed after each treatment 
group was given a letter code. The lungs of the mice were infla-
ted with a 15% solution of india ink for enumeration of metasta-
tic pulmonary nodules (Wexler, 1966). Metastases are readily 
countable when "bleached" by Fekette's solution up to 2:. 250. 
Lungs with metastases too numerous to count were therefore 
assigned an arbitrary value of 250. In both tumor models some 
experiments were scored for survival. 
Statistical Analysis 
Overall significance of difference in the intraperitoneal tumor 
experiments was examined with the Jonckheere test for trend (Hol-
lander and Wolfe, 1973). If this test showed a two sided p value 
:::_ 0. 05, pairwise comparisons of differences in tumor load were 
examined with the Wilcoxon rank sum test with a correction for 
ties. Significance of differences in the numbers of pulmonary 
metastases or differences in survival between groups was deter-
mined by the Wilcoxon rank sum test ( Gehan, 19 6 5) . Two-sided p 
values are presented in all experiments. In all intraperitoneal 
tumor experiments where the end point was scored with the peri-
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toneal cancer index, the size of the experimental groups varied 
from 6 to 12 animals. In all pulmonary metastasis experiments the 
experimental groups consisted of 12 animals. In all survival ex-
periments size varied from 12 - 24 animals per group. 
RESULTS 
Effect of different doses of cyclophosphamide on intraperitoneal 
tumor growth 
BL/6 mice where inoculated intraperitoneally (i.p.) with 
1 x 10s MCA-tumor cells. ~n day 3, 8, or on day 3 and day 8, the 
mice received 10 mg/kg up to 75 mg/kg of CY i.p. or i.v. depen-
ding on experimental design. Around day 14, the mice were sacri-
fied and the intraperitoneal tumor load was assessed in a blinded 
way using the peritoneal cancer index scoring system. The results 
are summarized in Table I. It is clearly shown that reduction of 
i.p. tumor load by CY is a dose-related phenomenon. When doses of 
50 mg/kg or higher are used, a consistently significant reduction 
in i.p. tumor load is achieved when CY is administered on day 3. 
The administration of this dose on day 8 only seems to have litt-
le if any effect. However, the administration of 50 up to 75 
mg/kg of CY i.p. or i .. v. had a consistent impact on i.p. tumor 
load. In most experiments that will be discussed, CY was given 
i.p. at a dose of 50 mg/kg. As is shown in Table I there was no 
differen9e in antitumor effect after i.p. or i.v. administration. 
The antitumor effect of cyclophosphamide is related to the 
immunogenicity of the tumor 
BL/6 mice were inoculated with 1 x 10 5 tumor cells of the 
immunogenic MCA-105 or -38, or the nonimmunogenic MCA-101 or 102. 
They were treated with CY (50 mg/kg) on day 3 ,8 or 3 and 8. The 
results are summarized in Table II. The immunogenic tumors 
appeared to be quite sensitive to treatment with CY in contrast 
to the nonimmunogenic tumors. A single dose of CY on day 8 was 
ineffective in virtually all experiments regardless of the tumor. 
In contrast when preceded by a dose on day 3 a strong additive 
antitUmor effect was seen. 
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Table I. 
EF'E'ECT OF DIE'FERE:Nr OOSES OF CYCLOPHOSPHAMIDE ON INIRAPERI'IONEAL TUMOR GRCm'H 
MEAN PCI + SEM 
TUMOR EX!?. OOSE CONTROL DAY 3 DAY 8 DAY 3-8 
MCA-10S 1 (A) 10 !!9:/kg 2.7S:!: 0.13 2.67 :!: 0.21 2.67 :!: 0.21 3.00:!: 0 
(iv) 
MCA-10S 1 (B) 10 m::r/kg 2.7S:!: 0.13 2.67:!: 0.21 2.SO :!: 0.22 2.83 :!: 0.17 
(ip) 
MCA-10S 2 2S m::r/kg 2.80 + 0.09 2.67 :!: 0.21 2.SO:!: 0.34 
(ip) 
MCA-10S 3 2S m::r/kg 2.67 :!: 0.14 2.SO :!: 0.34 1.83 + 0.40 
(ip) (0-:-07) 
MCA-10S 4 2S m;r/kg 2.7S + 0.11 2.67.:!: 0.21 2.SO :!: 0.34 2.17 :!: 0.27 
(ip) 
MCA-10S s so !!9:/kq 2.83 :!: 0.11 2.SO:!: 0.22 1.83 + 0.31 
(ip) (0.006) 
MCA-10S 6 so m::rfkq 2.87 + 0.09 1.83 + 0.31 o.so + 0.21 
(ip) (0.002) (O.OOOOS) 
MCA-10S 7 (A) so m::r/kq 2.86 :!: 0.10 2.08 + 0.23 1.08 + 0.19 
(iv) (0-:-02) (0.00002) 
MCA-10S 7 (B) so !!9:/kq 2.86 :!: 0.10 2.00 + 0.26 1.33 + 0.33 
(ip) (0.004) (0.0003) 
MCA-10S 8 so m::r/kg 2.80:!: 0.09 2.SO:!: 0.22 2.83 :!: 0.17 1.17 + 0.31 
(ip) (0.0002) 
MCA-10S 9 so !!9:/kq 2.67 + 0.14 2.17 + 0.40 o.so + 0.22 
(ip) (0.0004) 
MCA-10S 10 7S m::r/kg 2.80 :!: 0.09 l.SO + 0.43 o.so + 0.22 
(ip) (0.002) (0.00004) 
MCA-10S ·n 7S m::r/kg 2.67 :!: 0.14 1.83 + 0.31 0.17 + 0.17 
(ip) (0-:-03) (0.0004) 
MCA-10S 12 7S m::r/kg 2.7S:!: 0.11 l.SO + 0.43 2.17 + 0.40 0.33 + 0.14 
(ip) (O.OOS) (O.OOOOOS) 
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Table II 
EFFECT OF CYCIDPHOSPHAMIDE (50 M:;/KG) ON INI'RAPERITONEAL TUMOR GROWI'H OF 
IMMUNCX;ENIC AND NONm:IONCGENIC TUMORS 
MEAN PCI ~ SEM 
TUMOR EXP. CONI'ROL DAY 3 DAY 8 DAY 3-8 
MCA-105 1 2.83 ~ 0.11 2.50 + 0.22 1.83 + 0.31 
(0.006) 
MCA-105 2 2.87 :t 0.09 1.83 + 0.31 0.50 + 0.21 
(0.002) (0.00005) 
MCA-105 3(iv) 2.86 :t 0.10 2.08 + 0.23 1.08 + 0.19 
(0-:-2) (0.00002) 
MCA-105 3(ip) 2.86 ~ 0.10 2.00 + 0.26 1.33 + 0.33 
(0.004) (0.0003) 
MCA-105 4 2.80 + 0.09 2.50 ~ 0.22 2.83 + 0.17 1.17 + 0.31 
(0.0002) 
MCA-105 5 2.67 ~ 0.14 2.17 + 0.40 0.50 + 0.22 
(0.0004) 
MCA-38 6 2.80 :t 0.13 1.67 + 0.22 2.08 + 0.23 0.33 + 0.14 
(0.002) (0-:-03) (0.00004) 
MCA-38 7 2.47 + 0.17 1.40 + 0.22 2.20 ~ 0.23 0.60 + 0.22 
(0.004) (0.0002) . 
MCA-101 8 2.10 :t 0.23 1.60 + 0.43 
MCA-102 9 2.58 ~ 0.15 2.00 + 0.21 2.60 + 0.22 2.00 + 0.25 
(o-:-os) (o-:-o8) 
MCA-102 10 2.67 ~ 0.19 2.00 + 0.25 
( o-:-os) 
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Early chemoimmunotherapy of immunogenic and nonimmunogenic 
intraperitoneal tumors 
BL/6 mice received 1 x 10 5 MCA-105, 38, or 102 tumor cells 
i.p. and were subsequently treated on day 3 with 10 mg/kg up to 
75 mg/kg of CY i.p. or i.v. depending on experimental design as. 
is shown in Table III. 12 Hours after the administration of CY, 
250 mg/kg of ABPP was administered i .p. The antitumor effects 
achieved by CY alone·, ABPP on day 3 and 4 or by the combination 
of CY and ABPP are shown in Table III. It is clearly demonstrated 
that when CY was given prior to ABPP the most powerful antitumor 
effect was seen which led consistently to a highly significant 
reduction in i.p. tumor load. Even when only 10 mg/kg of CY was 
administered, the combination with ABPP reduced i.p. tumor signi-
ficantly. It must further be noted that the administration of 
ABPP alone had very little effect and that the administration of 
various doses of CY alone resulted in a dose dependent reduction 
of i.p. tumor. Furthermore, the immunogenic tumors MCA-105 and 
MCA-38 seemed to be more sensitive to the antitumor effects of 
CY. In 4 out of 6 experiments, when a dose of 50 mg per kg of CY 
was used, the combined treatment with ABPP was significantly bet-
ter than the treatment with CY alone and always more. effective 
than the treatment with ABPP alone. 
Effects of late chemoimmunotherapy on immunogenic and 
nonimmunogenic intraperitoneal tumors 
The antitumor effects of CY (50 mg/kg, i.p.) and the admin-
istratio'n of 250 mg/kg of ABPP i.p. on day 8 and 9 or the com-
bination of these two drugs against far advanced tumor (day 8 re-
presents grossly visible i. p. tumor) was as·sessed. The- results 
are shown in Table IV. A significant reduction in i.p. tumor load 
was achieved in all experiments by combination treatment. There 
seemed to be a difference in sensitivity to this treatment be-
tween the different tumors. The nonimmunogenic MCA-102 showed 
hardly any tumor reduction after treatment. The tumor reduction 
achieved with combination treatment against MCA-105 was consis-
tent but marginal. Against MCA-38, however, a highly significant 
tumor reduction was obtained in all three experiments and combi-
nation treatment was clearly better than treatment with CY alone. 
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Table III 
EARLY CHEMOIMMUNOI'HERAPY OF IMMUNCX;ENIC AND NOtiDlMUNOOENIC INI'RAPERI'IONEAL TUMORS 
MEAN PCI + SEM 
TUMOR OOSE CY (ng/kg) CONI'ROL ABPP 3-4 CY3 CY 3/ABPP 3-4 
MCA-105 10 2.75 + 0.13 2.67 .± 0.21 2.67 .± 0.21 1.83 + 0.40 
(0-:-06) 
MCA-105 10 2.75 .±. 0.13 2.67 .±. 0.21 2.67 .±. 0.21 2.00 + 0.26 
(0-:-02) 
MCA-105 50 2.87 + 0.09 2.83 .±. 0.17 - 1.83 + 0.31 0.50 + 0.34 
(0.002) - 0.03 - (0.00007) 
0.004 I I 
MCA-105 50 2.86 + 0.10 3.00 .±. 0.0 2.08 + 0.23 1.00 + 0.37 
(0.02) - 0.03 - (0.0003) 
0.003 : 
MCA-105 25 2.80 + 0.09 2.67 .±. 0.17 2.67 .±. 0.21 2.33 + 0.21 
( o-:-o4 l 
50 2.50 ± 0.22 2.00 + 0.37 
( o-:-o2 l 
75 1.50 + 0.43 1.17 + 0.31 
(0.002) (0.0002) 
0.008 I I 
MCA-38 50 2.80 .± 0.13 2.42 + 0.15 1.67 + 0.22 0.75 + 0.25 
(0.002) - o.o3 - (o-:-ooo1) 
0.0002 I I 
MCA-38 50 . 2.47 .± 0.17 2.20 + 0.29 1.40 + 0.22 1.00 + 0.52 
(0.004) (0-:-02) 
0.06 I I 
MCA-38 50 2.60 .±. 0.13 2.32 + 0.15 1.55 + 0.16 0.83 + 0.23 
(0-:-04) (O.ooo04) - o.o2 - (o-:-ooooo4) 
I 0.0003 : I 
MCA-102 50 2.58 .±. 0.15 1.90 + 0.28 2.00 + 0.21 1.92 + 0.23 
(0-:-06) (o-:-o5) ( o-:-o4 l 
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Table IV 
LATE CHEMOIMMUNOI'HERAPY OF IMMUl'mENIC AND NONJM1UN(X;ENIC JNI'RAPERI'IONEAL TUMORS 
MEAN PCI + SEM 
EXP TUMOR CONI'ROL ABPP 8,9 CY(50m;r/kg) clay 8 CY 8/ABPP8,9 
1 MCA-105 2.75 + 0.11 2.83 .±. 0.17 2.50 + 0.23 2.33+ 0.19 
(0-:-07) 
2 MCA-105 2.80 + 0.09 2.83 .±. 0.17 2.83 .±. 0.17 2.67 + 0.21 
3 MCA-105 2.67 + 0.14 2.83 .±. 0.17 2.17 + 0.40 2.00 .±. 0.26 
0.03 
4 MCA-38 2.60 + 0.13 2.67 .±. 0.11 2.14 + 0.17 1.44 + 0.23 
(0.03) - 0.03 - (0.0003) 
0.0003 
5 MCA-38 2.80 .±. 0.13 2.58 .±. 0.15 2.08 + 0.23 1.33 + 0.31 
(0.03) - 0.08 - (0.002) 
0.004 
6 MCA-38 2.47 + 0.19 2.83 .±. 0.17 2.20 + 0.25 1.67 + 0.33 
(0.05) 
0.03 
7 MCA-102 2.58 + 0.15 2.50 .±. 0.21 2.60 + 0.22 2.25 + 0.25 
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Effects of two courses of chemoimmunotherapy on early established 
intraperitoneal tumor 
ABPP was administered on days 3 and 4, and days 8 and 9 
after i.p. tumor inoculation. CY was given either alone on day 3 
and 8 or on day 3 and 8, twelve hours prior to the administration 
of ABPP. An important and consistent highly significant reduction 
of i.p. tumor was seen in those mice treated with .the combination 
of CY and ABPP. The results are shown in the Tables Va and Vb. 
Table Va EFFECT OF 2 COURSES OF CHEMOIMMUNOI'HERAPY ON INI'RAPERI'IONEAL MCA-105 
MEAN PCI + SEM 
EXP TUMOR I:OSE CY (mg/kg) CONI'ROL ABPP 34-89 CY 3-8 CY 3-8/ABPP 34-89 
1 MCA-105 50 2.87 + 0.09 2.50 + 0.21 0.50 + 0.21 0.00 + o.oo 
ip (0.08) (O.OOOOS) - 0.8 - (0.00004) 
I o.oo2 I I 
1 MCA-105 50 2.86 + 0.10 3.00 + 0.00 1.08 + 0.19 0.83 + 0.31 
iv (0.00002) (0.0002) 
0.003 I I 
2 MCA-105 10 2.75 + 0.13 2.67 + 0.21 2.83 + 0.17 1.40 + 0.37 
iv (NS) - 0.02 - (0~004) 
o.o4 I 
2 10 2.75 ±. 0.13 2.67 + 0.21 3.00 + 0.00 1.17 + 0.31 
ip (NSJ- 0.003 - (0~0009) 
o.oo8 I 
3 MCA-105 25 2.80 + 0.09 2.67 + 0.21 2.50 + 0.34 2.33 + 0.33 
ip 
50 1.17 + 0.31 0.33 + 0.21 
(0.0002) -0.07- (0.00004) 
0.003 I I 
75 0.50 + 0.22 0.00 + o.oo 
(0.00004)-0.08-(0.00003) 
0.002 I I 
4 MCA-105 50 2.67 + 0.14 2.83 + 0.17 0.50 + 0.22 0.00 + 0.00 
ip (0.0004)-0.08-(0.0003) 
0.002 I I 
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TABLE Vb 
EFFECI' OF 2 COURSES OF CHEMOIMMUOOIHERAPY ON INr.RAPERI'IDNEAL MCA-38, -101 AND -102 
EXP 
s 
ip 
6 
ip 
7 
ip 
8 
ip 
MEAN PC! 2:_ SEM 
TUMOR lXJSE CY (:rrg/kg) CONTROL ABPP 34-89 CY 3-8 CY3-8/ABPP 34-89 
MCA-38 so 2.80 2:. 0.13 2.42 * 0.1S 0.22 + 0.14 0.00 + 000 (NS) (0.00004)-0.0S-(0.00002) 
I 0.0009 I I I 
MCA-38 so 2.60 + 0.13 2.60 + 0.16 0.4S + 0.13 0.09 + 0.06 (NS) (0.000003)-0.02-(0.000003) 
I 0.000003 I I I 
MCA-101 so 2.10 2:. 0.23 2.83 2:. 0.17 1.60 2:. 0.43 1.00 + 0.37 
( o-:-o4) 
o.os I I 
MCA-102 SO· 2.S8 + 0.1S 2.33 + 0.22 2.00 + 0.2S 2.00 + 0.21 (NS) (0-:-08) - NS - (o-:-os) 
I NS I I I 
The antitumor effect of this combination treatment was especially 
powerful against the immunogenic tumors MCA-lOS and MCA-38. A 
modest reduction in i.p.tumor load was obtained against the non-
immunogenic tumors MCA-101 and 102. The combination ·treatment of 
immunogenic tumors was consistently better than treatment with 
ABPP alone or with CY alone. These differences were much less 
pronounced with the nonimmunogenic tumors. 
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Efficacy of chemoimmunotherapy with cyclophosphamide and ABPP 
prolongs survival in intraperitoneal tumor model 
As is shown in Figures lA, lB and lC, the combination of 
ABPP and CY , administered at different intervals after the i.p. 
inoculation of MCA-105 tumor was always superior to single agent 
therapy. The combination treatment enhanced antitumor effects and 
prolonged survival. These results confirmed the results described 
above in the PC! experiments with tumor MCA-105. 
Figure I (a-b-c) Efficacy_of Chemoimmunotherapy on i.p. MCA-105 
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Figure 1 : Superiority of combination treatment with CY and ABPP 
over single agent treatment. BL/6 mice received 1 x 10 5 MCA-105 
tumor cells ip and· were treated with different treatment 
schedules with CY and/or ABPP as indicated in the right .upper 
corners of the survival curves. CY always enhanced the antitumor 
effect of ABPP especially against established (middle) (B) and 
advanced ip tumor (bottom)(C). 
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High cure rate by weekly administrat~on of combination treatment 
with cyclophosphamide and ABPP in mice with early established 
intraperitoneal tumor 
An extraordinary potentiation of treatment was achieved by 
giving CY (50 mg/kg) weekly followed by one injection of ABPP 12 
or 24 hours later. The results of this drug combination schedule 
are shown in Figure 2. This treatment resulted in more than 60% 
long term survivors. These mice all lived for 100 days at which 
point in time they were sacrificed and an autopsy was performed. 
None of the mice had tumor in the peritoneal c_avi ty upon exami-
nation. 
Figure 2 
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Cure ~f early established intraperitoneal tumor by 
weekly administration of cyclophosphamide and ABPP 
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Figure 2 : Cure by weekly administration of combination treatment 
Treatment of established MCA-105 tumor ip in BL/6 mice with a 
weekly administration of CY and ABPP demonstrated highly syner-
gistic antitumor activity and cured the majority of mice. 
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Significant reduction of pubnonary metastases of immunogenic 
tumors but not of nonimmunogenic tumors after chemoimmunotherapy 
with cyclophosphamide and ABPP 
BL/6 mice were inoculated with 3 x 10 5 tumor cells of either 
the weakly immunogenic tumors MCA-105 or MCA-38 or the nonimmuno-
genic tumor MCA-102, intravenously on day 0. CY (50 mg/kg) was 
given on day 3 and ABPP was administered either alone or 12 hours 
after the administration of CY. As is demonstrated by the scatter 
diagrams in Figures 3A, 3B and 3C, a dramatic reduction in the 
number of pulmonary metastases was seen after treatment with the 
combination of CY and ABPP in the mice with the immunogenic tu-
mors MCA-105 and MCA-38, but not so in the mice inoculated with 
the nonimmunogenic tumor MCA-102. 
Effects of cyclophosphamide, ABPP or the combination treatment on 
advanced pubnonary metastases 
In the next series of experiments, the impact on grossly 
visible lung metastases was evaluated. BL/6 mice were inoculated 
with 3 x 10 5 tumor cells of either MCA-105, MCA-38, or MCA-102. 
Treatment was started on day 10. The mice either received HBSS or 
one injection of CY (100 mg/kg) i.p. or one injection of ABPP 250 
mg/kg on day 10 and 11 alone or 12 hours after the administration 
of CY. The survival curves in Figure 4 a, b and c show a signif-
icant survival benefit as a result of the treatment with 100 
mg/kg of CY i.p. This effect was significantly enhanced if the 
treatment with CY was followed by two injections of ABPP on days 
10 and 11 in the mice inoculated with the immunogenic tumors. 
With MCA-102 this phenomenon was much weaker. These experiments 
were all repeated with virtuaily identical results. 
92 
Figure 3 (a,b,c) : Efficacy of combination treatment of esta-
blished pulmonary metastases with CY and ABPP depends on 
immunogenicity of the tumor. BL/6 mice received 3 x 10 5 tumor 
cells iv and were treated with CY (50 mg/kg) and/or ABPP as 
indicated on the x-axis of the scatter diagrams. Each dot 
represents one mouse -and indi-cates the number of pulmonary 
metastases in this mouse as scored on day 14. Treatment of the 
immunogenic tumors MCA-105 (3A) and MCA-38 (3B) with CY and. 
e9pecially with the combination of CY and ABPP was .very 
effective. MCA-105 : HBSS vs CY : p < 0.0001 ; HBSS vs CY+ABPP : 
p < 0.0001 ; CY vs CY+ABPP : p < 0.05 ); MCA-38 : Left: HBSS vs 
CY : p < 0.0005 ; Right : p <0.01 ; HBSS vs CY+ABPP : Left: p < 
0.0005 ; Right : p < 0.005; left: CY vs CY+ABPP: p < 0.05 ; 
right : N.S. No significant reduction was seen after treat -ment 
with ABPP on days 3,4 and 8,9 in any experi-ment. CY+A.BPP was 
significantly better in all experiments than treatment with ABPP 
only. No significant reduction of tumor was seen with the 
nonirnmunogenic MCA-102 (3C) with any treatment schedule. 
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Figure 4 (a-b-c) : 
Effect of Chemoimmunotherapy on advanced pulmonary metastases 
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Figure 4 (a,b,c) : Efficacy of treatment of advanced pulmonary 
metastases with CY and ABPP depends on immunogenici ty of the 
tumor. The survival curves of mice with advanced (day 10) 
pulmonary metastases of MCA-105 (A), MCA-38 (B) and MCA-102 (C) 
treated with CY and/or ABPP demonstrate the efficacy of CY and 
especially of the combined treatment of CY+ABPP against the 
immunogenic tumors (A and B). MCA-102 appears much less 
sensitive. ABPP alone has no antitumor effect against day 10 
metastases regardless of tumor immunogenicity. 
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DISCUSSION 
The experiments presented here are the first to show that 
ABPP can be used effectively in the treatment of established and 
advanced tumor. The administration of ABPP alone was totally in-
effective in this setting. The administration of low or moderate 
doses of CY had a moderate effect against early established 
tumors, but very little against advanced tumors. In contrast, 
combination treatment with CY and ABPP was quite effective and 
displayed a clearly synergistic antitumor effect. Similar syner-
gism has been observed with combined treatment of early establi-
shed intraperitoneal tumor with cyclophosphamide and IL-2 and LAK 
cells (Eggerrnont and Sugarbaker., 1987g}. Multiple.cycles of the 
combined treatme.nt modality were very effective and cured the 
majority of mice with early established i.p. tumor. 
Several explanations for the synergism may be offered: (i) Tl;e 
administration of cyclophosphamide may reduce early established 
(day 3) tumor load to a level that corresponds with day 1 tumor 
load. ABPP has a significant antitumor effect against this tumor 
load (Eggerrnont et al., 1987a) and is therefore likely to contri-
bute to the increased tumor reduction after combination therapy. 
This mechanism may explain the synergism observed in the treat-
ment of day 3 tumor. Since the administration of CY has virtually 
no effects on day 8 i.p. tumor or day 10 pulmonary metastases a 
different mechanism may be involved in this setting. (ii) Removal 
of suppressor cells has been suggested by several authors to be 
the main mechanism by which CY may enhance the antitumor effect 
of immunotherapeutic regimens (Bear, 1986; Evans, 1983; Greenberg 
et al., 1985; North, 1982). It has been shown that suppressor 
cells emerge about one week after tumor inoculation and play an 
increasingly important role in the immune status of the tumor 
bearing host (North, 1984). Removal of these cells by CY may well 
be the most important mechanism by which synergism between CY and 
ABPP in the treatment of advanced tumors in our experiments was 
achieved. (iii) A third factor may play a role in both the early 
established and the advanced tumor setting. Papa and coworkers 
(1987) have shown that tumor cells from a tumor bearing mouse, 
treated with CY 24-36 hours earlier, are more easily lysed in 
vitro by lyrnphokine activated killer cells than tumor cells from 
97 
untreated mice. We have shown previously (Eggermont et al., 
1987a). that ABPP induces lymphokine activated killer cell like 
activity in vivo and the activity of these cells may well be 
facilitated in vivo as well by the administration of CY prior to 
ABPP. 
Chemoimmunotherapy was much more effective against immunogenic 
tumors than against nonimmunogenic tumors. The immunogenic tumors 
have been shown more sensitive to treatment with ABPP alone 
(Eggermont et al., 1987a) and displayed a greater sensitivity 
than nonimmunogenic tumors to CY in the experiments reported in 
this communication. This observation suggests that ,t~e elimina-
tion of suppressor cells. that may be e·licited by immunogenic but 
not by nonimmunogenic tumors may in part be responsible for dif-
ference in the degree of synergy that is observed with the com-
bined treatment. Alternatively one may hypothesize that immuno-
genic tumors induce cytotoxic T lymphocytes ( CTL) in numbers 
large enough to competitively inhibit LAK function by consumption 
of IL-2 as we have shown previously (Eggermont et al., 1986e; 
Sugarbaker et al., 1987a; 1987b). Cyclophosphamide can abrogate 
the primary immune response (Eggermont et al., 1987c; Peppeloni 
et al., 1986) and thereby remove the for IL-2 competing popula-
tion of CTLs and consequently enhance LAK cell function (Anderson 
et al., 1986; Eggermont et al., 1986e). The greater sensitivity 
of the immunogenic tumors may also be due to an ABPP-induced 
increase in antibody production and the subsequent increased 
clearance of tumor cells (Fast et al., 1982; Li et al., 1985). 
Important is the efficacy of repetitive cycles of the com-
bined treatment. An interval of 5-7 days was chosen in order to 
avoid hyporesponsiveness to the administration of ABPP. Oku et 
al. ( 1984) have shown that the induction of IFN by ABPP, when 
administered repetitively, is effective only when an interval of 
at least
1
s days is observed. When treatment cycles were adminis-
tered at weekly intervals a majority of mice with established 
MCA-105 tumor i.p. was cured. This observation shows that there 
may be a place for chemoimmunotherapeutic regimens in the adju-
vant treatment setting of solid tumors and that further research 
is warranted and should be directed at the optimalization of 
treatment schedules based on a better understanding of the kine-
tics and the temporary effects of its constituents. 
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Clinical and immunological evaluation of 20 patients with 
metastatic colorectal cancer treated with high dose recombinant 
leukocyte interferon-alphaA (riFN-alphaA) 
Alexander M. M. Eggermont, Willem Weimar, Bhupendra Tank, Amelie 
M. Dekkers Bi jma, Richard L. Marquet, Johannes S. Lamer is, 
Dick L. Westbroek and Johannes Jeekel. 
Summary 
Twenty patients with advanced colorectal cancer were treated 
with high dose recombinant leukocyte interferon-alphaA ( riFN-
alphaA). Patients were treated either chronically (Group I: twice 
a week up to 20 x 10 6 I.U./m2 i.m.) or cyclically (Group II: 1-4 
periods of 8 consecutive days up to 20 x 106 I.U./m2 i.m. daily 
a,t 20 . days intervals) during a period of 12 weeks. Growth of 
marker lesions was monitored by physical examination, 
computerized tomography and ultrasonography. For immunological 
monitoring the following tests were performed sequentially: tube 
leukocyte adherence inhibition (LA!), natural killer (NK) cell 
activity, interferon-gamma production capacity upon induction by 
Concanavalin A and the phytohaemagglutinin (PHA) induced 
blastogenesis. There was one patient with a partial response, one 
with stable disease and one with a mixed response. Seventeen 
patients showed growth of metastatic marker lesions but only 
seven patients qualified for having progressive disease ( >25% 
increase in tumor mass ). Overall mean survival was 14.5 months, 
median survival was 15.5 months. Follow up was determined by 
survival and ranged from 3 - 20 months after stopping treatment. 
Survival was significantly shorter when the extent of hepatic 
disease was >25% (p=O.OS), when extensive extra-hepatic disease 
was present (p<O.OOS), when alkaline phosphatase level serum 
levels were >2x normal (p<O. 02) or when the performance status 
was .<100% (p<0.001). Toxicity consisting mainly of fever, 
fatigue, anorexia and weight loss was serious in Group I a:nd 
min-imal in Group II. There was virtually no haematological 
toxicity in Group I whereas transient leukocytopenia and mild 
thrombocytopenia occurred at the end of each cycle in Group II. 
There were no drug related deaths. CEA-levels corresponded to 
stage and course of disease in 18 out of 20 patients. LA! assays 
remained unaltered irrespective of the mode of therapy. In both 
chronically and cyclically treated patients riFN-alphaA led to a 
"short lived" augmentation of NK cell activity. In the cyclically 
treated group this was are current phenomenon at the start of 
each cyle whereas a significant depression of NK cell activity 
was seen in chronically treated patients throughout the rest of 
the course of treatment. Interferon-gamma production capacity 
upon stimulation with concanavalin-A was impaired in most 
patients when they entered the study and was s_ignificantly 
stimulated during riFN-alphaA therapy whereas a reduction in the 
response to phythaemagglutinin (PHA) was seen. It was concluded 
from this study that riFN-alphaA has no significant antitumor 
activity in patients with metastatic colorectal cancer. The 
differences in toxicity and in immunomodulative effects between 
the two treatment schedules may have important implications for 
the design of future studies with riFN-alphaA in humans in a 
different setting. 
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INTRODUCTION 
Colorectal cancer is second only to lung cancer as the most 
common malignancy in the western hemisphere and causes 10-15% of 
all cancer deaths. Five year survival has not improved over the 
last 30 years as the tumor proved refractory to most chemothera-
peutic agents. Five-fluorouracil (5-FU), the standard agent in 
this disease, has no effect on long term survival in metastatic 
colorectal cancer when given alone or in combination with other 
drugs (Davis and Kisner, 1978; Falkson and Falkson, 1981; York-
shire Gastrointestinal Study Group, 1984). Adjuvant therapy with 
5-FU alone (Grage and Moss, 1981) or in combination with MeCCNU 
(Higgins et al., 1984) and/or MER (GITSG, 1984) showed only a 
minor benefit in patients with Dukes C disease and in patients 
with rectal cancer, or showed no benefit at all. 
In view of the absence of an effective adjuvant therapy regimen 
for colorectal cancer one was justified to perform phase II 
trials in patients with metastatic colorectal cancer as soon as 
interferon became available in large enough quantities to perform 
these studies. With the advent of recombinant interferon prepar-
ations it became possible to perform clinical studies. 
Interferons are proteins with anti-viral, anti-proliferative and 
immunomodulatory activity (Ho and Amstrong, 1975). Amongst the 
group of solid tumors interferon-induced tumor regression had 
been reported in metastatic breast cancer (Gutterman et al., 
1980; Borden et al., 1982), renal cell carcinoma (Quesada et al., 
1983) and in malignant melanoma when combined with cimetidine 
(Flodgren et al., 1983) at the onset of our study. In the present 
phase I-II study the potential antitumor efficacy, the toxicity 
and the immunomodulatory effects of high dose riFN-alphaA therapy 
in patients with advanced metastatic colorectal cancer were 
evaluated. 
PATIENTS, MATERIALS AND METHODS 
Patients 
Entry criteria 
Patients with histologically confirmed resected colorectal can-
cer, without invasion into neighbouring organs and with histolog-
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ically or cytologically confirmed measurable metastatic lesions 
were eligible for treatment; ascites, pleural fluid and bone 
metastases were not considered evaluable lesions. Patients who 
entered the study could not have other malignant disease nor 
previous or concurrent chemo-, irnrnuno- or radiotherapy. Other 
entry criteria included: age < 80 years, Karnofsky index > 70%, 
bilirubin < 20 rnrnol/1, creatinine clearance > 50 ml/min, no 
uncontrolled infections, no symptomatic cardiovascular disease, 
white blood cell count > 3 x 10 9 /l and no non-steroid antiinflam-
matory therapy. 
Patients characteristics 
Twenty patients'· 11 females and 9 males entered the study. Their 
median age was 62.5 years (range 39-78). The median interval 
between surgical resection of th.e primary tumor and interferon 
treatment was 5 months (range 1-49 ) . Metastatic lesions were 
clearly measurable with CT-scan and ultrasonography in all cases. 
CT and ultrasonography were done every 6 weeks. CEA-levels were 
determined every 6 weeks. In 18 patients liver metastases provid-
ed the measurable lesions, in one patient retroperitoneal and 
supraclavicular lyrnphnodes and in one patient retroperitoneal 
lyrnphnodes and peritoneal lesions. Extent of hepatic and extra-
hepatic disease are summarized in table I. 
Interferon 
Recombinant leukocyte interferon-alphaA (riFN-_alphaA , Ro-22-8181 
made by Hoffmann - LaRoche, Basel) was used. The material has 
been purified up to > 96% homogeneity and is free of detectable 
endotoxin when checked with the limulus test. 
Treatment schedules 
Ten patients were treated chronically (Group I) and recieved 
twice weekly up to 20 x 10" I. U. /m2 of r!FN-alphaA i .m. for a 
period of 12 weeks on an outpatient basis. The other 10 patients 
were treated cyclically (Group II) and recieved for 1-4 periods 
of 8 consecutive days up to 20 x 10 6 I.U./m2 i.m. daily at inter-
vals of 20 days. The total dose strived at in 12 weeks was 24 x 
20 x 10 6 I.U./m2 per patient. 
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Response catagories 
The usual response catagories were used: complete response (CR) 
was defined as disappearance of all evidence of disease lasting > 
6 weeks; partial response (PR) was defined as > 50% decrease in 
the sum of the product of diameters of marker lesions lasting > 6 
weeks, without appearance of new lesions; progressive disease 
(PD) was defined as an increase of > 25% in the diameters of 
marker lesions and/or the appearance of new lesions; stable 
disease (SD) was defined as failure to qualify for CR, PR or PD. 
Patients receiving at least 8 x 20 x 10 6 I.U./m2 were considered 
evaluable. 
Immunological monitoring 
For immunological monitoring the following tests were performed 
sequentially : tube leukocyte adherence inhibition (LAI) assays 
were performed in 10 patients on days 0, 28, 56 and 77 using 
colon cancer extracts of proved specificity as specific antigen 
and breast cancer extracts as non-specific antigen as is routine 
in our laboratory ( 22). A non-adherence index (NAI) > 30 was 
considered as positive, a NAI < 30 as negative; NK cell activity 
was sequentially evaluated in 8 chronically treated patients on 
days 0, 2, 7, 28, 56 and 77 and in 2 cyclically treated patients 
on days 0, 2 and 7 of each cycle while simultaneously assays 
using in vitro riFN-alphaA pretreated effector cells were per-
formed to determine boostability; on ·the same days gamma-Inter-
feron production capacity upon stimulation by Concanavalin A and 
the blastogenesis response upon stimulation by PHA. were deter-
mined in these patients. Details of the methods used·are describ-
ed by Tank et al.(1984; 1985). 
RESULTS 
All patients were evaluable for tumor response and toxicity. 
Follow up ranged from 3 - 20 months after stopping treatment as 
was determined by survival. The characteristics of the patients 
and their response to the chronical (A) or cyclical (B) treatment 
with riFN-alphaA are summarized in table I(A) and table I(B). 
'12\BIE I (A) : Cllaracteristics of patients treated with riFN-al);ilaA twice a week (Chronically) 
Patient Extend Extend CEA. Total dose of Tunor Survival 
(sex:, age) Hepatic Disease Extrahepatic Disease start- end riFN in U/m2 Response (nonths) 
1. M, 59 Illllltiple R + L 
------
> 600 - > 600 260 X 106 PD* 20 
25% < X < 50% 
2. M, 66 Illllltiple R + L ~etroperitoneal lnn. > 600 - > 600 360 X 106 PD 20 
X > 50% 
3. F, 76 Illllltiple R + L retroperitoneal lnri. 96 - 423 205 X 106 PD* 18 
X < 25% 
4. M, 62 Illllltiple R + L retroperitoneal lnn. 12 - 12 600 X 106 PR 26 
25% < X < 50% 
5. F, 48 
----
retroperitoneal lnri. 175 - 398 480 X 106 PD* 12.5 
perit. carcincmatosis 
6. M, 39 ---- retroperitoneal lnn. 49 - 94 280 X 106 PD 5 
supraclavicular lnri. 
7. F, 61 solitary. central ------ 354 - 228 180 X 106 PD* 8 
X < 25% 
a. M, 69 Illllltiple R + L ------ 14 - 95 400 X 106 l'!:i* 16 
X < 25% 
9. F, 60 Illllltiple R + L ------ 471 - > 600 380 X 106 PD* 22 
X < 25% 
10. M, 62 Illlll tiple R + L ------ 116 - 269 325 X 106 PD* 18.5 
X < 25% 
TABLE I (B) : Characteristics of patients treated with riEN-al{ilaA in cycles of 8 consecutive days (Cyclically) 
Patient Extend ·Extend CEA Total dose of Turror Survival 
(sex, age) Hepatic Disease Extrahepatic Disease start- end riFN in U/m2 Response (m:::>nths) 
11. M, 66 solitaJ:y R ------ 2.4 - 3.6 . 480 X 106 PO 28 
X < 25% 
12. F, 57 multiple R + L ------ 19.9 - 19.5 480 X 106 SD 16 
X < 25% 
13. M, 64 multiple R + L 
------
11.9 - 30 480 X 106 PO* 11.5 
X< 25% 
14. F, 65 diffuseR+ L Retroperitoneal lnn. 210 - > 600 160 X 106 PD 3.5 
X > 50% Lung netastases 
15. F, 72 diffuseR+ L Lung netastases 48 - > 600 160 X 106 MR 6.5 
X > 50% 
16. M, 54 multiple R + L Lung netastases 288 - > 600 480 X 106 PO 9 
25%<X<50% 
17. F, 78 solitaJ:y L ~troperitoneal lnn. 120 - 318 640 X 106 PO* 12 
X < 25% Lung netastases 
18. F, 78 multiple R + L ------ 98 - 120 240 X 106 PO* 15 
X < 25% 
19. F, 65 multiple R + L Retroperitoneal l.nn. 2.5 - 2.5 160 X 106 PO 4.5 
25% < X < 50% 
20. F, 73 multiple R ------ 132 - 258 640 X 106 PO* 17 
X < 25% 
M = male; F = fe:oale; PD = progressive disease ( > 25%) ; PD* = progressive disease ( <25%) ; SD = stable disease; 
MR = mixed :r:esp:x!S8; l'R = partial :r:esp:x!S8; X = % of liver replaced by tum:Jr; lnn. = lynpmodes. 
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Tumor response 
The tumor response to treatment of the 20 patients is listed 
in table I. One patient (no.4, group I) had a partial remission 
at 12 weeks after starting treatment. Treatment had to be discon-
tinued at that point because of severe fatigue and weakness. The 
partial remission however progressed to a near total remission ( 
> 90% tumor reduction ) during the following months. His perfor-
mance status was rapidly reestablished at 100% and previously 
severely disturbed liver functions became normal. Seven months 
after stopping treatment, CEA-levels rose and progressive disease 
compared to the state of near total remission was demonstrated by 
CT and ultrasonography. A second course of 10 x 10 6 I.U./m2 twice 
weekly was given for 6 weeks at which point it had to be stopped 
because of intolerable toxicity. Disease was slowly progressive 
from then on and the patient died 26 months after the initial 
diagnosis of metastatic disease. One patient (no 12, group II) 
had no tumor growth at all over a period of 5 months while CEA 
levels remained unchanged. She was classified as having stable 
disease. One patient (no 15, group II) developed a partial remis-
sion of her liver metastases after one course of treatment. Three 
weeks later a brain metastasis became clinically evident and was 
confirmed by CT. Her performance status deteriorated rapidly and 
further treatment was not given. She was classified as having a 
mixed response (MR). Ten patients showed continuous but minimal 
growth (increase < 25%) of their marker lesions throughout treat-
ment. All these patients but one (no 7, group I) had a marked 
concomittant increase in CEA-levels and had slowly progressive 
disease after stopping treatment. Patient no 7 developed obstruc-
tive jaundice and died 6 months after stopping treatment. 
Although the measured increase in tumor mass was < 25% these 
patients are listed in table I as having progressive disease 
(PD*). Seven patients had unequivocal progressive disease 
throughout treatment and are listed as PD. 
Overall mean survival from the date of diagnosis of metastatic 
disease was 14.5 ( SD .±. 7. 0) months. Median survival was 15.5 
months. Mean survival in Group I was 16.6 (.±. 6.4) months vs. 12.3 
(.±. 7. 2) months in Group II (NS). u·sing the student-t test the 
following factors, as determined at the date of diagnosis of 
metastatic disease, were found to correlate with survival: Extent 
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of hepatic disease (x) : x < 25% vs. x > 25% ; 17.3 (~ 5.8) vs 
10.6 (~ 7.5)mts , p = 0.05. Extent of extra hepatic disease : Eo 
(none), 17.2 (~ 5.5), E1 (only retroperitoneal lymphnodes), 15.9 
(~ 8.0), E2 (retroperit. lnn. +lung or carcinosis peritonei), 
7.5 (~ 4.4) :Eo vs. E1: NS, Eo vs. E1 + E2: NS (p < 0.08), Eo 
vs E2 : p =· 0.005. Liver Metastases (LM') only vs. LM + E1-E2 : 
17.2 (~ 5.5) vs. 12.4 (~ 8.1), NS ; LM only vs. LM + E2 : 17.2 (~ 
5.5) vs. 6.7 (~ 4.6), p < 0.02. Alkaline Phosphatase (AlkPhos) 
levels : Normal (N) or < 2 x N .vs. AlkPhos > 2 x N : 15.7 (~ 6.5) 
vs. 6. 0 (~ 2. 3), p < 0. 02. Performance Status (PS) of the pa-
tient at the time o~ diagnosis of metastatic disease correlated 
best with survival : PS = 100% (16 pts.) 
80-90%) 1 16.8 (~ 5.6) VS, 4.9 (~ 1.3) 
vs PS <100% ( 4 pts., 
p < 0. 001. Survival 
from the date of diagnosis of metastatic disease in these pa-
tients did not show a correlation with : patients sex ; site, 
diameter and histologic grade of the primary tumor nor with the 
stage of disease at the time of diagnosis of the primary tumor. 
The correlation between the different factors at the time of 
diagnosis of metastatic disease and survival are summarized in 
table II. 
Table II : 
Factors correlating with survival in metastatic colorectal cancer 
Extend of hepatic disease < 25% vs > 25% p 0.05 
- Extend of extrahepatic disease Eo vs E2 p < 0.005 
- Liver Metastases (LM) only vs LM + E2 p < 0.02 
- Alk. Phos. Normal (N) VS Alk. Phos. > 2 X N p < 0.02 
- Performance Status (PS) 100% VS PS < 100% p < 0.001 
(Factors as determined at the time of diagnosis of metastatic 
disease) 
CEA-levels were elevated in all but two (no 11 and 20) patients. 
CEA-levels remained unchanged in the patients with a partial 
response and with stable disease. A steep rise or a maximal level 
was seen in 17 patients which corresponded well with their course 
of disease. Only in one patient (no 7) a fall in CEA-level occur-
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red which did not reflect her course of disease. Overall perfor-
mance of CEA as a monitoring device was excellent. 
Toxicity 
High dose riFN-alphaA treatment when administered twice 
weekly caused far more and heavier side effects than expected. 
High fever with chills after each dose, prolonged nausea, 
anorexia, fatigue and weight loss were pronounced as is indicated 
in table III. Hallucinations, confusion and lethargy occurred in 
3 patients but dis,appeared upon reducing the dose. In all but two 
patients (no' 4 ,5) in group I dose adjustment had to be made as 
can be deducted from the total dose recieved by each patient as 
indicated in table I. Cyclic treatment was very well tolerated. 
High fever with chills and nausea occurred only on day one of 
each cycle. Anorexia, fatigue and weight loss were absent or much 
less pronounced (table III). Six patients recieved 3 - 4 com.,-
plete full dose cycles. One patient (no 18) withdrew from treat-
ment after 1.5 cycles in spite of only mild side effects. Three 
patients (no 14, 15, 19) with extremely advanced disease recieved 
only 1 cycle because of rapidly progressive disease (no 14,19) 
and .brain metastasis (no 15). Other side effects were relatively 
benign. Eleven patients complained of getting numb fingers for a 
period of 1/2 - 2 hours after each dose of interferon given. A 
bitter taste was a side effect in 12 patients. Objective neuro-
toxic effects or permanent sequelae were not found by a consul-
tant neurologist at the end of treatment in any of the patients. 
·Four patients developed Herpes Hominis lesions of the lips in the 
first week of treatment which disappeared while continuing treat-
ment. Mild alopecia was seen in six patients and lasted for about 
2 months. Virtually no haematological toxicity was seen in Group 
I. Daily injections had a significantly more pronounced (p < 
0.01, Wilcoxon) depressive effect on white blood cell and plate-
lets count than did twice weekly administration. Transient mild 
disturbance of liver functions was seen only in one patient in 
Group II. Renal functions were not affected in any of the pa-
tients but in one (no 7, group I) who developed transient pro-
teinuria. No cardiotoxicity was observed in any of the patients 
when electrocardiograms made at the start and at the end of 
treatment were compared. 
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Table III TOXICITY of riFN-alphaA 
SYMPTOMS 
Flue-like symptoms 
Weight loss 
- none 
- mild (<5%) 
- moderate (5-10%) 
- severe (>10%) 
Anorexia 
Nausea 
Fatigue 
- none 
- mild 
- moderate 
- severe 
Numb Fingers (l/2-2hrs) 
Bitter Taste 
Hallucinations 
Lethargy 
Herpes Facialis 
Alopecia (mild) 
Haemoglobin > 7.5 mmol/1 
< 7.5 mmol.l 
WBC (cells/mm3 ) > 4000 
3000 - 4000 
1500 - 3000 
Platelets (cells/mm3) 
> 150,000 
100,000 - 150,000 
50,000 - 100,000 
Rise in Liver Enzymes 
Proteinuria 
GROUP I (lOpts) 
10 
4 
2 
1 
2 
8 
3 
0 
3 
3 
4 
6 
8 
3 
4 
3 
3 
8 
2 
7 
3 
0 
9 
1 
0 
0 
1 
* = only on first day of treatment cycle; WBC 
count; hrs = hours; pts = patients 
GROUP II (!Opts) 
10* 
7 
1 
2 
0 
4 
3* 
3 
3 
3 
1 
5 
4 
0 
1 
1 
3 
9 
1 
1 
3 
6 
1 
7 
2 
1 
0 
white blood cell 
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Immunological monitoring 
Sequential tube LAI assays were performed in 10 patients. In 
7 patients the LAI was positive and negative in three. The react-
ions before, during and after treatment with riFN-alphaA did not 
change. 
Sequential N.K cell activity tests showed in all chronically 
treated patients tested a 2 fold increase of NK cellactivity on 
day 2 after the start of treatment. Continuation of twice weekly 
injections resulted in a rapid decline of activity (on day 7) , 
followed by a permanent marked two fold depression and loss of 
boostability by riFN-alphaA in vitro for the rest of the 
treatment period as is 'illustrated in Figure 1. 
Figure 1 
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Figure 1 : Typical NK cell cytotoxicity profile at effector 
target ratio of 40 : 1 of patients treated with high dose riFN-
alphaA twice a week. 1---1 No effector pretreatment with riFN-
alphaA; 0---0 effector pretreatment with riFN-alphaA. A 2-3 fold 
increase of NK cell cytotoxicity is seen at the start of 
treatment. This is followed by a 2-fold depression of NK cell 
cytotoxicity during the rest of the treatment period. Also the 
loss of boostability of NK cell activity by effector pretreatment 
with riFN-alphaA is noted. 
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The cyclically treated patients tested showed a two fold increase 
of NK cell activity on day 2 of each cycle. NK cell activity 
levels at the start of each cycle were normal and there was no 
loss of boost-ability in vitro as is depicted in Figure 2. 
Figure 2 : 
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Figure 2 : Typical NK cell cytotoxicity profile at effector 
target ratio of 40 : 1 of patients treated cyclically (3 cycles 
of 8 consecutive days) with high dose riFN-alphaA. 1---1 no 
effector cell pretreatment with riFN-alphaA. 0---0 effector cell 
pretreatment with riFN-alphaA. A + two fold increase of NK cell 
cytotoxicity is seen at the start of each treatment cycle. No 
chronic depression of NK cell activity is seen. No loss of 
boostability of the effector cells is seen when pretreated with 
riFN-alphaA. 
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Gamma-Interferon Production Capacity upon induction with Con A 
proved to be extremely low ( < 10 urni ts/ml) as was the PHA 
response (60% of the normal) in the patients when tested as the 
entered the study. RIFN-alphaA therapy resulted in most of them 
( 6 out of 8) in a significant production of IFN-gamma. In the 
only two patients that had a base line GIPCA > 0 units/ml a 
depression was noted following riFN-alphaA treatment. The most 
consistent finding in the chronically treated patients was an 
inverse correlation between the GIPCA and PHA response. This 
pattern is shown in Figure 3. 
Figure 3 : 
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Figure 3 Typical response pattern of the Gamma-Interferon 
Production Capacity (GIPCA) and blastogenesis response to PHA in 
a patient treated twice weekly with high doses of riFN-alphaA. 
1----1 GIPCA ; 0---0 PHA response. The GIPCA level before the 
first dose of riFN-alphaA is undetectable but is boosted to 
normal levels upon administration of riFN-alphaA. There is an 
inverse correlation bedtween the GIPCA and the PHA response. 
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In 2 cyclically patients the GIFCA and FHA responses were deter-
mined. In 1 patient a cyclic in-crease was registered in the 
GIFCA after riFN-alphaA adminis-tration as is depicted in Figure 
4. In the other patient GIFCA remained undetectable. 
Figure 4 
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Figure 4 : GIFCA and FHA response pattern in a patient treated 
with high doses of riFN-alphaA for 3 cycles of 8 consecutive 
days. 1---1 GIFCA; 0---0 FHA response. GIFCA levels were unde-
tectable before riFN-alphaA treatment and boosted to normal 
levels by the administration of riFN-alphaA. An inverse correla-
tion seems to exist between the GIFCA and the FHA response. 
DISCUSSION 
High dose riFN-alphaA treatment when administered twice 
weekly proved to be quite toxic. Especially anorexia and fatigue, 
reflected in considerable weight loss were pronounced. High dose 
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cyclic treatment appeared ,except for transient leukocyte- and 
thrombocytopenia, comparatively nontoxic and was well tolerated. 
Paresthesias, taste disturbances, fatigue, lethargy and halluci-
nations suggest a certain degree of neural involvement. 
Interferon-induced, dose-dependent, reversible central nervous 
system toxicity with alterations in electroencephalograms and 
electroneuromyograms has been reported by Smedley et al. ( 1983) 
and by Mattson and Niiranen ( 19 83) . We did not perform these 
investigations but thorough neurological examinations revealed no 
objectively demonstrable damage in any of our patients. 
Reactivation of endogenous Herpes virus Hominis was observed in 4 
patients. Apparently the classic inhibitory effect of interferon 
I ' 
on virus replication is "overruled" by non-antiviral effects in 
the high doses used. Only one partial response in 20 patients was 
seen. This is in agreement with Neefe et.al.(1984), who reported 
one partial remission in 18 patients treated with the same riFN-
alphaA preparation for previously untreated colorectal cancer. 
Studies with low dose natural IFN-a1pha (Figlin et al., 1983; 
Oberg et al., 1983), low dose lymphoblastoid IFN (Chaplinski et 
al., 1983), and another recombinant IFN-alpha preparation given 
in large doses (Lundell et al., 1984; Silgals et al., 1984) were 
not able to demonstrate anti tumor effects in this disease. The 
results and ,some details of the trials performed in metastatic 
colorectal cancer are summarized in table IV. Wrigley et al. 
(1984) reported 2 patients with a partial response out of 20 
patients treated with- either high or low dose riFN-alpha when 
combined with 5-FU. 
One of our patients had a mixed response and in one patient 
unequivocal stable disease lasted for 5 months. Growth of the 
marker lesions was very slow (increase < 25%) in 10 patients. 
According to the official criteria they all could have been clas-
sified as having stable disease during their period of treatment. 
CEA-levels rose markedly over the same period and no acceleration 
but continuous slowly progressive disease was seen after stopping 
treatment. In our opinion these patients should not be classified 
as stable disease since most likely they suffered from slowly 
progressive disease before, during and after treatment. 
It remains to be seen wether stable disease is a usefull response 
category in phase-II studies since reporting that interferon 
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induced stable disease in 11 out of 20 patients would leave a 
falsely positive impression about the effectiveness of treatment 
with riFN-alphaA in advanced colorectal cancer. In 7 patients 
measurements of marker lesions showed unequivocal progressive 
disease. 
Table IV 
Reference 
Phase II trials with IFN in patients with metastatic 
colorectal cancer 
Interferon 
Type 
Qose No evaluable Resp9nse 
10 6 Units patients CR/PR 
% 
Chaplinski HuiFN(Ly) 3 (i.m) 18 0/0 0 
1983 tiw 
6 wks 
Fig lin HuiFN(Le) 3 (i.m.) 18 0/0 0 
1983 qd 
5 wks 
Oberg HuiFN(Le) 3 (i.m.) 9 0/0 0 
1983 qd 
4 wks 
Silgals riFN-alpha2 30,50 (i.v.) 21 0/0 0 
1984 qd X 5 d 
q 2-3 wks 
Lundell riFN-alpha2 50 (i.v.) 18 0/0 0 
1984 qd X 5 d 
q 6 wks 
Neefe riFN-alphaA 50 (i.m.) 21 0/1 5 
1984 tiw 
Flodgren riFN-alphaA 7.5 (i.m) 16 0/0 0 
1985 tiw 6 wks 
.:!:. cimetidine 
Eggermont riFN-alphaA 20 (i.m.) 10 0/1 10 
1986 biw 12 wks 
qd X 8 d 10 0/0 0 
q 3 wks 
HuiFN(Ly) = human lymphoblastoid IFN;_ HuiFN(Le) = Human leukocyte 
IFN; CR = complete response; PR = partial response; q = every; qd 
= daily; biw = twice a week; tiw = three times a week; wk = week; 
i.m. = intramuscularly; i.v. = intravenously. 
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Survival in metastatic colorectal cancer was found to correlate 
with extent of hepatic disease, extent of extrahepatic disease, 
level of alkaline phosphatase and with performance status. 
Similar correlations have been reported by others (Goslin et al., 
1982; Petrelli et al, 1984; Wagner et al., 1984). Survival in 
metastatic disease did not show a correlation with patients sex, 
site, diameter and histologic grade of the primary tumor or with 
the stage of disease at the time of diagnosis of the primary 
tumor. Alkaline phosphatase levels were normal (N) in 9 patients 
and < 2 x N in 7 patients when metastatic disease was diagnosed. 
Other liver function tests were even less sensitive which is 
consistent with the re~ort by Schreve et al.(1984). For diagnosis 
as well as monitoring of metastatic colorectal cancer there seems 
hardly any place left for liver function tests since CEA-levels 
were found to be very; reliable. 
Tube LAI test results were not affected by interferon treatment 
and the test was found to be of little value in monitoring meta-
static disease in these patients. The negative LAI results in 3 
patients could be attributed to an inherent insensitivity of the 
assay or to a tumor overload phenomenon as described by Thomson 
et al. (1982). Monocytes play a central role in triggering the 
cascade of events leading to non-adherence in the tube LAI . Our 
results indicate that the administration of riFN-alphaA does not 
affect this monocyte activity. Modulation of human NK cell activ-
ity by exogenous administration of human leukocyte interferon is 
well documented (Einhorn et al., 1978; Herberman et al., 1979; 
Huddlestone et al., 1979; Lindal et al., 1972). After an initial 
"short lived" two fold augmentation of NK cell activity this 
cytotoxicity was markedly depressed during interferon treatment 
when administered chronically. This confirms the work of Herber-
man' s group (Mal uish et al. , 19 8 3) and could be explained by an 
interferon-induced exhaustion of the precursor NK cell popula-
tion. Restoration of this precursor population apparently occur-
red during the 20-day-interferon-free intervals in the cyclically 
treated patients since a normal level of NK cell activity was 
found at day 0 of each cycle. A significantly augmented peak 
level was seen on day 2 of each cycle which tapered off·to normal 
levels on day 7 of each cycle. In vitro tests with riFN-alphaA -
pretreated lymphocytes showed significantly enhanced NK cell 
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activity only on day 0 of the chronically treated patients and 
only on day 0 of each cycle in the cyclically treated patients. 
This indicates that in vivo administration of riFN-alphaA leads 
to a maximum attainable NK cell activity as has been reported by 
Einhorn et. al. (Einhorn et al., 1980 and 1984). RIFN-alphaA 
treatment resulted in normalisation of initially impaired inter-
feron-gamma production in our patients. NK cells have the abili-
ty to produce interferons (Ratliff et al., 1982) and Interleu-
kine-2 ( IL-2) is known · to increase interferon-gamma production 
(Kawade et al., 1983). These findings suggests a network of 
interactions between ·IFN-alpha , IL-2 , IFN-gamma and NK cells 
that remains to be elucidated. The mode of action by which 
interferon treatment can result in an. antitumor effect in vivo 
has not been clarified. The odds for clinically relevant succes 
should however be more in favor for interferon .therapy when less 
tumor cells are present than in the situation of advanced meta-
static cancer. With one partial response, one mixed response and 
one stable disease , riFN-alphaA treatment was shown to exert an 
antitumor effect in some patients in spite of the overwhelming 
number of tumor cells present. Cyclic treatment appeared the best 
scheme in view of its low clinical toxicity and its immunostimu-
lative properties. It deserves further investigation in a setting 
where less tumor cells are present. 
CHAPTER IX 
GENERAL DISCUSSION 
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GENERAL DISCUSSION 
The experimental work in rodents with the interferon inducer 
ABPP, presented in this thesis, has demonstrated the limited 
antitumor effects of ABPP when administered alone. The results of 
our experiments with ABPP were in line with the general observa-
tion that biological response modifiers are effective only when 
the tumor load is small. ABPP was only effective when administer-
ed within 24 hours after tumor inoculation, when tumor load is 
small and tumor cells are still in their highly vulnerable blood 
born and early lodging phase. No significant effect was noted in 
the clinically much more important experimental setting e.g. 
against early established (day 3) or advanced (day 7 - 10) tumor. 
When ABPP was administered in combination with other biologicals 
like IFN-gamma or TNF however, significant antitumor activity was 
seen also against established tumor. This is an encouraging ob-
servation since it shows the usefulness of combining biologicals 
that may exert their antitumor effects through different mecha-
nisms. Further more it may lead to the development of effective 
treatment schedules with reduced toxicity as a result of dose 
reductions of the individual biologicals in combinations with 
synergistic antitumor activity. Superior activity was demon-
strated when chemoimmunotherapeutic treatment schedules, in which 
the administration of cyclophosphamide preceded ABPP were applied 
to early established as well as far advanced metastatic tumors. 
Repetitive treatment cycles were highly effective and even cured 
the majority of mice with established intraperitoneal tumor. 
Given the fact that the administration of ABPP is associated with 
very little toxicity it can be concluded that ABPP may be used 
clinically with success in an adjuvant setting, when administered 
in combination with cyclophosphamide. Special care should be 
taken to design a treatment schedule that consists of repetitive 
cycles at time intervals avoiding the hyporesponsiveness observed 
characteristically when multiple doses of biologicals are given 
within a short period of time. 
The observation that in vivo generation of LAK cell activity 
after the intraperitoneal administration of ABPP was superior at 
the local-regional level, in the peritoneal cavity, special 
attention should be given to the possibilities to use ABPP as an 
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adjunct in intracavitary treatment protocols. It is our feeling 
that ABPP has shown enough potential in these experiments that 
justify clinical studies, preferably in an adjuvant setting in 
which ABPP is administered systemically (orally) or intracavitary 
as an adjunct to another treatment modality. 
The set up and the results of the Phase II trial with riFN-
alphaA that we performed in patients with metastatic colorectal 
cancer are typical examples of the "interferon experience". It 
is rather appalling to see with how little success the enormous 
number of phase II trials, performed with various interferon 
preparations and tested in a wide array of malignancies over the 
last 5 years, has met (Goldstein and Laszlo, 1986). With excep-
tion of the big success in the treatment of hairy cell leukemia 
(Quesada et al., 1985a; Thompson et al., 1985) and the modest 
success rates in the treatment of lymphoma (Foon et al., 1984), 
in Kaposi's sarcoma (Real et al., 1984), in multiple myeloma 
(Costanzi et al., 1984), and in renal cell cancer (Quesada et 
al., 1985b), no significant effect against any of the solid 
tumors has been observed. This situation may in part be due to 
the fact that too few phase I studies were performed before the 
"big boom" in phase II trials. Too little was known about op-
timal doses, routes of administration, local-regional versus 
systemic effects, induction of hyporesponsiveness etc. when most 
phase II studies were embarked upon. Too many similar phase II 
studies were performed, generating many overlapping data, answer-
ing few new scientific questions. Illustrative of this situation 
is that the most interesting result of our phase II trial was the 
phase I aspect of the study by applying two treatment schedules 
that appeared to differ greatly with respect to the associated 
toxicity and immunomodulative properties. This observation is 
indicative of the fact that with the same amount of effort, time 
and money that was invested in the big wave of phase II trials 
with IFN conducted up till now, much more valuable information 
could have been gathered and might have been successfully applied 
in those areas where interferons have proven to be clinically 
successful. 
A more fundamental question is whether the classical phase 
II trial in patients with advanced, measurable metastatic disease 
is an appropriate and justified method to reach conclusions 
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concerning the efficacy, potential clinical value and biological 
activity of biological response modifiers. It is well known and 
has been shown again in this thesis that biologicals are effec-
tive only when the tumor load is small. From a theoretical point 
of view and as a result of the overwhelming evidence from exper-
imental work in animals it is not logical to perform these phase 
II trials and look for tumor response rates in advanced cancer, 
as is done in the standard screening procedure for chemother-
apeutic drugs. 
A different approach in the clinical evaluation of biological 
response modifiers may well be justified by focusing on extensive 
phase I studies aimed at arriving at treatment schedules with 
optimal immunostimulatory effects and minimal toxicity. Once 
such a schedule is obtained its clinical value would be best 
tested in an adjuvant setting, alone and in combination with 
other treatment modalities in patient populations that have a 
particularly poor prognosis like "radically operated" pancreas, 
gastric of esophageal cancer patients, Dukes c~~ colorectal can-
cer patients, stage II melanoma patients etc. If results would be 
encouraging with these poor risk populations various groups of 
patients with a greater variety of malignancies could then be 
treated in phase III trials in order to establish the efficacy 
and the broad clinical value of the agent. 
Although "the interferon experience" has been a sobering one, 
especially for an overly optimistic laic society, it would be 
wrong to conclude that immunotherapy has no future. 
Breakthroughs in biotechnology have created unprecedented oppor-
tunities to do more basic, more refined, quantitatively and 
qualitatively superior research unraveling the complexity of the 
immune response to cancer and increasing the possibilities to 
manipulate it. 
It remains extremely difficult to predict immunotherapeutic ef-
fects since so many different factors influence the immune status 
of the host, determine the outcome of immunotherapy and influence 
tumor growth. We have shown elsewhere that surgery and blood-
transfusions can profoundly influence tumor growth and determine 
the effect of immunotherapy (Jeekel et al., 1982; Marquet et al., 
1986; Eggermont et al., 1987e). Repetitive treatment cycles with 
lymphokines may rapidly become ineffective when serum inhibiting 
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factors emerge and block the crucial lymphokines or neutralize 
the effector cells of immunotherapeutic regimens (Eggermont and 
Sugarbaker, 1987f). Actively ongoing immune responses in the 
tumor bearing host may consume lymphokines and thus competitively 
inhibit the action of killer cells and thus abrogate their anti-
tumor effects (Eggermont et al., 1987c; Sugarbaker et al.,l987b). 
On the other hand alloimmune responses at the site of the tumor 
may generate IL-2 and activated killer cells in situ and thus 
augment the efficacy of immunotherapeutic regimens (Eggermont et 
al.,l987h;). The generation of an inflammatory reaction within 
tumor tissue recruits inflammatory cells to the site of the tumor 
and may instigate aspecific kil'ling as well as augment the popu-
lation of killer cell precursors at the tumor site. Immunotherapy 
may be augmented by such a favorable concentration of effector 
cells (Steller et al., 1986; 1987). The above illustrates that 
systemically ongoing immune responses may have immunosuppressive 
effects and thus facilitate tumor growth or render immunotherapy 
ineffective, while similar processes at the local-regional level 
or at the site of the tumor can potentiate the antitumor effects 
of immunotherapy. 
Effective routing of lymphokines but especially of the effector 
cells to the tumor site may well be the crucial step towards suc-
cessful immunotherapy. Local-regional treatment concepts (Sugar-
baker et al., 1987a; Eggermont et al.,l987i; 1987j), adoptive 
immunotherapy regimens improved by specificity of the effector 
cells and the use of monoclonal antibodies may improve the 
efficacy of immunotherapeutic regimens in the future by increas-
ing effector cell - tumor cell contact and effector cell to 
tumor cell ratios. 
In few scientific fields has the increase in knowledge been as 
spectacular as in immunology over the last two decades. It is 
therefore impossible to predict which developments lay ahead, but 
most likely immunotherapy will develop further and establish 
itself as the fourth modality in the treatment of cancer. 
CHAPTER X 
SUMMARY 
SAMENVATTING 
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SUMMARY 
The first part of this thesis consists of a series of 
experiments, conducted in rats and mice, with the low molecular 
weight interferon-inducer ABPP (2-amino-5-bromo-6-phenyl-4(3H)-
pyrimidinone) . Its anti tumor and immunomodulating effects were 
evaluated in vitro and in vivo using a variety of tumors differ-
ing in immunogenicity and histology. In various tumor models the 
role of tumor load and tumor site in the outcome of immunotherapy 
with ABPP were investigated. Further more the efficacy of combin-
ing ABPP with other biologicals like recombinant Rat Interferon-
gamma (rRIFN-gamma) and recombinant Murine Tumor Necrosis Factor 
(rMuTNF) and recombinant Human Interleukin-2 (IL-2) or with the 
cytostatic agent cyclophosphamide (CY) was studied. 
In chapter III and rv we showed that ABPP has no direct 
antiproliferative or cytotoxic effect in vitro and that therefore 
the antitumor effects in vivo were most likely mediated by its 
immunomodulating properties : the induction of IFN and the activ-
ation of natural killer (NK) cells and macrophages. It was demon-
strated that pretreatment of BN rats with the strong interferon-
inducer ABPP significantly retarded tumor growth of the nonimmun-
ogenic liposarcoma LS175 in the subcutaneous (s.c.) tumor model, 
whereas the administration of the very weak interferon-inducing 
homologue AIPP did not. Since we subsequently showed that both 
agents enhanced NK cell activity equally effectively it was con-
cluded that the difference between the two agents in antitumor 
activity in the s.c. model might reflect their capacities to 
induce IFN. Further more these results suggested that the capa-
city to enhance NK cell activity might not depend on the prior 
induction of IFN. Also we demonstrated that both agents inhibited 
equally effectively the development of lung metastases with LS175 
in BN rats. Since both agents are equally potent activators of 
NK cells and as NK cells are known to be most effective against 
tumor cells in their blood born or early lodging phase the result 
in the lung metastasis model strongly suggested that the anti-
tumor effects in this tumor model were mediated by NK cells. 
In experiments with the weakly immunogenic colon adenocar-
cinoma (CC531) in WAG rats we further demonstrated the role of 
tumor load and tumor site on the outcome of treatment with ABPP. 
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In the subrenal capsule assay (SRCA) as well as in the liver 
metastasis model significant antitumor effects were obtained when 
ABPP was administered early (day 0,1) but not when given late 
(day 6,7). This was in line with the general observation that 
biologicals are effective provided tumor load is small. In the 
liver metastasis model administration of ABPP 1 week after tumor 
inoculation even enhanced the development of liver metastases. 
This tumor site-related phenomenon was reminiscent of earlier 
observations in the liver metastasis model after treatment with 
IFN-alpha and suggested that the immunological "make-up" of the 
liver could be responsible for the observed enhancement of tumor 
growth.. In the setting of 7 day old established liver metastases 
activation of NK cells is known to have no significant impact on 
tumor growth. Other mechanisms may also be involved at this stage 
in containing tumor growth like antibody dependent cellular cyto-
toxicity (ADCC) and cytotoxic T cell mediated killing of the 
immunogenic tumor CC531. Since ABPP enhances phagocytosis by 
macrophages we speculated that the facilitated growth of liver 
metastases after the late administration of ABPP might be the 
result of an increased clearance of tumor antigens and antigen 
reactive T cells by activated Kupffer cells in the liver. Recent-
ly others have shown that activated Kupffer cells inhibit NK cell 
activity by way of secretion of prostaglandins. These data sup-
port a crucial role for ABPP-activatyed Kupffer cells in this 
tumor site specific phenomenon of enhanced growth of liver meta-
stases. The potentially different outcome of immunotherapy in 
different organs or body compartments should prompt us to pay 
attention to this aspect in the evaluation of biologicals in 
clinical studies and shows the need for strict criteria that 
define enhanced tumor growth as a response catagory, a catagory 
often not included in phase II trials. 
In chapter V we described the experiments exploring the 
benefit that can be obtained by combining different biologicals. 
Reports in the literature have claimed synergistic antitumor 
activity in vitro of combinations of Type I and Type II IFNs as 
well as combinations of IFNs with TNF. We investigated whether 
ABPP-induced endogenous IFN might synergize with exogenous rRIFN-
gamma or rMuTNF. It was found that rRIFN-gamma alone had no anti-
tumor effect, in spite of its previously demonstrated immunomodu-
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lative activity. When administered simultaneously with ABPP no 
additional anti tumor effect was observed. However when rRIFN-
gamma was administered prior to the otherwise ineffective late 
administration of ABPP a synergistic antitumor effect was seen. 
We speculated that this " priming effect " of rRIFN-gamma was due 
to an upregulation of Type I IFN receptors on the tumor cells, 
thereby significantly increasing their sensitivity to the ABPP 
induced Type I IFN. Combination treatment with rMuTNF had clearly 
additive antitumor effects. These experiments showed that differ-
ent biologicals can be used effectively when combined. Timing of 
treatment appeared crucial and illustrates the need for further 
investigations in this area. 
In chapter VI and VII the experimental work with ABPP in 
mice was described. First we showed that the in vivo administra-
tion of ABPP intraperitoneally (i.p.) enhanced NK-cell activity 
in the spleen and more effectively in the peritoneal exudate, as 
assessed in "'-Chromium release assays with Yae-l target cells. 
More importantly, by using various fresh tumor cell preparations 
as targets, we were able to demonstrate that the administration 
of ABPP generated LAK cell activity in the spleen and especially 
in the peritoneal exudate. The level of LAK cell activity gene-
rated in vivo as assessed in vitro 3 days after the administra-
tion of 250 mg/kg of ABPP i.p. was comparable to the effect seen 
after the administration of 10,000 units of IL-2, i.p., twice a 
day for three consecutive days. The in vivo generation of LAK 
cells by IL-2 appeared dose dependent and was so effective in the 
peritoneal exudate that cytotoxicity levels after 3 days of i.p. 
administration of 100,000 units of IL-2 twice daily resulted in 
cytotoxicity levels equal to or even superior to those obtained 
by standard 3 day in vitro culture techniques. It can be conclu-
ded from these experiments that IL-2 as well as ABPP may hold 
promise for clinical application in particular in an intraperi-
toneal local-regional treatment setting. Subsequently we investi-
gated whether ABPP and IL-2 might potentiate each others effects. 
Because of the potential upregulating effects on IL-2 receptors 
by ABPP we investigated whether in vivo pretreatment of spleen 
donors would augment subsequent in vitro generation of LAK cells 
from their spleens. No beneficial or detrimental effect was seen. 
In vivo experiments in the i.p. as well as the pulmonary metasta-
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sis model showed that early administration of ABPP (day 1,2) in-
hibited tumor growth significantly but that ABPP when given in 
the setting of early established (day 3) tumor or far advanced 
(day 8-10) tumor was ineffective. The weakly immunogenic sarcomas 
MCA-105 and -106 and the weakly immunogenic murine colon adeno-
carcinoma MCA-38 were more sensitive to treatment with ABPP than 
the nonimmunogenic sarcomas MCA-101 and -102. Further more we 
showed that combined treatment with ABPP and IL-2 alone or with 
ABPP and IL-2 + LAK cells did not augment the therapeutic effects 
of IL-2 + LAK treatment unless ABPP was administered early, prior 
to IL-2 + LAK, which led to an additive ABPP-mediated antitumor 
effect. These experiments showed that ABPP and IL-2 both induced 
discernable levels of LAK cell activity in vivo and that their 
effects did not synergize. This suggested that these are attained 
by at least in part common pathways. 
In chapter VII we explored the therapeutic potential of the 
combination of two different treatment modalities e.g. chemo-
therapy with cyclophosphamide (CY) and immunotherapy with ABPP. 
After a dose-finding study with (CY) the effect of a moderate 
dose of CY (SO mg/kg), with a moderate effect on day 3 tumor and 
little if any effect on day 8-10 tumor, was evaluated when given 
12 hours prior to the administration of ABPP i.p .. A remarkable 
synergistic antitumor effect of the combined treatment schedule 
was seen in both early established and far advanced tumors in the 
i.p. as well as the pulmonary metastasis model. This effect was 
much stronger against the weakly immunogenic tumors than the 
nonimmunogenic tumors. The efficacy of various treatment sche-
dules was evaluated and it could be shown that a second treatment 
cycle, given at a 5 day interval in order to avoid hyporesponsi-
veness induced by ABPP, was highly effective. Repetitive treat-
ment cycles at weekly intervals were able to even cure over 70% 
of the mice with early established i. p. tumor. The synergistic 
antitumor activity of combined treatment with CY and ABPP could 
be the result of various effects : (i) tumor reduction caused by 
CY and thus enabling ABPP to be effective; (ii) selective eradi-
cation of suppressor-T cells by CY, a mechanism that might at the 
same time explain the difference in efficacy of the combined 
treatment against the immunogenic tumors and the nonimmunogenic 
tumors; (iii) the CY-induced increased lysability of the tumor; 
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(iv) abrogation of the primary response by CY and thus removal of 
a population of CTLs that would have competed with LAK cells for 
IL-2 and possibly other 1yrnphokines and thus could have abrogated 
their effect. These experiments highlighted the important poten-
tial that combined modality treatments may have and focus on the 
efficacy of repetitive treatment cycles and the importance of 
further research in this field. 
In chapter VIII we described the toxicity, the anti tumor 
effects and the irnrnunomodulating effects of two different treat-
ment schedules with high doses of recombinant Human Interferon-
alphaA (riFN-alphaA) in 20 patients with advanced metastatic 
colorectal cancer. Interferon was administered either chronically 
e.g. 20 x 10 6 units/m2 intramuscularly, twice a week over a 
period of 12 weeks; or cyclically, e.g. 20 x 10 6 units/m2 i.m. 
daily for 3 periods of 8 consecutive days at 3 week intervals. 
The chronical treatment schedule appeared to be far more toxic 
than the cyclical schedule. The main toxic side effects that were 
often dose limiting were fever with chills, fatigue, malaise, 
anorexia and weight loss, whereas the toxicity of the cyclical 
schedule was virtually restricted to a mild leukocytopenia at the 
end of each treatment cycle. 
The response rate was rather poor. Only 1 partial remission was 
seen in 20 patients. One patient had stable disease for a period 
of 5 months and one patient had a mixed response. In 7 patients 
progression of disease was so slow that on the basis of measure-
ments of their marker lesions they could have been qualified as 
stable disease. A concomittant sharp rise in CEA levels and the 
continued slow progressive natural course of disease after riFN-
alphaA was stopped prompted the decision to classify these 
patients as having progressive disease throughout treatment. The 
remaining 10 patients had unequivocal progressive disease 
throughout treatment. It was concluded therefore that riFN-
alphaA has no antitumor effect against advanced colorectal 
cancer. 
The irnrnunomodulative effects of riFN-alphaA appeared to differ 
depending on the type of treatment schedule. NK-cell activity was 
enhanced by riFN-alphaA only at the beginning of the chronic 
treatment schedule and depressed from day 7 on throughout the 
rest of the treatment. In patients treated cyclically, NK-cell 
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activity was enhanced by rRIFN-alphaA at the beginning of each 
treatment cycle and was not found to be depressed by riFN-alphaA 
at any point throughout this treatment schedule. The outcome of 
the leukocyte adherence assay (LAI) was not influenced by the 
administration of riFN-alphaA. The Gamma-Interferon Production 
Capacity (GIPCA) was found to be extremely depressed at the start 
of treatment in most patients and was restored by the riFN-alphaA 
in most patients to normal levels. A decreased blastogenesis in 
response to stimulation with Phytohaemagglutin (PHA) was observed 
after the administration of riFN-alphaA. 
It was concluded that in view of the few toxic side effects and 
in view of the favorable immunomodulative properties of the 
cyclical treatment schedule this schedule deserved to be tested 
in a different setting in a disease with greater sensitivity to 
treatment with IFN. 
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SAMENVATTING 
In het eerste deel van dit proefschrift worden experimenten 
met de interferon(IFN)-inducer ABPP (2-amino-5-bromo-6-phenyl-
4(3H)-pyrimidinone) in ratten en muizen beschreven. De antitumor 
en immunomodulerende effecten van ABPP werden geevalueerd in 
vitro en in vivo. Hierbij werd gebruik gemaakt van een verschei-
denheid aan tumoren die qua immunogenici tei t en histologie van 
elkaar verschillen. In diverse tumor modellen werd de invloed van 
massa en localisatie van de tumor op de effectiviteit van immuno-
therapie onderzocht. 
In hoofdstuk III en IV toonden wij aan dat ABPP geen direct 
antiproliferatief of cytotoxisch effect heeft in vitro en dat 
derhalve de antitumor effecten in vivo waarschijnlijk het gevolg 
zijn van de immunomodulatieve effecten van ABPP : inductie van 
IFN, activatie van natural killer (NK) cellen en macrophagen. 
Voorbehandeling van BN ratten met de krachtige IFN-inducer ABPP 
remde de groei van het niet-immunogene liposarcoma LS175 in het 
subcutane (s.c.) tumor model. Toediening van de zwakke IFN-
inducer AIPP had geen effect op s.c. tumor groei. Wij concludeer-
den derhalve dat de verschillen in antitumor effect" in het s.c. 
tumor model het verschil in IFN-inducerend vermogen van ieder 
agens weerspiegelde en dat het vermogen om NK cellen te activeren 
mogelijk onafhankelijk was van voorafgaande inductie van IFN. 
Vervolgens toonden wij aan dat beide pyrimidinonen in dezelfde 
mate NK cellen activeerden en in het longmetastase model de 
ontwikkeling van longmetastasen in gelijke mate tegengingen. Deze 
resultaten suggereerden dat de inhibitie van longmetastasen 
gerelateerd was aan de activatie van NK cellen waarvan bekend is 
dat hun antitumor effect het grootst is op circulerende tumor 
cellen en op metastasen in de vroege innestelings fase (<24 uur). 
In hoofdstuk IV wodt in experiment&n met het zwak immunogene 
colon adenocarcinoma (CC531) in WAG ratten, de invloed van de 
tumor massa en tumor localisatie op het resultaat van immuno-
therapie met ABPP beschreven. Zowel in het tumor model waarbi j 
stukjes tumor onder de nierkapsel worden geimplanteerd (sub-
renal capsule assay = SRCA) als in het levermetastase model was 
vroege toediening van ABPP ( op dag 0 en 1; dag 0 is dag van 
implantatie van de tumor) effectief. Geen significante antitumor 
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activiteit werd gezien als ABPP laat (op dag 6 en 7) werd toege-
diend. Deze resultaten komen overeen met de algemene waarneming 
dat agentia met immunomodulatieve activiteit (biological response 
modifiers = BRM) alleen significante antitumor activiteit tonen 
als de tumor massa klein is. In het levermetastase model werden 
na late toediening van ABPP zelfs significant meer levermetasta-
sen waargenomen. Dit aan de tumor-localisatie gerelateerde ver-
schijnsel was al eerder in ons laboratorium waargenomen bij de 
behandeling van levermetastasen met IFN-alpha. Deze resul taten 
suggereerden dat de immunologische "infrastructuur" van de lever 
verantwoordelijk zou kunnen zijn voor de versnelde tumorgroei. 
Het is bekend dat NK cellen geen significant effect hebben op de 
groei van 7 dagen oude "gevestigde" levermetastasen. Andere immu-
nologische processen kunnen mogelijk tumorgroei in di t stadium 
beinvloeden zeals antilichaam afhankelijke cellulaire cytotoxi-
citeit (ADCC : antibody dependent cellular cytotoxicity) en T-
cel cytotoxiciteit gericht tegen de zwak immunogene tumor CC531. 
Aangezien ABPP phagocytose door macrophagen verhoogt, suggereer-
den wij dat de versnelde groei van 7 dag oude levermetastasen na 
de late toediening van ABPP het gevolg zou kunnen zijn van een 
verhoogde eliminatie van tumor antigenen en antigeen reactieve T-
cellen door de door ABPP geactiveerde Kupffer cellen in de lever 
en dat dit zou leiden tot een verlaging van ADCC en T-cel anti-
tumor activiteit. Recent werd door anderen aangetoond dat geacti-
veerde Kupffer cellen NK eel activiteit kunnen remmen middels 
productie van prostaglandinen. Deze gegevens steunen de hypothese 
dat Kupffer cellen een centrale rol spelen in di t aan de lever 
gerelateerde phenomeen van versnelde tumor groei na behandeling 
met ABPP of IFN. Deze observatie dat het resultaat van immunothe-
rapie sterk kan afhangen van de localisatie van de tumor heeft 
ons inziens consequenties ten aanzien van de evaluatie van immu-
notherapie in de kliniek. Strikte criteria zijn nodig om versnel-
de tumorgroei te definieren als een respons catagorie die tot op 
heden niet routinematig bij phase II trials wordt gehanteerd. 
In hoofdstuk V worden de experimenten beschreven waarin de 
effectiviteit van combinatie behandeling met verschillende BRMs 
werd bestudeerd. Verscheidene auteurs hebben synergistische anti-
tumor activiteit in vitro beschreven van combinaties van type I 
en type II IFNs. Wij toonden aan dat de combinatie van ABPP 
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(inductie van endogeen IFN type I) met exogeen recombinant ratten 
IFN-garoroa (rRIFN-garoroa) en met recombinant muizen tumor necrosis 
factor (rMuTNF) een synergistische respectievelijk additieve 
antitumor activiteit vertoonde afhankelijk van tijdstip en volg-
orde van toediening van de BRMs. Monotherapie met rRIFN-garoroa 
bleek ondanks eerder aangetoonde irorounomodulatieve effecten geen 
antitumor activiteit te hebben. Bij gelijktijdige toediening in 
combinatie met ABPP werd geen additioneel antitumor effect waar-
genomen. Echter als rRIFN-garoroa werd toegediend voorafgaand aan 
de late toediening van ABPP ( dag 6, 7), werd een synergistische 
antitumor activiteit gezien. Wij speculeerden dat dit "priming 
effect" van rRIFN-garoroa mogelijk het gevolg was van een door IFN-
garoroa geinduceerde verhoogde expressie van IFN-type I receptoren 
op tumor cellen, met als gevolg een verhoogde gevoeligheid van de 
tumor cellen voor het door ABPP geinduceerde IFN type I. ABPP in 
combinatie met rMuTNF had een duidelijk additief antitumor 
effect. Deze experimenten toonden aan dat verschillende BRMs 
mogelijk met succes in combinatie kunnen worden toegediend en dat 
veel van de effectiviteit blijkt af te hangen van de opzet van de 
behandelingsschemas. 
In hoofdstuk VI en VII wordt het experimentele werk met ABPP 
in muizen beschreven. Met behulp van 51 Chromium release assays 
met Yae-l target cellen toonden wij aan dat de intraperitoneale 
( i. p. ) toediening van ABPP NK acti vi tei t in vivo induceert in 
milt en vooral in peritoneale exudaat cellen (PEC). Door gebruik 
te maken van verscheidene NK-cell-resistente verse tumor cellen 
als target, toonden wij ve.rvolgens aan dat ABPP LAK (lyrophokine 
activated killer) eel activiteit induceert in vivo. Het niveau 
van LAK eel activiteit in miltcellen en PEC 3 dagen na 1 injectie 
van 250 mg/kg ABPP, kwaro overeen met de LAK eel activiteit die na 
toediening van 2 X 10,000 eenheden IL-2, gedurende drie dagen, 
werd waargenomen in dezelfde eel populaties. De in vivo inductie 
van LAK eel activiteit door IL-2 bleek dosis-afhankelijk en was 
zo effectief dat de toediening van 2 X 100,000 eenheden IL-2, 
gedurende 3 dagen even effectief (miltcellen) of zelfs effectie-
ver (PEC) was dan de standaard in vitro LAK eel kweek methoden. 
Wij concludeerden derhalve dat ABPP en IL-2 mogelijk van bijzon-
dere klinische waarde kunnen zijn als zij in een locoregionale 
setting (bv. intracavitair) aangewend worden. Vervolgens onder-
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zochten wij of ABPP en IL-2 elkaars antitumor effecten konden 
potentieren. Aangezien ABPP de expressie van IL-2 receptoren kan 
verhogen onderzochten wij of voorbehandeling van miltdonoren met 
ABPP de effectiviteit van de daarop volgende in vitro kweek 
methode van LAK cellen kon vergroten. Dit bleek niet het geval. 
In vivo experimenten met zowel het i. p. tumor model als het 
longmetastase model toonden aan dat alleen vroege toediening van 
ABPP (dag 1,2) tumorgroei significant vertraagde. Toediening van 
ABPP had vrijwel nooit een significant antitumor effect op dag 3 
gevestigde tumoren en nooi t op ver voortgeschreden tumorgroei 
(dag 8-10). De zwak immunogene tumoren: de sarcomen MCA-105,-en 
106 and het coloncarcinoom MCA-38, bleken gevoeliger voor behan-
de1ing met ABPP dan de niet immunogene sarcomen MCA-101 en ,-102. 
Combinatie behandeling met ABPP en IL-2 of ABPP en IL-2 met LAK 
cellen vergrootte het therapeutisch effect van IL-2 met of zonder 
LAK cellen niet, tenzij ABPP werd toegediend op dag 1 en 2, voor-
afgaand aan de standaard behandeling met IL-2 en LAK cellen. In 
dat geval werd een additief antitumor effect waargenomen. Deze 
experimenten toonden aan dat ABPP en IL-2 beide duidelijke LAK 
eel activiteit in vivo kunnen induceren maar dat hun effecten 
elkaar niet versterken. 
In hoofdstuk VII onderzochten wij de waarde van het combine-
ren van 2 verschillende behandelings modaliteiten, te weten 
chemotherapie met cyclophosphamide ( CY) , en immunotherapie met 
ABPP. Het effect van een bescheiden dosis CY (SO mg/kg), toege-
diend 12 uren eerder dan ABPP, op dag 3 tumor en op dag 8-10 
tumor in het i. p. en in het longmetastase tumor model werd ge-
evalueerd. In beide tumor modellen werd een sterk synergistisch 
antitumor effect waargenomen bij het toedienen van de combinatie 
therapie zowel ten aanzien van dag 3 tumor als ten aanzien van 
ver voortgeschreden dag 8-10 tumor. Dit effect was veel sterker 
t.a.v. de immunogene tumoren dan de niet immunogene tumoren. De 
effectiviteit van verschillende behande1ingsschemas werd geevalu-
eerd en het kon worden aangetoond dat een tweede behandelings 
cyclus, toegediend 5 dagen na de eerste cyclus om door ABPP 
geinduceerde hyporeactiviteit te vermijden, bijzonder effectief 
was. Herhaalde behandelingen met tussenpozen van 1 week waren 
zelfs in staat om > 70% van de muizen met dag 3 i.p. tumor te 
genezen. De synergistische antitumor activiteit van cyclophos-
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phamide in combinatie met ABPP zou het gevolg kunnen zijn van : 
(i) tumor reductie veroorzaakt door CY waarna ABPP effectief kan 
zijn; (ii) selectieve eliminatie van suppressor-T cellen door CY, 
een mechanisme dat tevens het verschil in effectiviteit van de 
combinatie behandeling van immunogene t.o.v. die van niet immune-
gene tumoren kan verklaren; (iii) een door CY geinduceerde 
verhoogde kwetsbaarheid van de tumor cell en; ( i v) het te niet 
doen van de primaire immuunrespons door CY en de verwijdering 
derhalve van een populatie cytotoxische T-cellen die met LAK 
cellen om het binden van interleukine-2 en mogelijk ook andere 
lymphokinen zouden hebben gestreden, en derhalve hun effect te 
niet hadden kunnen doen. Deze experimenten toonden aan dat de 
combinatie van verschillende behandelingsmodali tei ten veelbelo-
vend kan zijn en vestigden de aandacht op de effectiviteit van 
cyclische behandelingsschemas en het belang van verder onderzoek 
op dit gebied. 
In hoofdstuk VIII beschreven wij de toxiciteit, de antitumor 
activiteit en de immunomodulatieve effecten van twee verschillen-
de behandelingsschemas met hoge doses recombinant humaan inter-
feron-alphaA (riFN-alphaA) in 20 patienten met gemetastaseerd 
colon-/rectumcarcinoom. IFN werd chronisch (20 X 10 6 units/m2 , 
i.m., 2 maal per week, gedurende 12 weken) of cyclisch (20 X 10 6 
units/m2 i.m., gedurende 8 opeenvolgende dagen, met tussenpozen 
van 3 we-ken). Het chronische behandelingsschema bleek veel toxi-
scher dan het cyclische schema. De belangrijkste, vaak dosis-
beperkende, bijwerkingen waren koorts met koude rillingen, ver-
moeidheid, malaise, anorexie en gewichtsverlies. Toxiciteit van 
het cyclische schema bleef vrijwel beperkt tot het optreden van 
een matige leukocytopenia aan het einde van iedere behandelings 
cyclus. 
De tumorrespons was slecht. Slechts 1 partiele remissie werd 
waargenomen in 20 patienten. Een patient had stable disease 
gedurende 5 maanden en bij een patient werd een mixed response 
waargenomen. In 7 patienten verliep het voortschrijden van de 
ziekte zo traag dat zij op grand van metingen van de metastasen 
als stable disease konden worden geclassificeerd. Een gelijk-
tijdig scherpe stijging van serum CEA spiegels en het voortgezet-
te langzaam progressive beloop van de ziekte nadat de behandeling 
met IFN was gestaakt, deed ons besluiten deze patienten toch te 
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classificeren als progressive disease. De overige 10 patienten 
werden op grond van de response criteria als progressive disease 
geclassificeerd. Derhalve moest worden geconcludeerd dat riFN-
alphaA geen antitumor effect heeft in patienten met ver voortge-
schreden gemetastaseerd colon-/rectumcarcinoom. 
De immunomodulatieve effecten van riFN-alphaA bleken af te hangen 
van het behandelingsschema. Bij het chronische behandelingsschema 
bleek NK eel activiteit alleen de eerst dagen door riFN-alphaA 
te worden verhoogd en gedurende de rest van de behandeling lager 
te zijn dan de uitgangswaarde. Bij cyclische behandeling werd de 
NK eel activiteit aan het begin van iedere cyclus verhoogd en was 
zij tijdens de behandeling niet lager dan normaal. 
De resultaten van de leukocyte adherence assay (LAI) werden door 
IFN niet beinvloed. De Gamma-IFN Productie Capaciteit (GIPCA) 
bleek aan het begin van de behandeling bij de meeste patienten 
sterk verlaagd te zi jn. Zi j werd door de toediening van riFN-
alphaA in de meeste patienten op het normale niveau gebracht. De 
blastogenese als gevolg van stimulatie met phytohaemagglutin (PHA 
assay) daalde bij de meest patienten na de toediening van riFN-
alphaA. 
Gezien de geringe toxiciteit en de goede immunostimulatieve 
eigenschappen van het cyclische behandelingsschema met riFN-
alphaA concludeerden wij dat de effectiviteit van dit schema in 
een andere setting, bij een aandoening die gevoeliger is voor 
behandeling met IFN, dient te worden geevalueerd. 
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